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A B S T R A C T
Background
Chronic spontaneous urticaria (CSU) is characterised by the development of crops of red, itchy, raised weals or hives with no identifiable
external cause.
Objectives
To assess the effects of H1-antihistamines for CSU.
Search methods
We searched the following databases up to June 2014: Cochrane Skin Group Specialised Register, CENTRAL (2014, Issue 5), MED-
LINE (from 1946), EMBASE (from 1974) and PsycINFO (from 1806). We searched five trials registers and checked articles for
references to relevant randomised controlled trials.
Selection criteria
We included randomised controlled trials of H1-antihistamines for CSU. Interventions included single therapy or a combination of
H1-antihistamines compared with no treatment (placebo) or another active pharmacological compound at any dose.
Data collection and analysis
We used standard methodological procedures as expected by The Cochrane Collaboration.
Our primary outcome measures were proportion of participants with complete suppression of urticaria: ’good or excellent’ response,
50% or greater improvement in quality of life measures, and adverse events. We present risk ratios (RR) with 95% confidence intervals
(CIs).
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Main results
We identified 73 studies (9759 participants); 34 studies provided data for 23 comparisons. The duration of the intervention was up to
two weeks (short-term) or longer than two weeks and up to three months (intermediate-term).
Cetirizine 10 mg once daily in the short term and in the intermediate term led to complete suppression of urticaria by more participants
than was seen with placebo (RR 2.72, 95% CI 1.51 to 4.91). For this same outcome, comparison of desloratadine versus placebo in
the intermediate term (5 mg) (RR 37.00, 95% CI 2.31 to 593.70) and in the short term (20 mg) (RR 15.97, 95% CI 1.04 to 245.04)
favoured desloratadine, but no differences were seen between 5 mg and 10 mg for short-term treatment.
Levocetirizine 20 mg per day (short-term) was more effective for complete suppression of urticaria compared with placebo (RR 20.87,
95% CI 1.37 to 317.60), and at 5 mg was effective in the intermediate term (RR 52.88, 95% CI 3.31 to 843.81) but not in the short
term, nor was 10 mg effective in the short term.
Rupatadine at 10 mg and 20 mg in the intermediate term achieved a ’good or excellent response’ compared with placebo (RR 1.35,
95% CI 1.03 to 1.77).
Loratadine (10 mg) versus placebo (RR 1.86, 95% CI 0.91 to 3.79) and loratadine (10 mg) versus cetirizine (10 mg) (RR 1.05, 95%
CI 0.76 to 1.43) over short-term and intermediate-term treatment showed no significant difference for ’good or excellent response’ or
for complete suppression of urticaria, respectively.
Loratadine (10 mg) versus desloratadine (5 mg) (intermediate-term) showed no statistically significant difference for complete suppres-
sion of urticaria (RR 0.91, 95% CI 0.78 to 1.06) or for ’good or excellent response’ (RR 1.04, 95% CI 0.64 to 1.71). For loratadine
(10 mg) versus mizolastine (10 mg) (intermediate-term), no statistically significant difference was seen for complete suppression of
urticaria (RR 0.86, 95% CI 0.64 to 1.16) or for ’good or excellent response’ (RR 0.88, 95% CI 0.55 to 1.42).
Loratadine (10 mg) versus emedastine (2mg) (intermediate-term) showed no statistically significant difference for complete suppression
(RR 1.04, 95% CI 0.78 to 1.39) or for ’good or excellent response’ (RR 1.09, 95% CI 0.96 to 1.24); the quality of the evidence was
moderate for this comparison.
No difference in short-term treatment was noted between loratadine (10mg) and hydroxyzine (25mg) in terms of complete suppression
(RR 1.00, 95% CI 0.32 to 3.10).
When desloratadine (5 to 20 mg) was compared with levocetirizine (5 to 20 mg), levocetirizine appeared to be the more effective (P
value < 0.02).
In a comparison of fexofenadine versus cetirizine, more participants in the cetirizine group showed complete suppression of urticaria
(P value < 0.001).
Adverse events leading to withdrawals were not significantly different in the following comparisons: cetirizine versus placebo at 10 mg
and 20 mg (RR 3.00, 95% CI 0.68 to 13.22); desloratadine 5 mg versus placebo (RR 1.46, 95% CI 0.42 to 5.10); loratadine 10 mg
versus mizolastine 10 mg (RR 0.38, 95% CI 0.04 to 3.60); loratadine 10 mg versus emedastine 2 mg (RR 1.09, 95% CI 0.07 to 17.14);
cetirizine 10 mg versus hydroxyzine 25 mg (RR 0.78, 95% CI 0.25 to 2.45); and hydroxyzine 25 mg versus placebo (RR 3.64, 95%
CI 0.77 to 17.23), all intermediate term.
No difference was seen between loratadine 10 mg versus mizolastine 10 mg in the proportion of participants with at least 50%
improvement in quality of life (RR 3.21, 95% CI 0.32 to 32.33).
Authors’ conclusions
Although the results of our review indicate that at standard doses of treatment, several antihistamines are effective when compared
with placebo, all results were gathered from a few studies or, in some cases, from single-study estimates. The quality of the evidence
was affected by the small number of studies in each comparison and the small sample size for many of the outcomes, prompting us to
downgrade the quality of evidence for imprecision (unless stated for each comparison, the quality of the evidence was low).
No single H1-antihistamine stands out as most effective. Cetirizine at 10 mg once daily in the short term and in the intermediate
term was found to be effective in completely suppressing urticaria. Evidence is limited for desloratadine given at 5 mg once daily in
the intermediate term and at 20 mg in the short term. Levocetirizine at 5 mg in the intermediate but not short term was effective for
complete suppression. Levocetirizine 20 mg was effective in the short term, but 10 mg was not. No difference in rates of withdrawal
due to adverse events was noted between active and placebo groups. Evidence for improvement in quality of life was insufficient.
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P L A I N L A N G U A G E S U M M A R Y
H1-antihistamines for chronic spontaneous urticaria
Background
Chronic spontaneous urticaria (CSU) is a condition characterised by a rash of red itchy raised weals or hives, which appear for no
identifiable reason. Other names include chronic idiopathic or chronic ordinary urticaria. ’Spontaneous’ differentiates this type of
urticaria from ’inducible’ or ’physical’ urticaria, for which there are specific triggers such as cold or pressure. ’Chronic’ indicates that
the condition has continued for at least six weeks. Hives may be intensely itchy, and the appearance may be unsightly and distressing
to sufferers. In some cases, hives can be accompanied by deeper swelling, known as angio-oedema, which is most common around the
eyes and mouth.
Antihistamine drugs, specifically H1 antihistamines, are the mainstay of treatment for urticaria, although they control the condition
rather than cure it. Many antihistamines are available to buy without a prescription, including brand names such as Clarityn, Piriton,
Zirtek, Benadryl and Phenergan (brand names may differ by country).
Review question
Which H1-antihistamines are effective and safe for CSU?
Study characteristics
We included 73 randomised controlled trials, with 9759 participants of all ages and looked for complete suppression of urticaria. The
duration of the intervention was up to two weeks (short-term) or longer than two weeks and up to three months (intermediate-term).
Key results
We investigated clinical trials in which one therapy was compared against another or against placebo (direct comparisons). We found
that for general use, 10mg once daily of cetirizine for short-term and intermediate-term duration was effective in completely suppressing
urticaria, although not in all individuals. Some benefit may be associated with use of desloratadine at 5 mg for at least an intermediate
term and at 20 mg in the short term. Levocetirizine at 5 mg was effective for complete suppression in the intermediate term but not
in the short term. A higher dose of 20 mg was effective in the short term, but 10 mg was not.
Adverse events, such as headache or dry mouth, are tolerable with most antihistamines. Evidence is less clear for improvement in quality
of life (e.g. reduction in sleep disturbance from itching, less distress from the appearance of hives) as many studies did not address this.
We cannot say whether one antihistamine works better than all the rest, as we did not have head-to-head evidence for every possible
treatment comparison.
Quality of the evidence
The overall quality of the evidence found for most outcomes was low. Further well-designed and carefully reported comparative studies
are required, if we are to find out how well these medicines work, and if any adverse effects are reported, especially over periods of up
to several months.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Cetirizine 10 to 20 mg versus placebo for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: cetirizine 10 to 20 mg versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control (placebo) Cetirizine 10 to 20 mg
Complete suppression of
urticaria
Global assessment of
symptom scores
Study population RR 2.72
(1.51 to 4.91)
178
(2 studies)
⊕⊕©©
Lowa,b
Favours cetirizine
133 per 1000 363 per 1000
(201 to 655)
Moderate
146 per 1000 397 per 1000
(220 to 717)
Adverse events leading
to withdrawal
Study population RR 3
(0.68 to 13.22)
389
(3 studies)
⊕⊕©©
Lowa,b
Favours neither interven-
tion nor control
10 per 1000 30 per 1000
(7 to 132)
Moderate
14 per 1000 42 per 1000
(10 to 185)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bRelatively few participants and few events and/or wide confidence intervals.
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B A C K G R O U N D
Description of the condition
Urticaria is a condition characterised by the development of a rash
of red itchy raised weals or hives that blanch with pressure. The
main associated symptom is itching, which may be intense. Al-
though individual weals typically come and go within 24 hours,
the overall condition may persist, with fresh crops of weals occur-
ring on other areas of the body, even as the original lesions re-
solve. In some cases, the weals are accompanied by deeper swelling,
known as angio-oedema. If recurrent crops of urticaria continue to
occur for longer than six weeks, the condition is known as chronic
urticaria (to distinguish this from the more common acute ur-
ticaria, for which a cause is more often identified) (James 2011;
Sarbijt 2014). Chronic spontaneous urticaria may occur at any
age (Hellgren 1972). Recent publications show a female-to-male
predominance of 2:1 (Gaig 2004) with a prevalence of between
0.5% and 1% (Maurer 2011).
Causes
A careful history and physical examination are important, but
an underlying cause is never identified in most individuals with
chronic urticaria (Grattan 2001; Charlesworth 2002). In such
cases, the condition has also been called ’chronic idiopathic ur-
ticaria.’ This term was replaced by ’chronic ordinary urticaria’ to
include the subset of people who appear to have autoimmune dis-
ease, with a circulating antibody that is able to bind to mast cells,
thereby causing histamine release and weal formation. This group
makes up about 30%of thosewith chronic urticaria, but such indi-
viduals tend to respond in the same way to treatment as those with
non-autoimmune urticaria (Hauser 2003). Current consensus is
to use the term ’chronic spontaneous urticaria’ (Maurer 2013),
which describes the behaviour of the disease rather than assuming
a particular level of knowledge of its pathogenesis. By contrast,
when a trigger for urticaria can be identified, the term ’inducible’
is now preferred. In practice, chronic spontaneous urticaria cov-
ers the population of individuals who were previously labelled as
having chronic idiopathic or ordinary urticaria. Most of the extant
literature employs these outmoded terms. We therefore deemed it
appropriate to include such studies, whilst adhering to the term
’chronic spontaneous urticaria (CSU)’ throughout our review.
Impact
The severity of urticaria varies between individuals. Some of those
with the condition have several attacks each day for many months;
othersmay have an attack every week or everymonth. This can be a
very debilitating condition, particularly if the attacks are frequent.
The inability to predict an attack and the lack of an identifiable
cause are often sources of great frustration. Historically it has been
reported that after 10 years, at least 20%of those with urticaria still
suffer from it (Champion 1969; Humphreys 1998) and that half
of those with chronic urticaria and angio-oedema still had chronic
urticaria at five years (Champion 1969). However, the condition
is rarely permanent, and recent surveys suggest a higher chance of
disease remission (Kozel 2001).
Description of the intervention
The aim of treatment is to suppress urticarial activity completely.
In some individuals, only symptomatic improvement can be
achieved by reducing the severity and frequency of attacks. H1-an-
tihistamines (commonly called ’antihistamines,’ which are avail-
able over the counter for various complaints, including hay fever
and allergies) form the basis of treatment, providing symptomatic
relief for many affected individuals. Older (or ’first-generation’)
H1-antihistamines (e.g. hydroxyzine) are no longer recommended
for use in chronic urticaria, as they are more sedating than the
newer ’second generation’ of antihistamines (e.g. cetirizine) and
carry a higher risk of side effects such as drymouth, blurred vision,
headache, glaucoma and urinary retention.
Antihistaminesmay have to be taken over extended periods of time
to control the disease. High doses of H1-antihistamines may be
required to obtain sufficient symptom control in urticaria. Adverse
effects of H1-antihistamines vary between individuals, and some
of those with the condition may tolerate one antihistamine better
than another (Nolen 1997). Terfenadine and astemizole have been
associated with cardiac arrhythmias (DuBuske 1999) in a small
proportion of people and have been withdrawn from the market.
Oral corticosteroids have an occasional role as rescue therapy in
severe exacerbations of chronic urticaria.
Other treatments for difficult to control CSU include H2-anti-
histamines (also known as H2-receptor antagonists, or H2RAs)
such as ranitidine (these are not commonly referred to as anti-
histamines and are usually used for acid-related stomach condi-
tions). (This class of medications was systematically reviewed in
Fedorowicz 2012.) Other interventions include the leukotriene
receptor antagonist montelukast, immunosuppressive agents (e.g.
ciclosporin), diets and food avoidance, doxepin and the anti-im-
munoglobulin E (IgE) monoclonal antibody omalizumab.
Why it is important to do this review
Patients with chronic spontaneous urticaria can be difficult to
treat. Many of those with the condition do not respond to initial
treatment, and clear guidance is needed on which antihistamines
to use, appropriate dosing regimens and likely responses. As treat-
ment is usually aimed at reducing symptoms and improving the
lives of people with CSU, evidence regarding quality of life was
sought so an important outcome for this review could be assessed.
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Many randomised controlled trials (RCTs) related to the use of
antihistamines in CSU have been conducted. We sought to inves-
tigate:
• whether one antihistamine is superior to another;
• if combination therapy is superior to monotherapy;
• whether high-dose therapy is superior to standard doses;
• the duration of benefit from H1-antihistamines;
• risks and side effects of H1-antihistamines when used in the
treatment of individuals with chronic urticaria; and
• the effects of treatment on quality of life.
We have provided an assessment of the level and quality of cur-
rently available evidence, and we have identified areas that require
further research on this important condition.
O B J E C T I V E S
To assess the effects of H1-antihistamines for chronic spontaneous
urticaria (CSU).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only RCTs that evaluated the effectiveness of H1-
antihistamines compared with placebo or another active treatment
(including another H1-antihistamine) and those that compared
different doses. We did not include studies of other designs.
Types of participants
Participants were individuals of any age (children and adults) who
had been clinically diagnosed with CSU. The following were ex-
cluded.
• Participants with urticaria of less than six weeks’ duration;
• Participants with immune complex urticaria (urticarial
vasculitis or serum sickness), papular urticaria, angio-oedema
without weals or contact urticaria; and
• Participants with predominantly physical or cholinergic
urticaria, or other urticaria with a clearly identifiable causative
agent (e.g. medication), and those with auto-inflammatory
syndromes (e.g. Muckle-Wells syndrome, Schnitzler’s syndrome).
Types of interventions
Any first-generation (’sedating’) or second-generation (’non-sedat-
ing’) H1-antihistamines in current use, given at any dose (includ-
ing topical interventions and H2RAs given concomitantly). We
specifically excluded studies thatwould yield comparison data only
for terfenadine and astemizole, as these drugs have been with-
drawn because of safety issues. Interventions could be given as
single therapy or combination therapy. Comparators consisted of
no treatment (i.e. placebo) or another active compound.
Duration of the intervention was categorised as follows: up to two
weeks (short-term), longer than two weeks and up to threemonths
(intermediate-term) and longer than three months (long-term).
Types of outcome measures
Primary outcomes
• Proportion of participants with complete suppression of
urticaria whilst taking H1-antihistamines.
• Proportion of participants with ’good’ or ’excellent’
response to H1-antihistamines whilst taking H1-antihistamines.
• Proportion of participants with 50% or greater
improvement in quality of life measurements whilst taking H1-
antihistamines.
The abovemeasures were based predominantly on participant self-
reporting because of the transient nature of urticaria. We looked
at participant and clinician assessments separately and in combi-
nation.
Secondary outcomes
• Serious adverse events (i.e. serious enough to require
withdrawal of treatment).
• Minor participant-reported adverse events not requiring
withdrawal of treatment.
• Proportion of participants who relapse within one month of
stopping H1-antihistamines.
Search methods for identification of studies
We aimed to identify all relevant RCTs regardless of language
or publication status (published, unpublished, in press or in
progress).
Electronic searches
We revised our draft search strategy to update the names of specific
H1-antihistamines used to treat urticaria.
We searched the following databases up to 3 June 2014.
• Cochrane Skin Group Specialised Register (strategy in
Appendix 1).
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• Cochrane Central Register of Controlled Trials
(CENTRAL) (2014, Issue 5) (strategy in Appendix 2).
• MEDLINE via OVID (from 1946) (strategy in Appendix
3).
• EMBASE via OVID (from 1974) (strategy in Appendix 4).
• PsycINFO via OVID (from 1806) (strategy in Appendix 5).
Trials registers
We searched the following trials registers on 9 June 2014.
For the first three registers listed, we used the following search
string: ’chronic idiopathic urticaria AND anti-histamine AND
placebo.’ For the EUClinical Trials Register and theWorldHealth
Organization International Clinical Trials Registry, we used the
phrase ’chronic idiopathic urticaria.’
• metaRegister of Controlled Trials (www.controlled-
trials.com).
• US National Institutes of Health Ongoing Trials Register (
www.clinicaltrials.gov).
• Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• World Health Organization International Clinical Trials
Registry platform (www.who.int/trialsearch).
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/).
Searching other resources
References from published papers
We checked the bibliographies of reviews on treatment of individ-
uals with CSU to look for additional references to relevant RCTs.
Adverse effects
We did not perform a separate search for adverse effects of the tar-
get intervention. We considered adverse and side effects described
in the included studies. We checked the bibliographies of review
articles to look for additional references to relevant reports of ad-
verse effects.
Data collection and analysis
Selection of studies
We included in this review only RCTs evaluating H1-antihis-
tamines for chronic urticaria. We sought advice from translators
when the study report was written in a language other than En-
glish. At least two review authors (MS, CB and SNC) assessed all
titles and abstracts identified by the searches. These review authors
independently assessed each included study to determine whether
the predefined selection criteria had been met, and they resolved
differences of opinion through discussion within the review team.
We listed the excluded studies and the reasons for their exclusion
in the Characteristics of excluded studies section of the review and
presented the study flow chart in PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) (Figure 1).
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Figure 1. Study flow diagram.
Data extraction and management
Three review authors (MS, CB and SNC) extracted data indepen-
dently using a data extraction form, and disagreements on data ex-
traction were resolved by consensus. In the case of studies written
in Chinese, German or another foreign language, a translator ex-
tracted data, and MS and SNC checked the numerical outcomes.
We contacted principal investigators of trials and asked them to
provide missing data when possible. Review authors (MS, CB and
BC) checked and entered the data (numerical outcomes data and
non-numerical data) into RevMan 2014.
Assessment of risk of bias in included studies
At least two review authors (MS, CB and SNC) independently
assessed the risk of bias in included studies using the risk of bias
assessment tool provided in Chapter 8 of theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We com-
pared the evaluations and discussed and resolved inconsistencies
between review authors’ decisions.
We rated the following domains separately for each of the included
studies as ’low risk of bias,’ ’high risk of bias’ and ’unclear’ if
the risk of bias was uncertain or unknown. These assessments are
reported in the ’Risk of bias’ table for each individual study in the
Characteristics of included studies section of the review.
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• Allocation sequence was adequately generated (’sequence
generation’).
• Allocation was adequately concealed (’allocation
concealment’).
• Knowledge of allocated interventions was adequately
prevented during the study (’blinding’).
• Incomplete outcome data were adequately addressed.
• Reports of the study were free of suggestions of selective
outcome reporting.
• The study was apparently free of other sources of bias that
could put it at high risk of bias (i.e. potential conflicts of interest,
pharmaceutical funding/support or both).
We also categorised and reported the overall risk of bias of each of
the included studies according to the following.
• Low risk of bias: plausible bias unlikely to seriously alter the
results if all criteria were met.
• Unclear risk of bias: plausible bias that raises some doubt
about the results if one or more criteria were assessed as unclear.
• High risk of bias: plausible bias that seriously weakens
confidence in the results if one or more criteria were not met.
We reported these assessments in the Risk of bias in included
studies section of this review.
Measures of treatment effect
We planned to present continuous outcomes on the original scale
as reported in each individual study. We will report standardised
mean differences (SMDs) for continuous data in future updates
(i.e. if similar outcomes are reported using different scales, we
will standardise these by dividing the estimated coefficient by its
standard deviation (SD) to permit comparisons between scales).
We presented dichotomous outcomes data as risk ratios (RRs)
along with their associated 95% confidence intervals (CIs); we
analysed these in RevMan using the Mantel-Haenszel test, unless
stated otherwise.
Unit of analysis issues
Cross-over studies
We planned to analyse cross-over studies using first period data
only, unless an adequate washout between periods took place and
baseline data were presented for each period.
Multi-armed studies
To ensure that analyses from these studies were not falsely pow-
ered, we partitioned the number of participants analysed in the
comparison arm into each pair-wise comparison; thus a three-arm
study with 30 participants in each arm that resulted in two pair-
wise comparisons of placebo versus A and placebo versus B was
allocated the following numbers of participants: 15 versus 30, and
15 versus 30. Mean and standard deviation summary statistics for
comparator participants remained unchanged.
Dealing with missing data
We attempted to contact investigators to retrieve missing data.
We reanalysed data according to a treatment by allocation princi-
ple when possible, and in accordance with Section 16.2.2 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). If data were not reported and study authors had conducted
a per-protocol analysis, we assessed whether there was any imbal-
ance in the dropout rate between trial arms to determine the po-
tential impact of bias. In the absence of intention-to-treat data,
we used available case population data (per protocol) and reported
these accordingly.
Assessment of heterogeneity
We assessed clinical heterogeneity by examining trial conditions
(i.e. characteristics of the studies, similarity between types of par-
ticipants and the interventions). We assessed the degree of statis-
tical heterogeneity between studies using the I² statistic. We re-
ported heterogeneity as important if it was at least moderate to
substantial by the I² statistic > 60% (Higgins 2011). If this could
be explained by clinical reasoning and a coherent argument could
be made for combining the studies, we conducted a meta-analysis.
In many cases, heterogeneity could not be adequately explained,
and we did not pool the data.
Clinical diversity among the studies included in this review, as well
as the limited number of studies that could be combined for each
intervention, allowed us to assess heterogeneity between studies
for only one of the comparisons.
Assessment of reporting biases
Weplanned to carry out assessments of reporting bias when at least
10 studies were included in a meta-analysis, according to the rec-
ommendations on testing for funnel plot asymmetry as described
in Section 10.4.3.1 of the Cochrane Handbook for systematic Re-
views of Interventions (Higgins 2011). We planned to explore pos-
sible sources of asymmetry by performing an additional sensitivity
analysis.
Data synthesis
Review authors (MS, CB and BC) analysed the data in RevMan
2014 and reported them in accordance with the advice provided
in Chapter 9 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). If we were able to identify more than
one study that was clinically similar and exhibited not less than
moderate heterogeneity, we pooled the data into a meta-analysis
using a random-effects model, and we carried out a sensitivity
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analysis using a fixed-effect model to assess the degree of hetero-
geneity.
For some comparisons, we carried out reanalysis using Fisher’s
exact test because of the small number of participants,
Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses based on the duration of the
intervention. Duration of the intervention was categorised as fol-
lows: up to two weeks (short-term) and longer than two weeks up
to three months (intermediate-term).
Sensitivity analysis
We planned to conduct sensitivity analyses for primary outcome
measures to assess the effects of including only those studies with
low risk of bias and to assess the robustness of the results of this
review. Included studies with low risk of bias were too few to
permit this analysis.
R E S U L T S
Description of studies
Results of the search
We identified 1080 records in total through our electronic database
searches up to June 2014. We identified an additional 45 poten-
tial study reports from databases of clinical trials in progress and
from bibliographical searches. In total we screened 1125 records
and excluded 841 on the basis of examination of titles and ab-
stracts. We examined the remaining 284 records in detail. Sixteen
records could not be obtained in full text, and we list these in
the Characteristics of studies awaiting classification tables. Four-
teen studies were listed as ongoing (see Characteristics of ongoing
studies), and we will include these in future updates if the results
become available (Figure 1). We excluded 169 studies accounting
for 172 records. The remaining 82 records described 73 studies,
which were included.
At each stage of the selection process, at least two review authors
independently reviewed the search results and selected trials for
inclusion. The final list was agreed upon by two review authors
(MS and SNC), with involvement of a third review author (CB)
if necessary to resolve disagreements.
Included studies
Design
All included studies were randomised, and none was of quasi-
randomised design.
Some unusual designs were reported: Garavaglia 1995 reported a
randomised trial in which dropouts were replaced with new re-
cruits. It was unclear whether the new participants were randomly
assigned or were simply assigned to the intervention group of the
most recent dropout. Thompson 2000 Study 1 and Thompson
2000 Study 2 reported two trials within the same study report; it
is unclear why the results from both studies were not aggregated
and presented as a single two-centre trial, as trial conditions were
the same.Wang 2012 was a dose reduction study, andWeller 2013
selected a single body area for each participant. Staevska 2014 em-
ployed a cross-over trial design but after randomisation and initial
in-hospital treatment assessment tested the effectiveness and toler-
ability of levocetirizine versus hydroxyzine in an alternate-day reg-
imen. After five days, participants from arms 1 and 2 were crossed
over to the alternative treatment without washout between phases.
Twenty-six of the included trials were multi-centre in design (
Belaich 1990; Breneman 1995; Breneman 1996; Bronsky 2001;
Brostoff 1996; Dubertret 1999; Finn 1999; Gale 1989; Gimenez-
Arnau 2007; Godse 2007; Grant 1988; Gu 2002; Hao 2003;
Kalivas 1990; Kaplan 2005; Kint 1989; Monroe 1988; Monroe
2003; Nelson 2000; Ollert 1999; Ortonne 2007; Paul 1998; Peyri
1991; Pons-Guiraud 2006; Potter 2009; Zuberbier 2010).
Fourteen included studies were of a cross-over design. However,
none of these contributed data to the meta-analyses in this review,
althoughwe discuss the results narratively below (Commens 1978;
Gale 1989; Go 1989; Goh 1991; Harvey 1981; Hjorth 1988;
Juhlin 1987; Juhlin 1991; Kint 1989; Leyh 1989; Liu H-N 1990;
Marks 1980; Salo 1989; Staevska 2014).
Sample sizes
We included 73 studies with a total of 9759 randomly assigned
participants. Details of all included studies are provided in the
Characteristics of included studies tables. Sample sizes ranged from
several hundred, for example, 886 (Potter 2009), 525 (Zuberbier
2010), 468 (Nelson 2000), 334 (Gimenez-Arnau 2007) and 314
NCT00536380) to fewer than 25 (Gale 1989; Harvey 1981;
Juhlin 1987; Leyh 1989; Liu H-N 1990;Marks 1980; Salo 1989).
Setting
Most studies were carried out in a secondary care setting, including
hospital clinics, research clinics and dermatology centres. None
were based in primary care.
Studies were carried out mostly, but not exclusively, in Europe
and the USA. Outside these continents, Anuradha 2010; Dakhale
2014; Ghosh 1990; Godse 2007; Handa 2004 and Maiti 2011
were undertaken in India. Gu 2002; Hao 2003; Liu 2003; Wang
2012; Wu 2008; Yin 2003a; Yin 2003b and Zou 2002 were un-
dertaken in China, and Makino 2012 in Japan. Garavaglia 1995
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and Zuberbier 2010 were carried out in Argentina, Goh 1991 in
Singapore and Liu H-N 1990 and Wan 2009 in Taiwan. Marks
1980 took place in Australia, Monroe 2003 in the USA and Chile
and Phanuphak 1987 in Thailand. The location was not stated
for Patel 1997, although the study authors worked in American
and Canadian research centres.
Participants
The total number of participants randomly assigned was 9759.
Participants consisted of adults (i.e. over 18 years old) or mixed
groups including adolescents (i.e. over 12 years old). Most partic-
ipants were female.
The inclusion criteria were tightly defined as CSU, alternatively
described as chronic idiopathic or ordinary urticaria, of at least
six weeks’ duration. In Hjorth 1988, the diagnosis was not clearly
defined, and investigators may have included some participants
with atopic dermatitis. InWang 2012, disease duration and symp-
toms were comparable but were not defined clearly in the study.
Dakhale 2014; Finn 1999; Grant 1988; Kaplan 2005; Monroe
2003; Nelson 2000; Ortonne 2004 and Pons-Guiraud 2006 ex-
cluded participants who were previously unresponsive to antihis-
tamines, and in the Ghosh 1990 study, all participants were pre-
viously refractory to antihistamine treatment.
Interventions and comparisons
Intervention
H1-antihistamines usually are classified as first or second genera-
tion, according to their chemical structure and properties. First-
generation antihistamines may cause sedation and can be useful
for treating sleep disturbance due to itching. Second-generation
antihistamines are less sedating, as the molecule is less likely to
cross the blood-brain barrier; however, they are not without the
possibility of sedative effects, and some (particularly terfenadine
and astemizole) may also cause irregularities in heart rhythm (car-
diac arrhythmia). A category of third-generation antihistamines
has been used to describe some of the later antihistamines. This
term is not generally accepted, as such agents do not differ suf-
ficiently from earlier drugs in terms of desirable and undesirable
effects (Holgate 2003). In our analyses (of those trials that yielded
outcome data), we included the following.
First-generation antihistamines
• Hydroxyzine.
• Pheniramine.
Second-generation antihistamines
• Cetirizine.
• Desloratadine.
• Ebastine.
• Emedastine.
• Fexofenadine.
• Levocetirizine.
• Loratadine.
• Ketotifen.
• Mizolastine.
• Rupatadine.
Other interventions
Di Lorenzo 2004 used montelukast, a non-H1-antihistamine in-
tervention, as the comparator with desloratadine. Montelukast is
a leukotriene receptor antagonist (LTRA). Ghosh 1990 used as
a comparator doxepin, a sedative tricyclic antidepressant that has
antihistaminic properties.
Duration of intervention
Interventions were categorised by duration as follows: up to two
weeks (short-term), longer than two weeks and up to threemonths
(intermediate-term) and longer than three months (long-term).
Seventeen studies were short-term (Commens 1978; Go 1989;
Goh 1991; Harvey 1981; Hjorth 1988; Juhlin 1987; Juhlin 1991;
Kint 1989; Leyh 1989; Leynadier 2000; Locci 1991; Monroe
1992; Patel 1997; Peyri 1991; Phanuphak 1987; Salo 1989;
Staevska 2014); the duration of intervention was not explicitly
stated in Hoxha 2011, but we categorised this as short-term on
the basis of information given in the abstract report. One study
(Weller 2013) was of very short duration (five hours). The remain-
ing 55 studies were categorised as having an intermediate-term
duration of intervention. None of the studies had an intervention
period categorised as long-term.
Comparisons
A total of 73 trials met our inclusion criteria. Of these, only 34
trials provided outcome data for the following comparisons.
• Loratadine 10 mg versus placebo (Belaich 1990; Monroe
1992).
• Loratadine 10 mg versus cetirizine 10 mg (Patel 1997; Yin
2003b).
• Loratadine 10 mg versus desloratadine 5 mg (Gu 2002;
Hao 2003; Zou 2002).
• Loratadine 10 mg versus mizolastine 10 mg (Guo 2003;
Leynadier 2000; Liu 2003; Yin 2003b).
• Loratadine 10 mg versus emedastine 2 mg (Pons-Guiraud
2006).
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• Loratadine 10 mg versus hydroxyzine 25 mg (Monroe
1992).
• Cetirizine 10 mg versus placebo (Breneman 1995;
Breneman 1996; Go 1989; Kalivas 1990)..
• Cetirizine 10 mg versus hydroxyzine 25 mg (Breneman
1996; Kalivas 1990).
• Cetirizine 10 mg versus fexofenadine 180 mg (Handa
2004).
• Cetirizine 10 mg versus levocetirizine 5 mg (Yin 2003a).
• Cetirizine 10 mg versus mizolastine 10 mg (Yin 2003b).
• Desloratadine 5 mg to 20 mg versus placebo (Di Lorenzo
2004; Hoxha 2011; Monroe 2003; Nettis 2004; Ortonne 2007;
Ring 2001).
• Hydroxyzine 25 mg versus placebo (Breneman 1996;
Kalivas 1990; Monroe 1992).
• Levocetirizine 5 mg to 20 mg versus placebo (Hoxha 2011;
Nettis 2006).
• Rupatadine 10 mg to 20 mg versus placebo
(Gimenez-Arnau 2007).
• Desloratadine 5 mg to 20 mg versus levocetirizine 5 to 20
mg (Hoxha 2011; Potter 2009).
• Ebastine 10 mg versus placebo (Peyri 1991).
• Desloratadine 5 mg versus montelukast 10 mg (Di Lorenzo
2004).
• Fexofenadine 180 mg versus placebo (Kaplan 2005).
• Ketotifen 1 mg versus placebo (Phanuphak 1987).
• Cetirizine 5 mg and hydroxyzine 25 mg versus placebo
(Wan 2009).
• Azelastine 2 mg versus azelastine 4 mg (Wu 2008).
• Doxepin 10 mg versus pheniramine 22.5 mg (Ghosh 1990).
A number of studies compared interventions that could not be
included in our analyses because the outcomes measured did not
fit our inclusion criteria.
• Acrivastine 4 mg, placebo, clemastine 1 mg (Leynadier
2000).
• Acrivastine 8 mg, chlorphen(ir)amine maleate 4 mg (Gale
1989).
• Acrivastine 8 mg, clemastine 1 mg, placebo (Juhlin 1987).
• Acrivastine 8 mg, hydroxyzine hydrochloride 20 mg (Salo
1989).
• Azelastine 2 mg, azelastine 4 mg, azelastine and cimetidine
(H2RA) 2 mg (Wu 2008).
• Cetirizine 10 mg, placebo (Juhlin 1991).
• Cetirizine 10 mg plus placebo, terfenadine 60 mg, placebo
(Go 1989; Kint 1989).
• Cetirizine 10 mg, terfenadine 120 mg, placebo (Garavaglia
1995).
• Cetirizine 10 mg, placebo (cross-over) (Goh 1991); non-
cross-over (Alomar 1990a).
• Cetirizine 10 mg versus rupatadine 10 mg (Dakhale 2014).
• Chlorphen(ir)amine 4 mg, chlorphen(ir)amine 4 mg plus
cimetidine 400 mg (H1 + H2 antagonist), placebo (Marks 1980)
• Cimetidine 200 mg plus chlorphen(ir)amine 4 mg,
chlorphen(ir)amine 4 mg plus placebo, placebo (Commens
1978).
• Desloratadine 5 mg, placebo (Bronsky 2001; Monroe 2003;
Ortonne 2004; Ortonne 2007Ring 2001).
• Desloratadine 5 mg, desloratadine 10 mg, desloratadine 20
mg (NCT00536380).
• Desloratadine 5 mg, desloratadine 20 mg (Weller 2013).
• Desloratadine 5 mg and placebo, desloratadine 5 mg and
montelukast 10 mg, placebo (Nettis 2004).
• Fexofenadine 60 mg, 120 mg, 180 mg and 240 mg; placebo
(Paul 1988).
• Fexofenadine 60 mg, placebo (Thompson 2000 Study 1;
Thompson 2000 Study 2).
• Fexofenadine HCl 180 mg, levocetirizine 5 mg (Godse
2007).
• Fexofenadine HCl 20 mg, 60 mg,120 mg and 240 mg;
placebo (Finn 1999; Nelson 2000).
• Fexofenadine 180 mg, placebo (Degonda 2002).
• Hydroxyzine plus terbutaline (beta agonist) (25 mg plus 5
mg), hydroxyzine plus cyproheptadine (25 mg plus 4 mg),
hydroxyzine plus chlorphen(ir)amine (25 mg plus 4 mg),
hydroxyzine plus cimetidine (H2RA) (25 mg plus 300 mg),
hydroxyzine plus placebo (25 mg ) (Harvey 1981).
• Ketotifen 1 mg, fluoxetine 20 mg (selective serotonin
reuptake inhibitor-type antidepressant) (Sener 1999).
• Levocetirizine 5 mg, bilastine 20 mg (Zuberbier 2010).
• Levocetirizine 5 mg, desloratadine 5 mg (Potter 2009).
• Levocetirizine 20 mg, levocetirizine 15 mg plus
hydroxyzine 50 mg (Staevska 2014).
• Loratadine 10 mg, levocetirizine 5 mg (Anuradha 2010).
• Loratadine 10 mg, placebo (Monroe 1988).
• Mizolastine 10 mg, loratadine 10 mg, placebo (Dubertret
1999).
• Mizolastine 10 mg, placebo (Brostoff 1996; Ollert 1999).
• Mizolastine 10 mg in decreasing dose, mizolastine 10 mg
daily (Wang 2012).
• Nifedipine 10 mg, chlorphen(ir)amine 4 mg (Liu H-N
1990).
• Olopatadine 10 mg, olopatadine 5 mg, no medication
(Makino 2012).
• Oxatomide 30 mg, clemastine 1 mg (Beck 1985).
• Oxatomide gel 5%, dechlorpheniramine cream (Locci
1991).
• Rupatadine 10 mg, levocetirizine 5 mg (Maiti 2011).
• Rupatadine 10 mg, rupatadine 20 mg, placebo
(Gimenez-Arnau 2007).
• Rupatadine 5 mg, rupatadine 10 mg, rupatadine 20 mg,
placebo (Dubertret 2007).
• Terfenadine 60 mg, clemastine 1 mg, placebo (Hjorth
1988).
• Terfenadine 60 mg, chlorphen(ir)amine 4 mg, placebo
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(Grant 1988).
Outcomes
Timing of outcome assessment varied considerably. Studies re-
ported outcomes assessed at baseline and at the end of the inter-
vention period, with interim outcome assessments performed in
some studies. If a study reported serial times of duration of inter-
vention for the same participants, to reduce bias, we summarised
these only at the latest time point.
Nine studies reported outcomes measured after the treatment pe-
riod had ended (Di Lorenzo 2004; Ghosh 1990; Go 1989; Nettis
2006; Pons-Guiraud 2006; Potter 2009; Thompson 2000 Study
1; Thompson 2000 Study 2; Yin 2003b).
Outcomes included measures of weals, redness and itching as-
sessed through both participant diaries or reports and clinician as-
sessments, as well as size of weals and assessment of redness based
on visual analogue scales. Numbers of participants experiencing
improvement or cessation of symptoms were also reported.
Few of the studies directly reported our prespecified review out-
comes (Objectives).
Few studies reported quality of life measures: Degonda 2002 pro-
vided participant-assessed summaries of changes in quality of life,
and Maiti 2011 provided modified Dermatology Life Quality In-
dex (DLQI) scores. Nettis 2004 and Nettis 2006 also provided
quality of life assessment based on theDLQI. Potter 2009 reported
the results of a self-administered DLQI questionnaire; Staevska
2014 and Zuberbier 2010 also reported DLQI results. Ortonne
2007 reported disruption of sleep and daily activities, and Staevska
2014 reported effects on quality of nighttime sleep. Thompson
2000 Study 1 and Thompson 2000 Study 2 commented on sig-
nificant improvements in DLQI with fexofenadine.
Excluded studies
We excluded 169 studies. These consisted of studies that described
only chronic urticaria unless the text mentioned or provided de-
tails that confirmed a diagnosis of chronic spontaneous or idio-
pathic or ordinary urticaria. Studies that were conductedwith only
terfenadine or astemizole were excluded because the medications
had already been withdrawn for safety reasons. Further details can
be found in Characteristics of excluded studies.
Ongoing studies and studies awaiting assessment
We identified 14 ongoing studies through our searches of clinical
trials databases. Further detailsmay be found in theCharacteristics
of ongoing studies tables. Data from these studies if available will
be included in future updates of the review.
We identified 16 studies awaiting assessment, because we were
unable to obtain full-text copies at the time of writing of this
review. Further details are available in the tables of Characteristics
of studies awaiting classification.
Risk of bias in included studies
In this review, we included ’Risk of bias’ assessments. Please see
Figure 2, which shows our judgements about each ’Risk of bias’
item expressed as percentages of included studies in each category
of risk, and Figure 3, which shows the judgement for each domain
by study. When ’Risk of bias’ information was missing from the
trial report, we contacted the principal investigators of studies
published from 2001 onwards to ask for missing information.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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For studies with items judged as ’unclear,’ we requested clarifica-
tion from trial investigators, but no further information was forth-
coming at the time that this review was prepared. No study pro-
vided complete clarity on every item in our ’Risk of bias’ assess-
ment, indicating widespread suboptimal reporting of methodol-
ogy or results. Of the 73 included studies, 37 (50%) had at least
one domain that we rated as at high risk of bias.
Allocation
The randomisation process and concealment of allocation are the
most important and sensitive indicators that bias has been min-
imised in clinical trials. In one of the included studies (Garavaglia
1995), we assessed risk of bias as high, as the report of the
study stated that the participant group was “randomly divided (by
triplets) into three groups,” using a preestablished randomisation
list. As participants who dropped out were replaced with new par-
ticipants, it is unclear whether the trial design is truly randomised,
and whether new participants were randomly assigned de novo or
were assigned to the group of the most recent dropout. We were
unable to obtain further information from trial investigators to
clarify this. Among all 73 included studies, only 12 (Brostoff 1996;
Dakhale 2014; Di Lorenzo 2004; Gimenez-Arnau 2007; Handa
2004; Kint 1989; Monroe 2003; Ortonne 2007; Pons-Guiraud
2006; Ring 2001; Weller 2013; Zuberbier 2010) clearly described
adequate randomisation methods. For the rest, themethod of ran-
domisation was not described or was unclear, and either we were
unable to obtain further information or the trial was published
before 2001 and we did not attempt to do so.
Five studies demonstrated adequate concealment of allocation us-
ing codes sealedwithin envelopes (Dakhale 2014; Gimenez-Arnau
2007; Handa 2004; Monroe 2003; Pons-Guiraud 2006). We as-
sessed five of the studies to be at high risk of bias, as no attempt to
conceal allocation was made (Anuradha 2010; Goh 1991;Makino
2012;Wu2008; Yin 2003b). (Of these, Anuradha 2010;Wu2008
and Yin 2003b were explicitly open-label trials).
Blinding
Eight studies (Anuradha 2010; Kalivas 1990; Locci 1991;Makino
2012; Sener 1999; Wang 2012; Wu 2008; Yin 2003b) did not
blind participants or personnel to the intervention being studied
so were classed at high risk of bias. Twenty-two studies (Dakhale
2014; Degonda 2002; Di Lorenzo 2004; Garavaglia 1995;
Gimenez-Arnau 2007; Go 1989; Goh 1991;Handa 2004; Kaplan
2005; Kint 1989; Monroe 1992; Monroe 2003; NCT00536380;
Nettis 2004; Nettis 2006; Ortonne 2007; Phanuphak 1987;
Pons-Guiraud 2006; Ring 2001; Staevska 2014; Weller 2013;
Zuberbier 2010) adequately blinded participants and personnel
to the intervention so were judged at low risk of bias. In the re-
maining 45, it was unclear whether blinding was adequate. In Goh
1991, participants appear to have been adequately blinded as to
the identity of the medication studied.
Only 14 of the included trials demonstrated adequate blinding of
outcome assessment (Dakhale 2014; Degonda 2002; Di Lorenzo
2004; Gimenez-Arnau 2007; Handa 2004; Kaplan 2005;Monroe
1992; Monroe 2003; Nelson 2000; Nettis 2004; Nettis 2006;
Pons-Guiraud 2006; Staevska 2014; Weller 2013); eight studies
did not attempt this andwere judged at high risk of bias (Anuradha
2010; Kalivas 1990; Locci 1991;Makino 2012; Sener 1999;Wang
2012; Wu 2008; Yin 2003b). For the remaining 51 studies, we
rated risk of bias due to blinding of outcome assessment as unclear.
Incomplete outcome data
Some study investigators analysed their study data to show that
the numbers of participants who dropped out or were withdrawn
were not significantly different from the numbers analysed, but
this did not mean that bias was absent, as there may have been
imbalance between groups, or the reasons for dropout might have
differed between groups (e.g. adverse events, lack of efficacy).
The high rate of attrition in the included trials was a problem and
a potential source of bias. In 20 trials, the distribution or high
number of dropouts or losses to follow-up could have introduced
bias (Beck 1985; Belaich 1990; Breneman 1995; Brostoff 1996;
Commens 1978;Di Lorenzo 2004;Garavaglia 1995;Godse 2007;
Goh 1991; Guo 2003; Harvey 1981; Kalivas 1990; Leynadier
2000; Marks 1980; Monroe 1988; Monroe 2003; Nelson 2000;
Salo 1989; Thompson 2000 Study 2; Wu 2008); we rated these
as at high risk).
A high level of dropout was a feature of seven of the included
studies. In Brostoff 1996 51% of participants failed to complete
the study, and Breneman 1995 had 27.3% dropouts; in Commens
1978 24% dropped out. In the four-arm study of Di Lorenzo
2004, 38.8% of participants overall dropped out after randomi-
sation with high losses to follow-up, particularly in the placebo
group (88%) and the montelukast group (68%). Garavaglia 1995
experienced high levels of dropout and recruited additional partic-
ipants into the trial in an attempt to compensate. InMonroe 2003
19% dropped out of the desloratadine group and 31% from the
placebo group. A total of 34% dropped out from the Salo 1989
study.
Eighteen studies were rated as having low risk of attrition bias
(Anuradha 2010; Breneman 1996; Degonda 2002; Dubertret
1999; Grant 1988; Juhlin 1987; Kint 1989; Liu H-N 1990;
NCT00536380; Nettis 2004; Nettis 2006; Ollert 1999; Ortonne
2007; Patel 1997; Paul 1998; Peyri 1991; Phanuphak 1987;Wang
2012). In many trials, attrition data were poorly reported or were
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absent; despite our attempts to request further information from
trial investigators, we judged the remaining 35 as having unclear
risk of bias.
Selective reporting
We judged that 24 studies were at low risk of bias (Alomar
1990a; Anuradha 2010; Belaich 1990; Breneman 1995; Brostoff
1996; Dakhale 2014; Dubertret 2007; Gimenez-Arnau 2007;
Go 1989; Guo 2003; Hao 2003; Kalivas 1990; Makino 2012;
NCT00536380; Nettis 2004; Nettis 2006; Ortonne 2007; Patel
1997; Phanuphak 1987; Pons-Guiraud 2006; Ring 2001; Staevska
2014; Weller 2013; Zuberbier 2010).
We judged that 20 studies could have introduced an element of
bias through selective outcome reporting (Beck 1985; Breneman
1996; Bronsky 2001; Commens 1978; Finn 1999; Gale 1989;
Garavaglia 1995; Godse 2007; Goh 1991; Grant 1988; Harvey
1981; Hjorth 1988; Juhlin 1987; Juhlin 1991; Kaplan 2005; Kint
1989; LiuH-N1990;Monroe 1988; Salo 1989;Wu2008). Specif-
ically, in Beck 1985 and in Breneman 1996, outcomes were re-
ported only in graph form or by percentage and statistical differ-
ence (with no participant numbers stated). Similarly, in Commens
1978, Gale 1989 and Godse 2007, the results for numbers of par-
ticipants in each group were not reported-only mean scores with
standard deviations. In Grant 1988 and Hjorth 1988, results were
presented in graph form only. In Monroe 1988 only percentages
and P values were given, and the origin of the P values was not
stated. Salo 1989 provided only mean scores, and investigators of-
fered a subjective judgement as to the best treatment. In Bronsky
2001 scores were given on different days; Harvey 1981 did not re-
port adverse event results; and in Finn 1999 the analysis included
results only for participants with baseline and at least one post-
baseline mean pruritus score, thus a true intention-to-treat anal-
ysis was not provided. Juhlin 1987 states that both physician and
participant self-assessments were carried out, but the study report
provides only participant perceptions with no objective data. In
Juhlin 1991, extensive laboratory tests were carried out (for ad-
verse events) but were not reported. Kaplan 2005 combinedDLQI
score results from two weeks and four weeks and did not provide
separate scores for each time point; as we were unable to obtain
the disaggregated data, we could not use these conflated interim
and endpoint outcome results. Kint 1989 did not report results
clearly, and as rescue medication was permitted, we could not be
sure that any benefits were due to the study medications. We were
unable to determine the duration of follow-up in Liu H-N 1990,
and it was unclear whether concomitant medications were per-
mitted, or whether study participants were compliant. Garavaglia
1995 reported no results for the placebo arm.
For the remaining 29 studies, informationwas insufficient to allow
a judgement to be reached; we rated these as having unclear risk
of bias for this domain.
Other potential sources of bias
Weassessedwhether each study appeared to be free of other sources
of bias that could put it at high risk of bias (e.g. potential conflicts
of interest, pharmaceutical funding or support).We judged studies
as having unclear risk when the extent to which other factors
may have introduced bias could not be determined. Of the 73
included studies, most reports were unclear in terms of other bias
(Figure 2). This was the result of insufficient information to assess
whether risk of bias existed in some studies (Bronsky 2001; Hoxha
2011; Marks 1980; Monroe 1988; Ortonne 2004; Sener 1999;
Staevska 2014), or it reflected baseline imbalance between groups
(e.g. Breneman 1995; Finn 1999). In the remaining studies judged
as unclear, potential bias may have been present in the form of
industry sponsorship and funding.
A total of 19 studies for which no funding or sponsorship was
declared were assessed as having low risk of bias, as we detected no
other bias.
Effects of interventions
See: Summary of findings for the main comparison Cetirizine
10 to 20 mg versus placebo for chronic spontaneous urticaria;
Summary of findings 2 Desloratadine 5 to 20 mg versus
placebo for chronic spontaneous urticaria; Summary of findings
3Levocetirizine 5 to 20mg versus placebo for chronic spontaneous
urticaria; Summary of findings 4 Rupatadine 10 to 20 mg versus
placebo for chronic spontaneous urticaria; Summary of findings
5 Loratadine 10 mg versus placebo for chronic spontaneous
urticaria; Summary of findings 6 Loratadine 10 mg versus
cetirizine 10 mg for chronic spontaneous urticaria; Summary of
findings 7Loratadine 10mg versus desloratadine 5mg for chronic
spontaneous urticaria; Summary of findings 8 Loratadine 10
mg versus mizolastine 10 mg for chronic spontaneous urticaria;
Summary of findings 9 Loratadine 10 mg versus emedastine
2 mg for chronic spontaneous urticaria; Summary of findings
10 Loratadine 10 mg versus hydroxyzine 25 mg for chronic
spontaneous urticaria; Summary of findings 11 Cetirizine 10
mg versus hydroxyzine 25 mg for chronic spontaneous urticaria;
Summary of findings 12 Hydroxyzine 25 mg versus placebo for
chronic spontaneous urticaria
We have indicated in this section when our 23 comparisons of
interventions addressed our prespecified outcomes (for details of
outcomes, please see Types of outcome measures).
Numbers given show the total numbers of participants included
in the analysis. When it was possible to calculate an effect size,
we reported this with the 95% confidence interval. When the
calculated effect size was statistically significant (P value < 0.05),
we stated whether the result favoured the intervention group or
the control condition. In the text below, an I² statistical value for
heterogeneity is reported as high if it exceeds 50%.
We have summarised the results of included studies that could
not be combined in meta-analyses because of differences between
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studies in terms of design. We present the results of studies that
could not be pooled in meta-analyses using data and information
derived from the reports of individual studies (along with P values
when applicable).
Comparison 1
Loratadine 10 mg versus placebo
Two studies that compared these interventions were identified (
Belaich 1990; Monroe 1992). Both studies reported short-term
and intermediate-term interventions that favoured loratadine.
Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
Short-term duration of intervention
In this subgroup we found only one relevant trial (Monroe 1992)
(n = 12, risk ratio (RR) 3.0, 95% confidence interval (CI) 0.42 to
21.3; Analysis 1.1) (no statistically significant difference).
Intermediate-term duration of intervention
In this subgroup we found only one relevant trial (Belaich 1990)
(n = 112, RR 1.73, 95% CI 0.81 to 3.72) (no statistically signif-
icant difference). The study report states that 22/60 (loratadine)
and 5/52 (placebo) participants experienced complete cessation
of urticaria following an intermediate-term duration of the inter-
vention and that loratadine was significantly more effective than
placebo (P value < 0.01).
Our meta-analysis of Monroe 1992 and Belaich 1990, combining
data from short- and intermediate-term durations of intervention
(n = 124), found that loratadine may increase the chance that a
participant will experience a good response, expressed as RR of
1.86 (95% CI 0.91 to 3.79; P value 0.09; I² = 0%; Analysis 1.1),
but this difference was not statistically significant.
Comparison 2
Loratadine 10 mg versus cetirizine 10 mg
Two studies that compared these interventions were identified (
Patel 1997; Yin 2003b) (n = 103). The individual studies reported
similar proportions of participants with complete suppression of
urticaria.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
Short-term duration of intervention
In this subgroup we found only one relevant trial (Patel 1997). No
statistically significant difference between groups was noted (RR
1.13, 95% CI 0.64 to 2.01; participants = 37; I2 = 0%); Analysis
2.1).
Intermediate-term duration of intervention
In this subgroup we found only one relevant trial (Yin 2003b). No
statistically significant difference between groups was noted (RR
1.01, 95% CI 0.69 to 1.47; participants = 66; I2 = 0%; Analysis
2.1).
Overall, combining data from both studies (RR 1.05, 95% CI
0.76 to 1.43; n = 103; I2 = 0%); Analysis 2.1) yielded no evidence
of a difference in rates of complete cessation of urticaria. Data
from Yin 2003b showed that an additional proportion of partic-
ipants experienced at least a good response following treatment
with either drug (10/32 in the loratadine arm and 11/34 in the
cetirizine arm).
Comparison 3
Loratadine 10 mg versus desloratadine 5 mg
Three studies that compared these interventions were identified (
Gu2002;Hao2003;Zou 2002). Zou 2002 reportedno significant
differences in efficacy between desloratadine 5 mg once daily for
four weeks and loratadine 10 mg once daily for four weeks.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
Intermediate-term duration of intervention
Individual studies reported similar proportions of participants
with complete suppression of urticaria. Comparing loratadine
with desloratadine (Gu 2002; Hao 2003) revealed no significant
differences between loratadine 10 mg and desloratadine 5 mg for
complete suppression of disease (RR 0.91, 95% CI 0.78 to 1.06;
P value 0.22; I² = 0%; Analysis 3.1).
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Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
Intermediate-term duration of intervention
In this subgroup we found three relevant trials (Guo 2003; Hao
2003; Zou 2002) (n = 410). Individual studies reported similar
proportions of participants with at least good response to treat-
ment. No significant differences between loratadine 10 mg and
desloratadine 5 mg were noted (RR 1.04, 95% CI 0.64 to 1.71;
Analysis 3.2), and moderate heterogeneity was exhibited (I² =
40%; P value 0.191).
Primary outcome 3: proportion of participants with 50% or
greater improvement in quality of life measurements whilst
taking H1-antihistamines
Hao 2003 reported that at four weeks, 16/106 (loratadine) and 9/
105 (desloratadine) participants described at least 50% improve-
ment in quality of life (QoL) (P value 0.25).
Secondary outcome 2: minor participant-reported adverse
events not requiring withdrawal of treatment
All three studies (Guo 2003; Hao 2003; Zou 2002) individually
concluded that desloratadine was a safe and effective treatment for
CSU. However, we were unable to pool data on adverse events in
a meta-analysis. Desloratadine was found to be at least as effective
as loratadine in each individual study but was not compared with
placebo. Therefore it may be the case that desloratadine is as ef-
fective as loratadine, but this is assumed through speculative non-
superiority to loratadine.
We were unable to combine adverse effect data in a meta-anal-
ysis because the study reports are unclear about the number of
participants presenting with adverse effects in each group at each
time point. Zou 2002 reported that in the desloratadine group,
four participants had side effects: one severe headache, one dry
mouth and two sleepiness. In the loratadine group, one partici-
pant had dry mouth and three experienced sleepiness. Hao 2003
reported that adverse effect rates of desloratadine and loratadine
were 11.32% and 13.21%, respectively. The main side effects in-
cluded dry mouth, dizziness and headache. Gu 2002 reported that
no serious adverse effects were recorded for the duration of the
study.
Comparison 4
Loratadine 10 mg versus mizolastine 10 mg
Four studies that compared these interventions were identified
(Guo 2003; Leynadier 2000; Liu 2003; Yin 2003b).
The authors of Guo 2003 reported that scores for pruritus and
weal number, size and persistence in the mizolastine group were
much lower than those in the loratadine group (P value < 0.05).
They concluded thatmizolastine could be considered the preferred
treatment for CSU (Guo 2003).
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
Intermediate-term duration of intervention
In this subgroup we found three relevant trials (Guo 2003; Liu
2003; Yin2003b) (n=316). These studies reported similar propor-
tions of participantswith complete suppression of urticaria, andno
significant difference between loratadine 10 mg and mizolastine
10 mg was noted (RR 0.86, 95% CI 0.64 to 1.16; Analysis 4.1);
heterogeneity was substantial (I² = 55%; P value 0.11; Analysis
4.1).
Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
These three studies also reported the proportions of participants
experiencing at least a good response to treatment. In comparing
loratadine with mizolastine, we found no significant differences
between loratadine 10 mg and mizolastine 10 mg (RR 0.88, 95%
CI 0.55 to 1.42; Analysis 4.2; P value 0.78; I² = 0%).
Primary outcome 3: proportion of participants with 50% or
greater improvement in quality of life measurements whilst
taking H1-antihistamines
Intermediate-term duration of intervention
In this subgroup we found two relevant trials (Guo 2003; Liu
2003) (n = 252). These studies reported the proportions of par-
ticipants who experienced improvement in QoL of at least 50%.
This amounted to 26/125 and 13/127 (loratadine and mizolas-
tine, respectively). No significant difference between loratadine
10 mg and mizolastine 10 mg was reported in either study; when
data were pooled (RR 3.21, 95% CI 0.32 to 32.33; Analysis 4.3),
important levels of heterogeneity were noted (Chi² = 2.86; df = 1;
P value 0.091; I² = 65%).
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Secondary outcome 1: serious adverse events (i.e. serious
enough to require withdrawal of treatment)
Liu 2003 reported that the incidences of adverse events for mi-
zolastine and loratadine were 28.6% and 25.5%, respectively; no
statistically significant differences between the two groups were
noted (Chi2 = 0.25; P value 0.62).
Leynadier 2000 reported minor adverse events requiring with-
drawal: in the mizolastine group, fatigue (n = 2) and drowsiness
(n = 1); in the loratadine group, drowsiness (n = 1), dizziness (n =
1) and rhinitis (n = 1).
Guo 2003 reported that data on one participant were excluded
from the analysis, but it is unclear whether this occurred because
of withdrawal due to adverse effects. No clear data about adverse
effects were presented, although study authors noted that no dif-
ferences between the two groups were noted. Adverse effects in-
cluded dry mouth, sleepiness and lethargy, but the numbers in
each group experiencing these effects were not stated.
Intermediate-term duration of intervention
Two studies (Leynadier 2000; Liu 2003) reported the numbers of
participants who experienced an adverse event that led to with-
drawal: One participant in the mizolastine group in Liu 2003 had
severe diarrhoea, and one in Leynadier 2000 had painful erythema
of the hands. In comparing loratadine with mizolastine in 267
participants, we found no significant differences between lorata-
dine 10 mg and mizolastine 10 mg (RR 0.38, 95% CI 0.04 to 3.6;
P value 0.40; I² value 0%; Analysis 4.4) in terms of the numbers
of participants withdrawing because of an adverse event.
Comparison 5
Loratadine 10 mg versus emedastine 2 mg
We report the results of our analysis of a single study for this
comparison (Pons-Guiraud 2006).
The study report states that the key finding was that no significant
differences between treatments at four weeks were noted by inves-
tigators or participants. Mean symptom scores improved signifi-
cantly frombaseline in both groups. The study authors state: “Also
the proportion of patients with no symptoms at the end of treat-
ment was similar (emedastine 52.4% versus loratadine 54.5% P =
0.41) and so was the proportion of patients with mild symptoms
(total score ≤ 8) (emedastine 92.9% versus loratadine 96.1% P
= 0.37)”; they also comment: “After 28 days of treatment mean
symptom scores recorded in patients improved significantly versus
baseline both with emedastine and loratadine (both P < 0.00005, t
test for paired samples). No significant difference between groups
was found (P = 0.48 for intensity of erythema, P = 0.30 for number
of hives, P = 0.39 for size of the largest hive, P = 0.45 for the extent
of the skin area involved and P = 0.19 for the overall assessment
of urticaria symptoms).”
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
Intermediate-term duration of intervention
Among 161 participants after four weeks of therapy in Pons-
Guiraud 2006, no difference between loratadine 10 mg and
emedastine 2mgwas noted for complete cessation of urticaria (RR
1.04, 95% CI 0.78 to 1.39; Analysis 5.1).
Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
Intermediate-term duration of intervention
Among 160 participants after four weeks of therapy in Pons-
Guiraud 2006, no difference between loratadine 10 mg and
emedastine 2 mg was noted for good or excellent response (RR
1.09, 95% CI 0.96 to 1.24; Analysis 5.2).
Secondary outcome 1: serious adverse events (i.e. serious
enough to require withdrawal of treatment)
Intermediate-term duration of intervention
In an analysis of 161 participants in total, one participant in
each group withdrew because of adverse effects. The study report
states: “Two patients were withdrawn because of serious adverse
events: a suicide attempt not related to study treatment (lorata-
dine) and a bilateral fracture of the calcaneum following a fall,
which led to hospitalisation, in the emedastine group. Although
the patient who fell was taking a number of medicinal products
besides emedastine (paracetamol, hydroxyzine, enoxaparin, keto-
profen and omeprazole), the causal relationship with emedastine
was not ruled out and considered possible.”
In our analysis, no statistically significant differences between
groups were noted (RR 1.09, 95%CI 0.07 to 17.14; Analysis 5.3).
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Comparison 6
Loratadine 10 mg versus hydroxyzine 25 mg
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
Short-term duration of intervention
One study that compared these interventions was identified
(Monroe 1992). The number of participants who experienced
marked or complete relief of symptoms was 3/6 with loratadine
and3/6with hydroxyzine (RR1.00, 95%CI0.32 to 3.10; Analysis
6.1).
This study reported that total symptoms score value decreased by
43% in the loratadine group andby 47% in the hydroxyzine group,
although actual mean scores for each group were not reported.
Secondary outcome 2: minor participant-reported adverse
events not requiring withdrawal of treatment
Overall in Monroe 1992, eight of 20 participants in the hydrox-
yzine group and one of 20 in the loratadine group (some with der-
matitis rather than CSU) reported sedation, a minor adverse event
that did not require withdrawal of the drug; the study report states
that differences between groups were significant (P value 0.02).
Comparison 7
Cetirizine 10 mg versus placebo
Four studies that compared these interventions were identified
(Breneman 1995; Breneman 1996; Go 1989; Kalivas 1990).
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
Short-term duration of intervention
In this subgroup we found only one relevant trial (Go 1989) (n =
56). A statistically significant difference between cetirizine 10 mg
to 20 mg and placebo was reported (RR 2.80, 95% CI 1.17 to
6.73; Analysis 7.1).
Intermediate-term duration of intervention
In this subgroupwe foundonly one relevant trial (Breneman 1995)
(n = 122). A statistically significant difference between cetirizine
10 mg to 20 mg and placebo was reported (RR 2.66, 95% CI 1.2
to 5.9; Analysis 7.1).
Meta-analysis
Combining the results of two studies across short-term and Inter-
mediate-term durations of intervention revealed that 32/88 and
12/90 participants experienced complete cessation of urticaria fol-
lowing treatment (cetirizine and placebo, respectively) (RR 2.72,
95% CI 1.51 to 4.91; P value < 0.001; I² = 0%; Analysis 7.1).
Thus, strong evidence showed that cetirizine increased the chance
of complete cessation of disease.
Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
One study (Breneman 1995) reported that at least a good response
following treatment was seen in 45/60 and 29/62 participants
(cetirizine and placebo, respectively) (P value 0.001).
Secondary outcome 1: serious adverse events (i.e. serious
enough to require withdrawal of treatment)
Intermediate-term duration of intervention
In this subgroup we found two relevant trials (Breneman 1995;
Breneman 1996) (n = 247). No significant differences between
cetirizine 10 mg to 20 mg and placebo were reported (RR 4.6,
95% CI 0.79 to 26.67; Analysis 7.2).
Intermediate-term duration of intervention
In this subgroup we found only one relevant trial (Kalivas 1990) (n
= 142). No significant differences between cetirizine 10 mg to 20
mg and placebo were reported (RR 1.06, 95% CI 0.07 to 16.59;
Analysis 7.2).
Meta-analysis
These three studies (Breneman 1995; Breneman 1996; Kalivas
1990) of 389 participants in total, reported that seven participants
withdrew because of adverse events whilst taking cetirizine, and
two withdrew whilst taking placebo (RR 3.00, 95% CI 0.68 to
13.22; P value 0.15; I² = 0%; Analysis 7.2). This does not consti-
tute adequate evidence to suggest that cetirizine is associated with
increased risk of withdrawal due to an adverse event.
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Comparison 8
Cetirizine 10 mg versus hydroxyzine 25 mg
Efficacy was not reported in a form commensurate with the out-
come measures of our review in either of the two studies that com-
pared these interventions (Breneman 1996; Kalivas 1990).
Secondary outcome 1: serious adverse events (i.e. serious
enough to require withdrawal of treatment)
Intermediate-term duration of intervention (cetirizine 10 mg)
In this subgroupwe foundonly one relevant trial (Breneman 1996)
(n = 123). No significant differences between cetirizine 10 mg and
hydroxyzine 25 mg were noted (RR 1.05, 95% CI 0.27 to 4.01;
Analysis 8.1).
Intermediate-term duration of intervention (cetirizine 5 mg
to 25 mg)
In this subgroup we found only one relevant trial (Kalivas 1990)
(n = 138). No significant differences between cetirizine 10 mg and
hydroxyzine 25 mg were noted (RR 0.33, 95% CI 0.04 to 3.13;
Analysis 8.1).
Meta-analysis
Both studies reported the numbers of participants who withdrew
because of an adverse event. Combining the two (n= 260 partic-
ipants) (RR of withdrawal 0.78, 95% CI 0.25 to 2.45; P value
0.67; I² = 0%; Analysis 8.1) revealed no evidence of a difference.
Comparison 9
Cetirizine 10 mg versus fexofenadine 180 mg
One study that compared these interventions was identified
(Handa 2004). No analysis was possible for this comparison.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
The key finding was that at four weeks, 27/59 participants in the
cetirizine group had complete suppression of urticaria compared
with 2/57 in the fexofenadine group (P value < 0.001). According
to the study authors, partial improvement was seen in a further
19 participants in each group. No improvement was noted among
six participants in the cetirizine group and 24 in the fexofenadine
group.
Secondary outcome 2: minor participant-reported adverse
events not requiring withdrawal of treatment
Minor adverse events noted in the cetirizine group included
drowsiness (four), constipation (three), epigastric pain (two) and
cough (two). In the fexofenadine group, drowsiness was experi-
enced by two participants; headache, swollen feet and abdominal
pain were reported by one participant.
Comparison 10
Cetirizine 10 mg versus levocetirizine 5 mg
One study that compared these interventions was identified (Yin
2003a). No analysis was possible for this comparison.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
This study reported that 16/22 and 19/22 participants had com-
plete suppression of urticaria following treatment with cetirizine
and levocetirizine, respectively, at 28 days (P value 0.309). A fur-
ther two participants had at least a good response to cetirizine
and one to levocetirizine, but without complete clearance. Overall
there was no statistically significant difference in clinical efficacy
between the two groups was noted (P value > 0.05).
Secondary outcome 1: serious adverse events (i.e. serious
enough to require withdrawal of treatment)
Noparticipantswithdrew from this study as the result of an adverse
event.
Comparison 11
Cetirizine 10 mg versus mizolastine 10 mg
One study that compared these interventions was identified (Yin
2003b). No analysis was possible for this comparison.
22H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
This study reported that 21/34 and 20/30 participants had com-
plete suppression of urticaria following treatment with cetirizine
and mizolastine, respectively (P value 0.600). This study also re-
ported that a further 11/34 and 9/30 had a good response to treat-
ment.
Comparison 12
Desloratadine 5 mg to 20 mg versus placebo
Six studies that compared these interventions were identified (Di
Lorenzo 2004;Hoxha 2011;Monroe 2003; Nettis 2004; Ortonne
2007; Ring 2001). Ortonne 2007 did not provide outcome data
on efficacy that could be included in our meta-analyses.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
Two studies (Di Lorenzo 2004; Hoxha 2011) reported on com-
plete suppression of urticaria. A short-term duration of interven-
tion was used in one study (Hoxha 2011), which investigated three
doses compared with placebo and reported that 4/34, 11/34, 21/
34 and 0/36 (desloratadine 5 mg, 10 mg and 20 mg and placebo)
achieved resolution of symptoms. Following an intermediate-term
duration of intervention, one study (Di Lorenzo 2004) reported
complete suppression of urticaria in 18/40 (desloratadine 5 mg)
and 0/40 (placebo) (additional data supplied by investigator); the
report of the study states that the difference between the total
symptom scores for the desloratadine and placebo groups was sta-
tistically significant (P value < 0.001).
These data from Hoxha 2011 suggest an association between
dosage and an increased chance of complete suppression of ur-
ticaria. We did not pool data across all dosages and durations of
intervention (Analysis 9.1), but as no participants allocated to
placebo exhibited suppression of urticaria, Fisher’s exact test was
used to compare the two interventions (53/142 desloratadine and
0/76 placebo), resulting in a 95% CI for the odds ratio (OR) of
between 7.12 and infinity (P value < 0.001),
Additional data obtained from the principal investigator of Di
Lorenzo 2004 revealed that 22/40 in the intervention group and
0/40 in the placebo group experienced an ’excellent’ response (P
value < 0.001).
Primary outcome 3: proportion of participants with 50% or
greater improvement in quality of life measurements whilst
taking H1-antihistamines
The numbers of participants who exhibited improvement in QoL
(Ortonne 2007) were 34/49 and 23/36 in the desloratadine 5 mg
and placebo groups, respectively. The study report states: “Deslo-
ratadine treatment was associated with significantly greater im-
provements from baseline to day 42 compared with placebo in
DLQI overall score (-6 versus -2.2 points; P < 0.002) and VQ-
Dermato score (18.5 versus 29.1 points; P = 0.009).”
Secondary outcome 1: serious adverse events (i.e. serious
enough to require withdrawal of treatment)
Intermediate-term duration of 5 mg of intervention
In this subgroup we found three relevant trials (n = 466).
Three studies (Monroe 2003; Nettis 2004; Ring 2001) of 466 par-
ticipants, reported similar numbers of participants who withdrew
as the result of adverse events, totalling 6/236 and 4/230 (deslo-
ratadine 5 mg and placebo, respectively). No significant difference
between desloratadine 5 mg and placebo were noted (RR 1.46,
95% CI 0.42 to 5.1; Analysis 9.2).
Differences between the three studies were examined: Monroe
2003 excluded participants with previous lack of response to an-
tihistamines, but this exclusion criterion was not stated in the re-
ports of Nettis 2004 and Ring 2001.
Comparison 13
Hydroxyzine 25 mg versus placebo
Three studies that compared these interventions were identified
(Breneman 1996; Kalivas 1990; Monroe 1992). Efficacy was not
reported in Breneman 1995 or Kalivas 1990 in a form commen-
surate with the outcome measures of our review.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
Short-term duration of intervention
One study (Monroe 1992) stated that 3/6 and 1/6 participants
exhibited at least a good response (marked or complete relief of
symptoms) following treatment (hydroxyzine and placebo, respec-
tively). After a reanalysis using Fisher’s exact test because of the
small number of participants, no difference between interventions
was reported (P value 0.27).
The study report stated that for this outcome, differences between
the placebo group and the two treated groups (hydroxyzine and
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loratadine) were statistically significant (P value < 0.05). The small
number of included participants limits firm conclusions that can
be drawn from this outcome.
Secondary outcome 1: serious adverse events (i.e. serious
enough to require withdrawal of treatment)
Intermediate-term duration of intervention
In a meta-analysis of Breneman 1996 and Kalivas 1990 (n = 270),
the pooled RR was 3.64 (95% CI 0.77 to 17.23; P value 0.10;
I² = 0%; Analysis 10.1). Therefore little evidence of differences
between interventions was found.
Comparison 14
Levocetirizine 5 mg to 20 mg versus placebo
Two studies that compared these interventions were identified (
Hoxha 2011; Nettis 2006).
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
Following a short-term duration of intervention, Hoxha 2011 re-
ported complete suppression of urticaria as 9/37, 17/37, 30/37
and 0/37 (levocetirizine 5 mg, 10 mg, 20 mg and placebo). In one
intermediate-term duration of intervention study (Nettis 2006),
complete suppression was noted in 27/51 and 0/51 participants
(levocetirizine 5 mg and placebo). No participants in the placebo
arm achieved complete suppression of urticaria (Analysis 11.1).
Analysis of the total counts was carried out with Fisher’s exact test;
the 95% CI for the OR was between 11.12 and infinity (P value <
0.001), suggesting that use of levocetirizine at least 5 mg increased
the chance of complete suppression of CSU.
Secondary outcome 1: serious adverse events (i.e. serious
enough to require withdrawal of treatment)
No withdrawals due to adverse events were seen in either arm fol-
lowing treatment (0/51 and 0/49, levocetirizine 5mg and placebo;
Nettis 2006). No serious adverse events were noted with levoceti-
rizine (at any dose) in the study by Hoxha 2011.
No data are available on the adverse events that followed when
a higher than standard dosage (10 mg and 20 mg per day) of
levocetirizine was prescribed.
Comparison 15
Rupatadine 10 mg to 20 mg versus placebo
Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
Intermediate-term duration of intervention (rupatadine 10
mg)
In this subgroup we found only one relevant trial (Gimenez-Arnau
2007) (n = 122). No significant difference between rupatadine 10
mg and placebo was reported (RR 1.28, 95% CI 0.86 to 1.91;
Analysis 12.1).
Intermediate-term duration of intervention (rupatadine 20
mg)
In this subgroup we found only one relevant trial (Gimenez-Arnau
2007) (n = 123). No significant difference between rupatadine 20
mg and placebo was reported (RR 1.42, 95% CI 0.98 to 2.06;
Analysis 12.1).
Meta-analysis
The pooled RR between rupatadine (at both doses) and placebo
in 245 participants was 1.35 (95% CI 1.03 to 1.77; P value 0.03;
I² = 0%; Analysis 12.1); thus rupatadine increased the chance of
a good response, but little evidence was found to indicate that 10
mg is more effective than 20 mg.
Comparison 16
Desloratadine 5 mg to 20 mg versus levocetirizine 5 mg to
20 mg
Two studies that compared these interventions were identified (
Hoxha 2011; Potter 2009). No meta-analysis was possible for this
comparison.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
InHoxha 2011, a three-arm study, 107participantswere randomly
assigned to double-blind treatment with levocetirizine, deslorata-
dine or placebo (37/34/36). Treatment started at a dose of 5 mg
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and then was increased weekly to 10 mg and 20 mg. The numbers
of participants who exhibited complete suppression of urticaria
following a week at each dose were as follows: 9/37, 17/37 and
30/37 (levocetirizine 5 mg, 10 mg and 20 mg) and 4/34, 11/34
and 21/34 (desloratadine 5 mg, 10 mg and 20 mg).
Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
A total of 294/438 and 256/448 participants in Potter 2009 exhib-
ited at least a good response following treatmentwith levocetirizine
5 mg and desloratadine 5 mg. The report of the study states that
levocetirizine “Decreased pruritus duration and the mean CSU
composite scores to a significantly greater extent than deslorata-
dine during the first week (P=0.002 and 0.005, respectively) and
over the entire study (P=0.009 and P<0.05, respectively).”
Secondary outcome 2: minor participant-reported adverse
events not requiring withdrawal of treatment
No serious adverse effects occurred with desloratadine. The au-
thors of Hoxha 2011 concluded that increasing the dose of either
drug up to four-fold was beneficial without compromising safety,
and that levocetirizine appeared to be more effective than deslo-
ratadine (P value < 0.02).
Comparison 17
Ebastine 10 mg versus placebo
One study that compared these interventions was identified (Peyri
1991).
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
In this study, 38/91 and 22/86 participants (ebastine and placebo,
respectively) exhibited complete suppression of urticaria following
an intermediate-term duration of intervention (Fisher’s exact test
P value 0.13). According to the investigators’ assessment, overall
efficacy was good or moderate in 76/95 participants (80%) treated
with ebastine compared with 52/102 participants (51%) treated
with placebo (P value < 0.001). Study investigators concluded that
ebastine could be an affective alternative to other non-sedating
antihistamines.
Secondary outcome 1: serious adverse events (i.e. serious
enough to require withdrawal of treatment)
A similar number of participants in each group withdrew from
this study because of an adverse event: 2/91 and 3/86 (ebastine
and placebo, respectively; Fisher’s exact test P value 0.68).
Comparison 18
Desloratadine 5 mg versus montelukast 10 mg
One study that compared these interventions was identified (Di
Lorenzo 2004). No analysis was possible for this comparison.
In the desloratadine group, 18/40 achieved complete suppression
of CSU and 22/40 had an excellent response, whilst in the mon-
telukast group, 4/40 achieved remission and 1/40 had an excel-
lent response (P value 0.008 and P value < 0.001). It is interesting
to note that 33/40 in the montelukast group showed no change
with the intervention, and two individuals actually felt worse. Sig-
nificant differences in total symptoms score, pruritus, number of
hives and size of largest hive were noted (P value < 0.001, P value
< 0.001, P value 0.017 and P value 0.003, respectively). Similar
significant difference were noted between groups of desloratadine
plus montelukast versus montelukast alone (P value < 0.001, P
value < 0.001, P value 0.01 and P value 0.003). No difference was
found between the group treated with desloratadine alone and the
group treated with desloratadine plus montelukast.
Secondary outcome 2: minor participant-reported adverse
events not requiring withdrawal of treatment
Adverse events were noted to be of low incidence and mild in
all groups. Withdrawals, reported in large numbers in this study,
appear to have been due to lack of efficacy in the groups not
receiving desloratadine-not to adverse effects.
Comparison 19
Fexofenadine 180 mg versus placebo
One study that compared this intervention was identified (Kaplan
2005). No analysis was possible for this comparison.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
No significant differences in complete suppression were reported
between the interventions: 6/91 and 19/162 (placebo and fexofe-
nadine, respectively; P value 0.272).
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Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
However, a difference was suggested between the proportions of
participants who experienced at least a good response (11/91 and
57/162, placebo and fexofenadine, respectively; P value < 0.001).
This study excluded participants who were previously unrespon-
sive to antihistamines, so this result may not be generalisable.
Secondary outcome 2: minor participant-reported adverse
events not requiring withdrawal of treatment
Whether any participants required treatment withdrawal as the
result of adverse effects was not stated, although one individual in
the fexofenadine group required hospital admission for asthma.
We conclude that this event is not likely to have been related to
the intervention.
Comparison 20
Ketotifen 1 mg versus placebo
One study that compared these interventions was identified
(Phanuphak 1987). No analysis was possible for this comparison.
Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
A total of 12/16 (ketotifen) and 2/14 (placebo) participants re-
ported at least a good response (P value < 0.005). Notably, partici-
pants were permitted to take a different H1-antihistamine, chlor-
pheniramine 4 mg as required up to six-hourly, then were ran-
domly assigned to ketotifen or placebo and were still allowed to
take chlorpheniramine concomitantly. Investigators recorded the
number of chlorpheniramine tablets taken, but this information
was not reported explicitly. Study investigators noted that the re-
quirement for chlorpheniramine dropped in significantly more
participants taking ketotifen than placebo (94% vs 7%). It is still
possible that positive results in the ketotifen group might have
been caused by this alone, or by taking a combination of ketotifen
and chlorpheniramine.
Secondary outcome 2: minor participant-reported adverse
events not requiring withdrawal of treatment
Noparticipants were withdrawn from either treatment as the result
of an adverse event.
Comparison 21
Cetirizine 5 mg and hydroxyzine 25 mg (CH) versus placebo
These interventions were compared in one study on the clinical
efficacy of a leukotriene receptor antagonist (LRA) plus an H1-
antihistamine, an H1-antihistamine plus H2RA, two H1-antihis-
tamines in combination and placebo for treating participants with
CSU (Wan 2009).We compared only the H1-antihistamine com-
bination and placebo arms. No analysis was possible for this com-
parison.
Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
This study reported that 7/30 participants in the CH group and
0/30 in the placebo group experienced at least a good response fol-
lowing treatment after an intermediate-term duration of interven-
tion (P value 0.01). Investigators concluded: “The combination of
LRA and H1 receptor antagonist is promising for CSU treatment
and is reasonably well tolerated by participants. The combination
of H1- and H2-receptor antagonists provided the greatest treat-
ment efficacy by the measures used in this small study.”
Comparison 22
Azelastine 2 mg versus azelastine 4 mg
One study that compared these interventions was identified (Wu
2008). No analysis was possible for this comparison.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
This study reported that 21/34 (2 mg) and 27/33 (4 mg) par-
ticipants experienced complete suppression of CSU following an
intermediate intervention (P value 0.103).
Primary outcome 2: proportion of participants with ’good’
or ’excellent’ response whilst taking H1-antihistamines
A further 6/34 (2mg) and 4/33 (4mg) participants exhibited good
or excellent response to treatment over the same period (P value
0.637).
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Comparison 23
Doxepin 10 mg versus pheniramine 22.5 mg
One study that compared these interventions was identified, al-
though participants previously non-responsive to antihistamines
were excluded (Ghosh 1990). No analysis was possible for this
comparison.
Primary outcome 1: proportion of participants with
complete suppression of urticaria whilst taking H1-
antihistamines
Following an intermediate-term duration of intervention, 8/28
and 3/28 participants experienced complete suppression of ur-
ticaria (doxepin and pheniramine, respectively; P value < 0.001).
Within seven days of treatment cessation, symptoms recurred in
three of the participants (37.5%) who had taken doxepin and in
all three who had taken pheniramine (P value 1.00).
Secondary outcome 2: minor participant-reported adverse
events not requiring withdrawal of treatment
Although drowsiness and dry mouth were commonly reported
in both groups (doxepin 37.5% and 64.3%, respectively; pheni-
ramine 60.7% and 46.4%, respectively), no withdrawals from this
study were reported.
Sensitivity and subgroup analyses
Only one comparison consisting of two studies (n = 260) com-
pared hydroxyzine first-generation (’sedating’) and cetirizine sec-
ond-generation (’non-sedating’) antihistamines individually (see
Comparison 8). No difference in adverse effects leading to with-
drawal was reported between these two groups (RR 0.78, 95% CI
0.25 to 2.45; Analysis 8.1).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Desloratadine 5 to 20 mg versus placebo for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: desloratadine 5 to 20 mg versus placebo
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control (placebo) Desloratadine
5 to 20 mg
Complete suppression of
urticaria: short-term du-
ration of intervention
(desloratadine 5 mg)
Global assessment of
symptom scores
See comment See comment Not estimable 46
(1 study)
⊕⊕©©
Lowa,b
Favours neither interven-
tion nor control
Only 1 study, a con-
ference abstract (Hoxha
2011)
Complete suppression of
urticaria: short-term du-
ration of intervention
(desloratadine 10 mg)
Global assessment of
symptom scores
See comment See comment Not estimable 46
(1 study)
⊕⊕©©
Lowa,b
Favours neither interven-
tion nor control
Only 1 study, a con-
ference abstract (Hoxha
2011)
Complete suppression of
urticaria: short-term du-
ration of intervention
(desloratadine 20 mg)
Global assessment of
symptom scores
See comment See comment Not estimable 46
(1 study)
⊕⊕©©
Lowa,b
Favours desloratadine
Only 1 study, a con-
ference abstract (Hoxha
2011)
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Complete suppression of
urticaria: intermediate-
term duration of inter-
vention (desloratadine 5
mg)
Global assessment of
symptom scores
See comment See comment Not estimable 80
(1 study)
⊕⊕©©
Lowa,b
Favours desloratadine
Only 1 study (Di Lorenzo
2004)
Adverse effects leading
to withdrawal: interme-
diate-term duration of 5
mg of intervention
Study population RR 1.46
(0.42 to 5.1)
466
(3 studies)
⊕⊕©©
Lowa,b
Favours neither interven-
tion nor control
17 per 1000 25 per 1000
(7 to 89)
Moderate
18 per 1000 26 per 1000
(8 to 92)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bRelatively few participants and few events and/or wide confidence intervals.
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Levocetirizine 5 to 20 mg versus placebo for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: levocetirizine 5 to 20 mg versus placebo
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control (placebo) Levocetirizine
5 to 20 mg
Complete suppression of
urticaria: short-term du-
ration of intervention (le-
vocetirizine 5 mg)
Global assessment of
symptom scores
See comment See comment Not estimable 49
(1 study)
⊕⊕©©
Lowa,b
Favours neither interven-
tion nor control
Only 1 study, a con-
ference abstract (Hoxha
2011)
Complete suppression of
urticaria: short-term du-
ration of intervention (le-
vocetirizine 10 mg)
Global assessment of
symptom scores
See comment See comment Not estimable 49
(1 study)
⊕⊕©©
Lowa,b
Favours neither interven-
tion nor control
Only 1 study, a con-
ference abstract (Hoxha
2011)
Complete suppression of
urticaria: short-term du-
ration of intervention (le-
vocetirizine 20 mg)
Global assessment of
symptom scores
See comment See comment Not estimable 49
(1 study)
⊕⊕©©
Lowa,b
Favours levocetirizine
Only 1 study, a con-
ference abstract (Hoxha
2011)
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Complete suppression of
urticaria: intermediate-
term duration of inter-
vention (levocetirizine 5
mg)
Global assessment of
symptom scores
See comment See comment Not estimable 100
(1 study)
⊕⊕©©
Lowa,b
Favours levocetirizine
Only 1 study (Nettis
2006)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bRelatively few participants and few events and/or wide confidence intervals.
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Rupatadine 10 to 20 mg versus placebo for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: rupatadine 10 to 20 mg versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control
(placebo)
Rupatadine
10 to 20 mg
Good or excellent re-
sponse
Global assessment of
symptom scores
Study population RR 1.35
(1.03 to 1.77)
245
(1 study)
⊕⊕©©
Lowa,b
Favours rupatadine
509 per 1000 687 per 1000
(524 to 901)
Moderate
509 per 1000 687 per 1000
(524 to 901)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bRelatively few participants and few events and/or wide confidence intervals.
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Loratadine 10 mg versus placebo for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: loratadine 10 mg versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control (placebo) Loratadine
10 mg
Good or excellent re-
sponse
Global assessment of
symptom scores
Study population RR 1.86
(0.91 to 3.79)
124
(2 studies)
⊕⊕©©
Lowa,b
Favours neither interven-
tion nor control
155 per 1000 289 per 1000
(141 to 588)
Moderate
160 per 1000 298 per 1000
(146 to 606)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bRelatively few participants and few events and/or wide confidence intervals.
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Loratadine 10 mg versus cetirizine 10 mg for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: loratadine 10 mg versus cetirizine 10 mg
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control
(cetirizine
10 mg)
Loratadine
10 mg
Complete cessation of
urticaria
Global assessment of
symptom scores
Study population RR 1.05
(0.76 to 1.43)
103
(2 studies)
⊕⊕©©
Lowa,b
Combined short and in-
termediate-term duration
of intervention
Favours neither interven-
tion nor control
588 per 1000 618 per 1000
(447 to 841)
Moderate
574 per 1000 603 per 1000
(436 to 821)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bRelatively few participants and few events and/or wide confidence intervals.3
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Loratadine 10 mg versus desloratadine 5 mg for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: loratadine 10 mg versus desloratadine 5 mg
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control
(desloratadine
5 mg)
Loratadine
10 mg
Complete suppression of
urticaria: intermediate-
term duration of inter-
vention
Study population RR 0.91
(0.78 to 1.06)
369
(2 studies)
⊕⊕©©
Lowa,b
Favours neither interven-
tion nor control
658 per 1000 598 per 1000
(513 to 697)
Moderate
670 per 1000 610 per 1000
(523 to 710)
Good or excellent re-
sponse: intermediate-
term duration of inter-
vention
Global assessment of
symptom scores
Study population RR 1.04
(0.64 to 1.71)
410
(3 studies)
⊕⊕©©
Lowa,b
Favours neither interven-
tion nor control
No participants reported
a good or excellent re-
sponse in the loratadine
group in Zou 2002
We found low levels
of statistical heterogene-
ity in this analysis I2 =
40%)
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263 per 1000 274 per 1000
(169 to 450)
Moderate
228 per 1000 237 per 1000
(146 to 390)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bRelatively few participants and few events and/or wide confidence intervals.
3
6
H
1
-a
n
tih
ista
m
in
e
s
fo
r
c
h
ro
n
ic
sp
o
n
ta
n
e
o
u
s
u
rtic
a
ria
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Loratadine 10 mg compared to mizolastine 10 mg for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: loratadine 10 mg
Comparison: mizolastine 10 mg
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control
(mizolastine
10 mg)
Loratadine
10 mg
Complete cessation of
urticaria: intermediate-
term duration of inter-
vention
Global assessment of
symptom scores
Study population RR 0.86
(0.64 to 1.16)
316
(3 studies)
⊕©©©
Very lowa,b,c
Overall, favours neither
loratadine nor mizolastine
In Guo 2003, more par-
ticipants in mizolastine
group had complete ces-
sation of urticaria than in
the other 2 studies (Liu
2003 and Yin 2003b)
675 per 1000 581 per 1000
(432 to 783)
Moderate
667 per 1000 574 per 1000
(427 to 774)
Good or excellent re-
sponse: intermediate-
term duration of inter-
vention
Global assessment of
symptom scores
Study population RR 0.88
(0.55 to 1.42)
314
(3 studies)
⊕⊕©©
Lowa,c
Favours neither loratadine
nor mizolastine
187 per 1000 165 per 1000
(103 to 266)
Moderate
174 per 1000 153 per 1000
(96 to 247)
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Adverse events leading
to withdrawal: interme-
diate-term duration of
intervention
Study population RR 0.38
(0.04 to 3.6)
267
(2 studies)
⊕⊕©©
Lowa,c
Favours neither loratadine
nor mizolastine
15 per 1000 6 per 1000
(1 to 53)
Moderate
19 per 1000 7 per 1000
(1 to 68)
Proportion of partici-
pants with at least 50%
improvement in QoL:
intermediate-term dura-
tion of intervention
Symptom score reducing
index (SSRI)
Study population RR 3.21
(0.32 to 32.33)
252
(2 studies)
⊕©©©
Very lowa,b,c
Favours neither loratadine
nor mizolastine
No participants in the mi-
zolastine group in Guo
2003 reported at least
50% improvement in QoL
104 per 1000 334 per 1000
(33 to 1000)
Moderate
64 per 1000 205 per 1000
(20 to 1000)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bWidely differing estimates of the treatment effect (i.e. heterogeneity or variability in results) across studies.
cRelatively few participants and few events and/or wide confidence intervals.
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Loratadine 10 mg versus emedastine 2 mg for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: loratadine 10 mg versus emedastine 2 mg
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control
(emedastine 2 mg)
Loratadine
10 mg
Complete cessation of
urticaria: intermediate-
term duration of inter-
vention
Global assessment of
symptom scores
Study population RR 1.04
(0.78 to 1.39)
161
(1 study)
⊕⊕⊕©
Moderatea
Favours neither loratadine
nor emedastine
Only 1 study (Pons-
Guiraud 2006)
524 per 1000 545 per 1000
(409 to 728)
Moderate
524 per 1000 545 per 1000
(409 to 728)
Good or excellent re-
sponse: intermediate-
term duration of inter-
vention
Global assessment of
symptom scores
Study population RR 1.09
(0.96 to 1.24)
160
(1 study)
⊕⊕⊕©
Moderatea
Favours neither loratadine
nor emedastine
Only 1 study (Pons-
Guiraud 2006)
819 per 1000 893 per 1000
(787 to 1000)
Moderate
819 per 1000 893 per 1000
(786 to 1000)
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Adverse events leading
to withdrawal: interme-
diate-term duration of
intervention
Study population RR 1.09
(0.07 to 17.14)
161
(1 study)
⊕⊕⊕©
Moderatea
Favours neither loratadine
nor emedastine
Only 1 study (Pons-
Guiraud 2006)
12 per 1000 13 per 1000
(1 to 204)
Moderate
12 per 1000 13 per 1000
(1 to 206)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aRelatively few participants and few events and/or wide confidence intervals.
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Loratadine 10 mg versus hydroxyzine 25 mg for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: loratadine 10 mg versus hydroxyzine 25 mg
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control
(hydroxyzine
25 mg)
Loratadine
10 mg
Complete suppression of
urticaria: short-term du-
ration of intervention
Global assessment of
symptom scores
Study population RR 1
(0.32 to 3.1)
12
(1 study)
⊕⊕©©
Lowa,b
Favours neither interven-
tion or control
Only 1 study (Monroe
1992)
500 per 1000 500 per 1000
(160 to 1000)
Moderate
500 per 1000 500 per 1000
(160 to 1000)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bRelatively few participants and few events and/or wide confidence intervals.4
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Cetirizine 10 mg versus hydroxyzine 25 mg for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: cetirizine 10 mg versus hydroxyzine 25 mg
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control
(hydroxyzine
25 mg)
Cetirizine
10 mg
Adverse events leading
to withdrawal
Study population RR 0.78
(0.25 to 2.45)
261
(2 studies)
⊕⊕©©
Lowa,b
Favours neither cetirizine
nor hydroxyzine
53 per 1000 41 per 1000
(13 to 130)
Moderate
54 per 1000 42 per 1000
(14 to 132)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bRelatively few participants and few events and/or wide confidence intervals.4
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Hydroxyzine 25 mg versus placebo for chronic spontaneous urticaria
Patient or population: patients with chronic spontaneous urticaria
Setting: research clinic
Intervention: hydroxyzine 25 mg versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control (placebo) Hydroxyzine
25 mg
Adverse events leading
to withdrawal: interme-
diate-term duration of
intervention
Study population RR 3.64
(0.77 to 17.23)
270
(2 studies)
⊕⊕©©
Lowa,b
Favours neither interven-
tion nor control
14 per 1000 53 per 1000
(11 to 250)
Moderate
15 per 1000 55 per 1000
(12 to 258)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDesign limitation (risk of bias).
bRelatively few participants and few events and/or wide confidence intervals.
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D I S C U S S I O N
Summary of main results
This review included 73 randomised studies with 9759 partici-
pants. For inclusion in our review, we would have preferred all
studies to define their inclusion criteria explicitly as individuals
with urticaria for a duration of at least six weeks, with the exclu-
sion of those with inducible urticaria. To avoid excluding multiple
studies that were likely to be relevant, we included studies that
clearly stated the diagnosis under investigation as chronic sponta-
neous (or idiopathic or ordinary) urticaria, with nothing included
in the paper to contradict this.
All studies were carried out in a secondary care setting, which in-
cluded hospitals, research centres and dermatology centres. Par-
ticipants were adults or were 12 years of age or older, and most
were female.
Seventeen studies looked at short-term response to treatment of
up to 2 weeks’ duration, whilst 55 assessed intermediate response
(longer than two weeks to three months). One study did not men-
tion the duration of treatment or follow-up. No study looked at a
long-term response of three months and beyond. Chronic sponta-
neous urticaria (CSU) can persist for years, and it would be useful
for future studies to address whether treatments are effective over
a longer period.
Considerable variation was noted in the interventions and com-
parators used in included studies; this limited the number of anal-
yses that we could carry out. Additionally, pooling of data was
not feasible for most of the treatment options, as the outcomes
reported were not comparable. Of the 23 comparisons we were
able to make, 10 provided outcome data that could be combined
in meta-analyses. Thus most of our findings are based on results
from individual trials.
Evidence suggests that some antihistamines appear to be more
effective than placebo in achieving complete suppression of ur-
ticaria. This is the case for cetirizine 10 mg in the short term and
in the intermediate term. Levocetirizine 20mg over the short term
also appears to be effective for complete suppression of urticaria
(Hoxha 2011); however Hoxha 2011 has been published only as a
conference abstract, and a fuller report or further information was
unavailable at the time of writing of this review. The Nettis 2006
study found levocetirizine 5 mg to be considerably more likely
to lead to complete suppression of urticaria over an intermediate-
term duration than Hoxha 2011 over a short duration. Given that
this information was derived from only two studies, each with
some factors carrying an unclear risk of bias, it may be the case that
levocetirizine is more beneficial when used for a longer duration.
Rupatadine in the study of Gimenez-Arnau 2007 was effective
(good or excellent response) at 10 mg or 20 mg when compared
against placebo. However, no difference was demonstrated be-
tween doses.
Meta-analyses assessing response to treatment with loratadine 10
mg indicate that its efficacy was not significantly different from
that of placebo in the short and intermediate time frame (interven-
tion for up to three months) for the outcome of ’good or excellent
response’ (Belaich 1990; Monroe 1992).
Comparisons of desloratadine versus placebo suggested a possible
relationship between dose, duration and response: Lower doses (5
mg) with a shorter intervention period led to similar results, but
a longer duration of a low dose (5 mg) or a shorter duration of a
higher dose (20mg) led to a higher rate of complete suppression of
urticaria. In Hoxha 2011, different doses of desloratadine 5 mg to
20 mg were compared with doses of levocetirizine 5 mg to 20 mg;
study investigators concluded: “increasing dose up to four-fold in
both active groups was beneficial without compromising safety.
Levocetirizine appeared to be more effective than desloratadine”
(P value < 0.02).
In comparisons of more than one active intervention, no signifi-
cant difference was found between loratadine 10 mg and cetirizine
10 mg at short- or intermediate-term durations in bringing about
complete suppression of urticaria (Patel 1997; Yin 2003b).
Similarly, for loratadine 10 mg versus desloratadine 5 mg for com-
plete suppression of urticaria and for good or excellent response,
no statistically significant difference was noted between groups
over an intermediate term of intervention (Gu 2002; Zou 2002).
For loratadine 10 mg versus mizolastine 10 mg, again with an in-
termediate term of intervention, no statistically significant differ-
ence was noted between groups for complete suppression of ur-
ticaria and for ’good or excellent response’ (Guo 2003; Liu 2003;
Liu H-N 1990; Yin 2003b). Loratadine 10 mg versus emedastine
2 mg (one study; n = 161) showed no statistically significant dif-
ference for complete suppression or good or excellent response, or
for withdrawals due to adverse effects (Pons-Guiraud 2006).
We investigated the frequency with which adverse events led
to withdrawal of treatment. No significant differences were ob-
served in efficacy or adverse events compared with placebo in
the intermediate term for cetirizine (doses from 5 mg to 20 mg)
(Breneman 1995; Breneman 1996; Kalivas 1990), desloratadine
(5 mg) (Monroe 2003; Nettis 2004; Ring 2001) or hydroxyzine
(25 mg) (Breneman 1996; Kalivas 1990).
For withdrawals in comparisons of two active interventions, no
significant differences were noted between loratadine 10 mg and
mizolastine 10 mg (Leynadier 2000; Liu 2003), loratadine 10 mg
and emedastine 2 mg (Pons-Guiraud 2006), cetirizine 10 mg and
hydroxyzine 25 mg (Breneman 1996) and cetirizine 5 mg to 25
mg and hydroxyzine 25 mg (Kalivas 1990).
Quality of life was assessed in one comparison of two trials (Guo
2003; Liu 2003), but no difference was noted between loratadine
10 mg and mizolastine 10 mg in the proportion of participants
with at least 50% improvement in quality of life.
Overall completeness and applicability of
44H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
evidence
The studies that met our criteria for inclusion in this review were
conducted all over the world. We searched exhaustively and iden-
tified studies conducted in many disparate populations, including
those in the USA, Australia, various European countries, South
America, China, Taiwan and India.We also searched for reports on
clinical trials in progress and for data from completed but unpub-
lished clinical trials. Translation of all relevant non-English stud-
ies was conducted, and data were extracted and included. Most
Japanese studies defined CSU as lasting four weeks or longer, and
as this differed from our more generally recognised definition of
CSU as lasting six weeks or longer, they could not be included.
Evidence within this review should be applicable to all populations
in which antihistamines are used for the treatment of CSU.
After discussion and consensus, we excluded studies that com-
pared terfenadine and astemizole unless other comparison trial
arms included interventions. These drugs are no longer in use for
the treatment of urticaria because of safety concerns.
It is interesting to note that eight studies excluded participants
previously unresponsive to antihistamines. The effect of this is that
a subset of those with CSU who were more likely to be refractory
to the intervention were screened out. These may be individuals
with more severe disease. This could have a large effect on ob-
served efficacy of an antihistamine in this trial, although it does
not render in-trial comparisons of different antihistamines com-
pletely invalid.
The durationofCSUvaries among individuals, although themean
duration may be prolonged (three to five years), and a small pro-
portion of people can have CSU for longer than 20 years (Demera
2001; Kaplan 2005). It was disappointing to note that the dura-
tion of interventions used in the studies included in this review
was relatively short (up to six weeks), and longer-term data are not
available.
It would also have been of interest to analyse each study by itch,
weal numbers and angio-oedema separately, as itch is a different
symptom from swellings, even though both are mediated by his-
tamine. Some of the original product licences for classical anti-
histamines were based on itch suppression rather than reduction
in wealing. Itch is often the most troublesome symptom for peo-
ple in terms of impairment of quality of life because of its effect
on sleep and its general propensity to cause distress. In clinical
practice, patients may refer to improvement in itch but not weals
(or the opposite) rather than both, so treatment effects should
ideally be reported separately rather than as an overall assessment
of improvement. Furthermore, physician-rated scales of itch are a
contradiction, as it is only the individual with the symptom who
can rate this. In our review, we were unable to look at itch or
weal numbers separately because not all of the included studies
reported these consistently. and our focus was on urticaria rather
than angio-oedema. We were reluctant to undertake further sub-
group analyses because the likelihood of false-positive significance
tests increases as more subgroup analyses are performed.
Quality of the evidence
The included studies had notablemethodological limitations; only
12 were clearly adequately randomised, and the randomisation
method used in the rest was unclear or at high risk. Only four de-
scribed adequate allocation concealment; in the remaining stud-
ies, this was unclear or was judged to confer high risk of selection
bias. Blinding of participants and personnel was adequate in only
20 studies, and blinding of outcome assessors was adequate in 14.
Twenty studies were at risk of bias from incomplete reporting of
outcome data (attrition bias), and 20 studies were at high risk of se-
lective reporting bias. We detected other sources of bias including
baseline imbalance within groups and potential bias from industry
sponsorship or funding in 55 of the included studies, but the ex-
tent to which these factors may have introduced bias was unclear.
It is therefore important to emphasise that any conclusions that
we have drawn are reliant on primary studies with varying degrees
of bias. Risk of bias should be considered when these results are
interpreted (Figure 2), and findings derived from studies with high
or unclear risk of bias should be viewed with caution.
Although we included a large number of studies, only a few for
each comparison reported outcome data that could be incorpo-
rated in meta-analyses. Several studies included small numbers of
participants. We have drawn limited conclusions from single study
analyses, or we have reported the results of the trial narratively or
we have presented results from small meta-analyses of up to three
studies (e.g. loratadine vs desloratadine, n = 410 from three stud-
ies; loratadine vs mizolastine, n = 204 from three studies).
Some studies showed some statistical heterogeneity, for exam-
ple, for the comparison of loratadine versus desloratadine, and
loratadine versus mizolastine. We give reasons for downgrad-
ing the quality of the body of evidence for each comparison in
the ’Summary of findings’ tables (Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4; Summary of findings 5; Summary
of findings 6; Summary of findings 7; Summary of findings 8;
Summary of findings 9; Summary of findings 10; Summary of
findings 11; Summary of findings 12) (as described in the foot-
notes of each table). Overall, the quality of evidence in each com-
parison was rated as low in most studies or of moderate quality,
meaning that further research is likely to have an important impact
on our confidence in the estimate of effect and may change the
estimate. The current body of evidence does not, therefore, allow
robust conclusions.
Potential biases in the review process
Risk of bias was assessed for all studies. Although we requested
additional details of trial conditions from study investigators, in
many cases we were unable to determine whether randomisation
and allocation concealment methods were adequate. Overall, a
high proportion of the included studies were assessed as having
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unclear or high risk of bias. Most although not all trials published
within the past 10 years provided enough information to enable
full assessment of risk of bias. Many studies were at high risk of
attrition bias as the result of dropouts and losses to follow-up. This
could often be attributed to participants who did not experience
symptomatic relief in the placebo arm of trials.
Of the 73 included studies with 9759 randomly assigned partici-
pants, 31were stated to be sponsored by the pharmaceutical indus-
try, and six through research grants or non-profit organisations. It
is unclear whether sponsorship was a source of bias in these trials.
We attempted to minimise publication bias by seeking out results
of unpublished trials. This review included 73 studies, of which
35 provided outcome data for 23 comparisons. Therefore, even
though we have included a large number of studies, clinical di-
versity and variation in the ways in which results were reported
led to only a few meta-analyses. Whilst every effort was made to
minimise the introduction of bias in this review, clinically diver-
gent interventions led to wide confidence intervals and potentially
imprecise results. Sensitivity analysis was not possible for primary
outcomes measures for studies at low risk of bias, as studies were
too few to permit assessment of the results of the review in this
way.
Although the evidence for cetirizine is somewhat more robust than
for other antihistamines, it should be borne inmind that cetirizine
was effective in suppressing urticaria completely in only some par-
ticipants. Bias may be present here because cetirizine has been on
the market for a long time and more data are available for this
agent in comparison with other drugs.
We were unable to include data from studies of participants with
varying types of urticaria if no disaggregated data specific to the
participants with CSU were available. Although some such stud-
ies may provide valuable information, we excluded them, as any
conclusions that we derived from studies with mixed populations
may not be applicable to populations with CSU.
The clinical heterogeneity that was present in the included studies
in terms of populations, interventions and outcomes contributed
to difficulties in pooling data for analysis. In some cases, smaller
unpublished studies that reported outcomes that fit our inclu-
sion criteria contributed data to several meta-analyses (e.g. Hoxha
2011).
Agreements and disagreements with other
studies or reviews
Kavosh 2011 reviewed second-generation H1-antihistamines and
found that limited data on comparisons of antihistamines led to
the recommendation to use cetirizine in preference to fexofena-
dine. In our review, the main finding from the key study (Handa
2004) was that at four weeks, 27/59 participants in the cetirizine
group had complete suppression of urticaria as compared with 2/
57 in the fexofenadine group (P value < 0.001). However, this re-
sult was derived from only 116 participants and no meta-analysis
was possible, so the finding may not be wholly conclusive.
The findings of this review are broadly in agreement with those of
the Kavosh 2011 review, which recommended use of levocetirizine
in preference to desloratadine. In our review, two studies were
identified that compared these interventions (Hoxha 2011; Potter
2009). In Hoxha 2011, study investigators concluded: “Increasing
dose up to four-fold in both active groups was beneficial without
compromising safety. Levocetirizine appeared to be more effective
than desloratadine” (P value < 0.02). However, this study was pub-
lished only as a conference abstract, and we were unable to obtain
study data from study investigators. Participants in Potter 2009
demonstrated at least good response following treatment with le-
vocetirizine 5 mg and desloratadine 5 mg. Levocetirizine “...de-
creased pruritus duration and the mean CSU composite scores to
a significantly greater extent than desloratadine during the first
week (P=0.002 and 0.005, respectively) and over the entire study
(P=0.009 and P<0.05, respectively).” No meta-analysis was possi-
ble for this comparison.
Other studies have investigated treatment withH1-antihistamines
at higher than recommended licensed doses (e.g. Finn 1999;
Nelson 2000; Weller 2013). In our review, one study compared
different doses of fexofenadine, but the outcomes did not fit our
criteria (Nelson 2000). Furthermore, in this trial, participants pre-
viously unresponsive to antihistamines were excluded.
A review by Church 2012 concluded that three clinical studies
(Hong 2010; Potter 2009; Staevska 2010) suggested that H1-an-
tihistamines, or at least desloratadine and levocetirizine, are effi-
cacious in the treatment of CSU. However, we excluded Hong
2010 and Staevska 2010 from our review, as they included par-
ticipants outside our inclusion criteria. We agree with the authors
of Church 2012 that an independent multi-centre study could
provide valuable information about the relative efficacy of these
interventions. Currently available evidence for use of higher doses
of H1-antihistamines for CSU is limited, and no long-term data
are available for any of the trials.
Guidelines of the British Association of Dermatologists for man-
agement of urticaria (Grattan 2007) suggested that patients should
be offered the choice of at least two non-sedating H1-antihis-
tamines, and that benefits of increasing the dose to above the li-
censed limit may outweigh risks, but we found limited evidence
in our included studies to support this approach.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review has found limited quality evidence to establish the
efficacy of H1-antihistamines compared with placebo in the treat-
ment of CSU. Several antihistamines were found to be superior
to placebo at standard (licensed) doses of treatment. Although the
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quality of evidence for adverse events was low, the direction of
effects in most of the analyses suggest that users generally found
these medicines tolerable.
Symptomatic relief has beendemonstrated to a variable extentwith
different antihistamines. However, only few studies have assessed
their effects on quality of life in urticaria.
On the basis of our data collection and analysis, it is evident that
a clear message does not emerge regarding whether one antihis-
tamine is better than another. Given the quality of trials and of
their reporting, as well as the wide variation in comparisons and
few opportunities to combine results in meta-analyses, we must
be guarded in putting forward specific treatment algorithms.
For general use, cetirizine at 10 mg once daily for short- and in-
termediate-term duration was found to be effective in completely
suppressing urticaria. However, three of the four trials that com-
pared this treatment against placebo did have factors that we rated
as suggesting high risk of bias. The two trials of loratadine 10 mg
once daily versus placebo failed to demonstrate efficacy and were
also at some risk of bias. Only two trials compared these two drugs:
They failed to show a difference in efficacy, although they were
not designed to demonstrate equivalence. Cetirizine and lorata-
dine offer the advantages of being cheap and widely available. It
would be reasonable to regard cetirizine as a first-line option.
Some benefit (for complete suppression of urticaria) may be de-
rived from using desloratadine at 5 mg once daily for at least an
intermediate term of intervention and 20 mg desloratadine in the
short term. Once again, risks of bias in trials of this drug were
significant.
Levocetirizine at 5 mg once daily in the intermediate term appears
to be effective in achieving complete suppression of CSU. This
is based on the results of only three trials. We rated two of these
as carrying an unclear risk of bias in every domain, although the
third, whilst small, was relatively well conducted and reported.
Evidence of benefit from increasing the dose to a ceiling of 20 mg
per day is limited. It is commonpractice to use higher than licensed
doses of various H1-antihistamines, at least in Europe, where the
guidelines recommend this (Zuberbier 2012). We included very
few RCTs that assessed the effects of this and found insufficient
evidence to support the practice, especially over longer durations.
For clarity, the maximum licensed dose for both cetirizine and
loratadine is 10 mg once daily, and for both levocetirizine and
desloratadine, 5 mg once daily.
Although we included trials on various other drugs, their data
are too sparse to allow firm conclusions about their relative ef-
ficacy. Furthermore, very few trials assessed combinations of an-
tihistamines at conventional or higher doses; although such pre-
scribing does occur in clinical practice, we have no basis on which
to make recommendations.
Implications for research
We found little research on the use of higher doses of H1-anti-
histamines, and no included studies continued over longer dura-
tions. Very few assessed whether responses were sustained after the
intervention was stopped; future work should address these gaps.
Study investigators should provide information about the duration
of urticaria for each participant before entry into a trial, as it is
conceivable that urticaria that has persisted for many years may
be more refractory to treatment than urticaria of only six weeks’
duration.
We would welcome trials with two (or more) active treatment
arms rather than a placebo that performed comparisons of differ-
ent doses over longer periods. Although trials including a placebo
yield useful data, particularly for new compounds, participants re-
ceiving placebo may find little benefit from taking part and seem
to be more likely to withdraw or to fail to comply with the medi-
cation schedule. This can lead to very high levels of dropout and
resulting difficulties in interpretation of study results. Trials should
preferably be conducted independently of involvement of phar-
maceutical companies.
Many dermatologists recommend higher, unlicensed doses of H1-
antihistamines in difficult cases of urticaria. Future studies should
address whether this is justified in terms of effectiveness and safety.
In this review, primary outcome scores were variable for several of
the trials, making it difficult for review authors to draw direct com-
parisons. This would be enabled by the use of a standardised out-
come score such as the Urticaria Activity Score. This instrument is
recommended in the European guidelines (Zuberbier 2012) and
comprises the sum of 4-point scales (0-3) for number of weals
and pruritus over a 24-hour period. In several studies, outcome
measures were not clearly defined, and for some measures, it was
not clear how improvements in composite scores really correlated
with symptomatic relief. For example, level of pruritus is likely to
be of far greater importance to an individual with urticaria than
the size of the largest weal.
In terms of reporting of results, we find that it is more meaningful
to the clinician and to the participant if outcomes can be related
to numbers of individuals who achieve a particular response. For
example, five out of 10 of those with CSU will attain complete
symptom relief, and a further three will experience greater than
50% improvement, rather than a particular drug will, on average,
lead to a 3-point reduction in total symptoms score. The latter
approach is often accompanied by a P value < 0.05, but clinical
significance and the spread of responses may be less clear: Was
there some improvement for all participants, or were complete
responses noted for a few and no response for others? We favour
clear outcomes such as number of participants achieving complete
suppression of urticaria, or 75% reduction in itch severity (which
could be equated with a good response).
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Wider use of standardised and validated quality of life (QoL) scores
for trial participants diagnosed with this often disabling condition
would provide measurable data to aid treatment decisions. For
example, QoL scores would help investigators to monitor change
in dosage or drug, or cessation of therapy.
Virtually no long-term studies have looked at treatment and out-
comes over much longer periods of time. Longer-term studies
should be designed, so that the extent of relief from symptoms
from participants’ perspective (symptoms, quality of life) and sa-
fety and efficacy should be included in the design of such stud-
ies. We do recognise that long-term studies may be difficult to
perform for reasons including expense and attrition, with fewer
participants remaining in the study over long periods of time.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alomar 1990a
Methods Design: randomised double-blind 2-arm parallel-group study of cetirizine hydrochloride
vs placebo
Duration: 15 days
Participants Number randomly assigned: 30 participants
Sex: 44% male, 56% female
Age of participants, years: 21 to 64
Unit of allocation: participant
Country and setting: Spain; secondary care, hospital clinic
Inclusion criteria of the trial
• Chronic idiopathic urticaria; none of the participants had been receiving systemic
corticosteroids, and all stopped all medications for at least 48 hours before starting the
study (15 days for other allergy medications)
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• 10 mg/d cetirizine hydrochloride
• Placebo
Duration of intervention: intermediate-term (15 days)
Length of follow-up: 15 days
Outcomes Timing of outcome assessment: baseline and 15 days
Primary outcomes of the trial
• Daily presence of itching and weals, rated on a scale between 0 and 4: 0 = absent,
1 = mild, 2 = moderate, 3 = severe, 4 = very severe. Participants also evaluated response
to treatment using a visual analogue scale 100 mm in length, graduated from 0 (very
poor) to 700 (excellent response)
• Quality of life measures: none
Secondary outcomes of the trial
• Laboratory values including blood electrolytes, cholesterol, triglycerides, kidney
and liver function
• Adverse events: somnolence, epigastric nausea, itching
Clinician or participant report: participant and clinician
Notes In Spanish with English abstract
Investigators concluded that cetirizine was more active than placebo in terms of clinician
reports of efficacy; findings were not statistically significantly different
Risk of bias
Bias Authors’ judgement Support for judgement
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Alomar 1990a (Continued)
Random sequence generation (selection
bias)
Unclear risk Described as random allocation, no details
given
Allocation concealment (selection bias) Unclear risk Not described in published report
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind, details of blind-
ing not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 30 randomly assigned: 15 intervention, 15
control. 13/15 completed intervention, 12/
15 control. 5 from each group experienced
adverse effects, but it is unclear whether
they withdrew from the study. Reasons for
dropout not stated
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk None detected. Funder: not stated
Anuradha 2010
Methods Design: randomised open comparative clinical study of loratadine vs levocetirizine
Duration: 4 weeks
Participants Number randomly assigned: 60 (loratadine n = 30; levocetirizine n = 30)
Sex: 40% male, 60% female; in loratadine group, 43.3% male; in levocetirizine group,
56.7% female
Age of participants, years: 12 to 60 (mean age 33.4 and 34.8 in loratadine and levoceti-
rizine groups, respectively)
Unit of allocation: participant
Country and setting: India; secondary, outpatient
Inclusion criteria of the trial
• Diagnosed with CSU
Exclusion criteria of the trial
• Other forms of urticaria with significant concomitant illness (e.g. malignancies;
hepatic, psychiatric, endocrine or other major systemic diseases); pregnant women,
lactating mothers, females on oral contraceptive pills; individuals taking antihistaminic
therapy for 72 hours or steroids for 1 month
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Loratadine 10 mg/d
• Levocetirizine 5 mg/d
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Anuradha 2010 (Continued)
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: 4 weeks
Primary outcomes of the trial
• Efficacy measures: All participants were evaluated for degree of pruritus, size of
weals, number of weals and number of separate urticarial episodes
• Efficacy measures were scored according to the following scales: pruritus: 0 =
none, 1 = mild, 2 = moderate and 3 = severe; number of weals: 0 (none), 1 (1-10), 2
(11-20) and 3 (> 20); size of weals (mean diameter): 0 (no lesions), 1 (< 1.27 cm), 2 (1.
27-2.54 cm) and 3 (> 2.54 cm); number of separate urticarial episodes: 0 (none), 1 (1),
2 (2-3) and 3 (> 3). Maximum value of total symptoms score (TSS) was 12
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: Safety and tolerability were assessed on the basis of adverse events
reported, or through comparison of baseline symptoms with postdrug symptoms, or
changes in vital signs and physical examination findings recorded before and at the end
of treatment
Clinician or participant report: clinician and participant
Notes Study authors conclude that this safety and efficacy study proves the superiority of
levocetirizine over loratadine for CSU
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear (described as quote from ‘Subjects’
section of report of study as ‘systematic ran-
domisation’)
Allocation concealment (selection bias) High risk Not stated, but trial described as ’open’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding in this open study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding in this open study
Incomplete outcome data (attrition bias)
All outcomes
Low risk 51/60 completed. Six participants did not
report for follow-up (no reasons given), and
3 participants were non-compliant with
treatment
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
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Anuradha 2010 (Continued)
Other bias Low risk None detected. Funder: none (drugs free of
charge from hospital pharmacy)
Beck 1985
Methods Design: randomised double-blind 2-arm parallel-group trial of oxatomide vs clemastine
Duration: 6 weeks
Participants Number randomly assigned: 30 participants (15 in each group)
Sex: 43% (13) male, 57% (17) female
Age of participants, years: between 15 and 67
Unit of allocation: participant
Country and setting: Denmark; setting unclear
Inclusion criteria of the trial
• With chronic urticaria for 3 months or longer
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Oxatomide 30 mg twice daily for 6 weeks
• Clemastine 1 mg twice daily for 6 weeks
Doses could be increased to 4 capsules daily. Cinnarizine 5 mg every 4 hours could be
added if insufficient efficacy in either group
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 6 weeks (duration of study)
Outcomes Timing of outcome assessment: 1, 3 and 6 weeks
Primary outcomes of the trial
• Efficacy (severity of weals, erythema and itching; 24-hour urine samples for
determination of 1,4 MIAA)
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: Any occurring were reported
Clinician or participant report: participants and clinician
Notes Study investigators concluded that the effect of oxatomide was equal to that of clemastine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 50): ”the 30 patients were
randomly assigned to a 6 weeks double-
blind treatment...” Unclear which method
of randomisation was used
Allocation concealment (selection bias) Unclear risk Not stated
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Beck 1985 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 50): “double-blind treatment”
Method used not described, no further in-
formation available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 50): ”double-blind treatment”
Method used not described, no further in-
formation available
Incomplete outcome data (attrition bias)
All outcomes
High risk 0/30 dropped out
Selective reporting (reporting bias) High risk No participant numbers given in results,
only statistical differences (and percentages
for adverse events). No figures given (graph
only)
Severity of weals, erythema and itching
noted but not mentioned in the results. No
figures given, graph only. No further infor-
mation available
Other bias Unclear risk No clear definition of disease given;
washout period not specified; concomitant
treatment permitted
Funder: not stated
Belaich 1990
Methods Design: randomised double-blind 3-arm parallel-group multi-centre study of loratadine
vs terfenadine vs placebo
Duration: 28 days
Participants Number of participants randomly assigned: 187 (61 in loratadine group; 64 in terfena-
dine group; 62 in placebo group)
Sex: 46% male, 53% female. Number of male/female: 32/27 loratadine; 36/24 terfena-
dine; 20/32 placebo
Age of participants, years: average 37
Unit of allocation: participant
Country and setting: France, Belgium, Germany; setting unclear, included private prac-
tice and dermatology clinics
Inclusion criteria of the trial
• Chronic idiopathic urticaria, duration of disease 3 to 4 years
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Loratadine 10 mg once daily
• Terfenadine 60 mg twice daily
• Placebo
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Belaich 1990 (Continued)
Loratadine 10 mg (active drug in the morning and placebo in the evening), 60 mg
terfenadine twice daily or placebo twice daily for 28 days
Duration of intervention: intermediate-term (28 days)
Length of follow-up: 28 days
Outcomes Timing of outcome assessment: participants seen at baseline (day 1), then at days 7, 14
and 28
Primary outcomes of the trial
• Numerical ratings of itching and erythema: 0 = none, 1 = mild, 2 = moderate, 3 =
severe. Count of weals: 0 (none), 1 (1-6), 2 (7-12), 3 (> 12)
• Size of largest weal: 0 (none), 1 (< 1.5 cm), 2 (1.5-2.5 cm), 3 (> 2.5 cm)
• Overall assessment: 0 = none, 1 = mild, 2 = moderate, 3 = severe
• Complete suppression of urticaria
• Proportion with good/excellent response
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events, including sedation, dry mouth
Clinician or participant report: investigator report
Notes Study investigators concluded that loratadine 10 mg once daily is safe and effective
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Qualified patients were randomly as-
signed...” Method of randomisation not
stated
Allocation concealment (selection bias) Unclear risk Not stated, unclear whether allocation was
concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be a double-blind study, method
of blinding not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be a double-blind study, method
of blinding not described
Incomplete outcome data (attrition bias)
All outcomes
High risk No ITT. 15/187 dropouts due to proto-
col violation (no details given): 1/61 lo-
ratadine; 4/64 terfenadine; 52/62 placebo
dropped out
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk Groups were comparable at baseline
Funder: not stated
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Breneman 1995
Methods Design: double-blind multi-centre 3-arm randomised trial of cetirizine vs astemizole vs
placebo
Duration: 4 weeks
Participants Number randomly assigned: 187 (62 patients in cetirizine group; 62 in astemizole group;
63 in placebo group)
Sex: 27% male, 73% female
Age of participants, years: > 12, average 37.7
Unit of allocation: participant
Country and setting: USA; university medical centres
• Chronic idiopathic urticaria
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Cetirizine 10 mg once daily
• Astemizole 10 mg once daily
• Placebo once daily for 4 weeks
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: 1, 2, 3 and 4 weeks
Primary outcomes of the trial
• Complete suppression
• Good/excellent response rated by investigator on a 4-point scale as follows: total
number of lesions: 0 (0), 1 to 10 (1), 11 to 20 (2), > 20 (3). Number of episodes: 0 (0),
1 (1), 2 or 3 (2), > 3 (3). Average lesion size (inches): 0 (0), < 1/2 (1), 1/2 to 1 (2), > 1
(3). Average duration of lesions (hours): none (0), up to 4 (1), > 4 to 12 (2), > 12 (3).
Pruritus: none = 0, mild = 1, moderate = 2, severe = 3
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events (requiring drug withdrawal): headache, vasovagal/vomiting/
palpitations, dizziness, nausea, lethargy, syncope
• Minor adverse events: headache, somnolence, fatigue, dry mouth
Clinician or participant report: participant and investigator
Notes Study investigators concluded that cetirizine provides effective relief of symptoms
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 192): “...patients were ran-
domly assigned to receive either 10 mg ce-
tirizine, 10 mg astemizole, or placebo once
each night for 4 weeks.” No further details
given
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Breneman 1995 (Continued)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear; stated to be ”double-blind trial”
(page 192) but no details given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear; stated to be ”double-blind trial”
(page 192) but no details given
Incomplete outcome data (attrition bias)
All outcomes
High risk 51/187 randomly assigned participants
dropped out/lost to follow-up; lost to fol-
low-up were 51 participants (27.3%). 43
participants were withdrawn before trial
completion; 1 failed to take astemizole; 7
were lost to follow-up
Serious adverse events (requiring drug
withdrawal): cetirizine: n = 2 (headache
n = 1; vasovagal/vomiting/palpitations n
= 1); astemizole: n = 1 (dizziness, nausea,
lethargy, syncope). Evaluable participants:
n = 136
Comment: high loss to follow-up
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Unclear risk Severity of urticaria comparable at baseline,
but statistical differences between other de-
mographic details (age and race)
Funder: Pfizer Labs
Breneman 1996
Methods Design: randomised double-blind placebo-controlled multi-centred 3-arm study of cet-
irizine vs hydroxyzine vs placebo
Duration: 4 weeks
Participants Number randomly assigned: 188 (60 in cetirizine group; 63 in hydroxyzine group; 65
in placebo group)
Sex: 32% male, 68% female
Age of participants, years: > 12; mean: cetirizine: 36.8; hydroxyzine: 34.5; placebo: 38.8
Unit of allocation: participant
Country and setting: USA; allergy practice settings
Inclusion criteria of the trial
• Symptomatic chronic idiopathic urticaria of at least 6 weeks’ duration
Exclusion criteria of the trial
• Within 36 hours of start of study, tranquillisers, hypnotics, antiepileptics,
antidepressants, agents acting on the CNS; within 1 week of start of study, astemizole;
73H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Breneman 1996 (Continued)
within 6 weeks of start of study, any participants with asthma using therapies other
than inhaled bronchodilator
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose duration
• Cetirizine 10 mg once daily plus placebo twice daily
• Hydroxyzine 25 mg 3 times daily
• Placebo 3 times daily
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: 4 weeks
Primary outcomes of the trial
• Efficacy (definite or complete improvement) on a 4-point scale as follows: total
number of lesions: 0 (0), 1 to 10 (1), 11 to 20 (2), > 20 (3)
• Number of episodes longer than 1 hour apart: 0 (0), 1 (1), 2 or 3 (2), > 3 (3)
• Average lesion size (cm): 0 (0), ≤ 1.25 (1), > 1.25 to ≤ 2.5 (2), > 2.5 (3)
• Average duration of lesion (hours): none (0), up to 4 (1), > 4 to 12 (2), > 12 (3)
• Pruritus: none = 0, mild = 1, moderate = 2, severe = 3
• Normal blood and urine values
• Quality of life measures: none
Secondary outcomes of the trial
• Serious adverse events (requiring withdrawal of drug): cetirizine: somnolence,
sweating, vertigo and vomiting, lethargy, headache; hydroxyzine: somnolence; placebo:
somnolence
• Minor adverse events: cetirizine: somnolence; hydroxyzine: somnolence; placebo:
somnolence
Clinician or participant report: participant and investigator
Notes Study investigators concluded that cetirizine 10 mg was equivalent to hydroxyzine 25
mg in symptom control
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1076) “randomised, parallel-
group...” but no further details
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-dummy used, but blinding not
fully described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear how blinding of outcome assessors
was achieved
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Breneman 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9/188 dropouts were recorded for each
group as the result of serious adverse events
requiring withdrawal of drug (1/60 in ce-
tirizine group; 4/63 in hydroxyzine group;
4/65 in placebo group)
Cetirizine: somnolence (n = 1)
Hydroxyzine: somnolence (n = 4)
Placebo: (n = 4) consisted of somnolence n
= 1; sweating, vertigo and vomiting (n = 1)
; lethargy n = 1; headache n = 1
Dropouts balanced between groups
Selective reporting (reporting bias) High risk Reporting of results in graph form (means
with statistical significance) only
Other bias Unclear risk No power calculation-may havemissed sig-
nificant differences between groups if un-
derpowered
Definition of disease partially defined, with
physical urticaria not explicitly excluded
Funder: Pfizer Laboratories
Bronsky 2001
Methods Design: multi-centre double-blind randomised parallel-group study comparing deslo-
ratadine 5 mg vs placebo
Duration: 6 weeks
Participants Number of participants randomly assigned: 225 (115 in desloratadine group and 110
in placebo group)
Sex: not stated
Age of participants: not stated
Unit of allocation: participant
Country and setting: USA; setting unclear
Inclusion criteria of the trial
• CSU 6 weeks
Exclusion criteria of the trial
• Not stated
Interventions Interventions, dose duration
• Desloratadine 5 mg
• Placebo for 6 weeks
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 6 weeks
Outcomes Timing of outcome assessment: twice daily for 6 weeks
Primary outcomes of the trial
• Change in symptom score TSS (number of hives, pruritus and size of largest weals)
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Bronsky 2001 (Continued)
• Quality of life outcomes not reported
Secondary outcomes of the trial
• Adverse events
Clinician or participant report: unclear
Notes Study investigators concluded that desloratadine produced substantial efficacy after just 1
dose, which was maintained throughout study. All measures were statistically significant
in favour of desloratadine vs placebo and were sustained at all time points
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind, unclear how this
was done
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind, unclear how this
was done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of dropouts/adverse events
Selective reporting (reporting bias) High risk Pruritus score given for days 1 to 8, then
total symptoms score given for days 2 to 8
Other bias Unclear risk None detected. Short report (abstract).
Funder: not stated
Brostoff 1996
Methods Design: randomised double-blind multi-centre 2-arm trial of mizolastine vs placebo
Duration: 28 days
Participants Number of participants randomly assigned: 56; 28 in each group
Sex: 55% male, 45% female
Age of participants, years: 18; mean 38 ± 15
Unit of allocation: participant
Country and setting: UK; setting research clinics
Inclusion criteria of the trial
• Urticaria of at least 6 weeks’ duration with at least 2 episodes per week
Exclusion criteria of the trial
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Brostoff 1996 (Continued)
• Pregnant, women not using contraception, driving, dangerous machinery,
inability to comply, concomitant disease or abnormal laboratory value
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
After single-blind placebo run-in period of 4 to 10 days:
• Mizolastine 10 mg a day
• Placebo once daily for 28 days
Duration of intervention: intermediate-term (28 days)
Outcomes Timing of outcome assessment: days 7 and 28
Primary outcomes of the trial
• Symptoms, including itch, sleep, daily activities, weals, erythema and discomfort
rated on a 4-point visual analogue scale
• Percentage of ”responders“ at 28 weeks
• Quality of life measures: none
Secondary outcomes of the trial
• Dropouts due to inefficacy
• Adverse events and dropouts reported
Clinician or participant report: clinician and participant
Notes Study authors concluded that mizolastine controlled symptoms of urticaria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 321): ”a two-centre, double-
blind randomised, placebo-controlled par-
allel group study... allocated according to
the randomisation”
Allocation concealment (selection bias) Unclear risk No details given about allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 321): “Patients received sin-
gle blind placebo medication for a variable
period of 4-10 days (initially, then were al-
located to one of two treatment groups)”
Quote (page 321): “All tablets were iden-
tical in appearance, ensuring double blind
nature of trial.” Unclear how investigators
were blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear how investigators were blinded to
treatment
Comment: participants probably blind, as
all tablets were identical
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Brostoff 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 29/56, 51% losses to follow-up (29/56with
10/28 in mizolastine arm and 19/28 in
placebo arm). A large proportion of par-
ticipants dropped out; this is unbalanced
across trial arms
1 participant in mizolastine group did not
take treatment
Lack of efficacy in 5 in mizolastine group
and in 17 in placebo group
Drowsiness in 1 in mizolastine group
Loss to follow-up at day 7 in 2 mizolastine
group
1 participant in each group “unco-opera-
tive”
1 in each group discontinued for reasons
unrelated to study
Analysis in the paper is presented as ITT
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Unclear risk Funder: Synthelabo
Key outcome based on physician VAS es-
timate of urticaria severity (i.e. totally sub-
jective); no indication of how many partic-
ipants were cleared on treatment
Commens 1978
Methods Design: double-blind cross-over 3-arm randomised controlled trial of cimetidine and
chlorpheniramine vs placebo
Duration: 2 weeks
Participants Number of participants randomly assigned: 25 entered study. Numbers in each group
not stated
Sex: 32% male, 68% female
Age of participants, years: 18 to 66
Unit of allocation: cross-over, without washout (consecutive 2-week treatments)
Country and setting: UK; outpatient clinic
Inclusion criteria of the trial
• Urticaria of unknown cause
Exclusion criteria of the trial
• Pregnant or lactating women
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Cimetidine 200 mg twice daily and chlorpheniramine 4 mg once daily
• Chlorphenamine 4 mg once daily and placebo for 2 weeks
• Placebo
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Commens 1978 (Continued)
Duration of intervention: short-term (2 weeks)
Outcomes Timing of outcome assessment: 2 weeks
Primary outcomes of the trial
• Estimation of number of weals present in clinic after each 2 weeks of treatment
(none/a few/many)
• Severity of itching
• Impression of participant (improvement/no change/deterioration)
• Quality of life measures: none
Secondary outcomes of the trial
• Laboratory values (blood, biochemistry)
• Adverse events: drowsiness, vomiting and dizziness, dry mouth, intestinal colic
Clinician or participant report: clinician and participant
Notes Study investigators concluded that chlorpheniramine is effective in controlling symptoms
in some patients with urticaria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated.
Quote: ”On entry to the trial patients were
allocated, on a random double blind basis,
to the consecutive 2-week treatment”
Cross-over studywith no apparent washout
Allocation concealment (selection bias) Unclear risk No allocation concealment stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study stated double-blinding; method un-
clear, no indication whether identical
tablets/capsules given, no details about
methods of blinding. Dosages were differ-
ent for each intervention, so blinding in-
complete (intervention group could poten-
tially be guessed by number of tablets)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study stated double-blinding; method un-
clear
Incomplete outcome data (attrition bias)
All outcomes
High risk 6/25 participants recruited (24%) were lost
to follow-up (non-compliance 5; sponta-
neous remission 1) and were not included
in the analysis. Unclear which group drop-
outs belonged to. No ITT
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Selective reporting (reporting bias) High risk Results not clearly reported. Results for
numbers of participants in each group not
stated, only mean scores (no SD) provided
Other bias Unclear risk Unclear schedule of assignment, unclear
whether each phase was given consecu-
tively, as results reported only for interven-
tion and control-not by phase of the study
Funder: Smith Kline and French Laborato-
ries Ltd
Dakhale 2014
Methods Design: double-blind 2-arm randomised controlled trial of cetirizine vs rupatadine
Duration: 6 weeks
Participants Number of participants randomly assigned: 70
Sex: cetirizine females 64.5%, rupatadine females 61.2%
Age of participants, years: cetirizine 41.5 (SD 11.49); rupatadine 43.81 (SD 12.30)
Unit of allocation: participant
Country and setting: India; secondary care
Inclusion criteria of the trial
• 18 to 65 years of age; men or women with a history of urticarial weal and/or
angio-oedema for ≥ 3 days per week for 6 consecutive weeks for which no obvious
cause had been established
• Patients using any antihistamines other than rupatadine and cetirizine were
included in the trial only after a washout period of 7 days, irrespective of doses of their
previous drugs
Exclusion criteria of the trial
• Acute and physical urticaria and all physical and other subtypes of urticaria, such
as aquagenic, cholinergic, contact and exercise-induced urticaria
• History of asthma or any other disease requiring long-term use of inhaled or
systemic corticosteroids
• Use of corticosteroids (inhaled or systemic)
• History of allergy to study medication or intolerance to antihistamines
• Use of study drug or topical steroid in previous 7 days
• Use of oral steroid in previous 8 weeks
• Parenteral steroids in previous 3 months
• Use of any other immunomodulatory therapy
• Systemic co-morbidities
• Pregnant and nursing mothers
Previous unresponsiveness to antihistamine: excluded any with previous failure to re-
spond to antihistamine
Interventions Interventions, dose, duration
• Cetirizine 10 mg daily, rupatadine 10 mg daily
Duration of intervention: intermediate
Length of follow-up: 6 weeks
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Outcomes Timing of outcome assessment: 6 weeks
Study outcomes
Primary outcomes of the trial
Trial was undertaken to test whether treatment with rupatadine was more successful than
treatment with cetirizine in resolving symptoms as follows:
• Mean number of weals (scored as 0 (none), 1 (1-5), 2 (6-15), 3 (16-25), or 4 (>
25))
• Pruritus: 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe
• Mean total symptoms score (MTSS) calculated by adding mean number of weals
(MNW) and mean pruritus score (MPS)
• Size of weal scored as 0 (no weal), 1 (< 0.5 cm), 2 (0.6-2.0 cm), 3 (2.1-4.0 cm) or
4 (> 4.0 cm); interference of weals with sleep (SIWS) (0 = none, 1 = mild, 2 =
moderate, 3 = severe)
• Sedation: visual analogue scale (VAS) for sedation (scored on a scale of 0-100,
where 0 = alert and 100 = very sleepy)
Secondary outcomes of the trial
• None
Adverse events: general clinical follow-up and monitoring of adverse events, no serious
adverse events requiring withdrawal of treatment; cetirizine group: total affected 12,
38.71% (headache n = 2, gastric irritation n = 1, dry mouth n = 1, sedation n = 8).
Rupatadine group: total affected 7, 21.21% (headache n = 2, dry mouth n = 1, sedation
n = 4)
Quality of life measures: none
Clinician or participant report: participant and clinician
Notes Study investigators concluded that rupatadine led to improvement in all outcomes by
the end of the trial, and that rupatadine is a particularly attractive therapeutic modality
compared with cetirizine for the treatment of CSU
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation, with block sizes of 4
in equal proportions to ensure a uniform
allocation ratio. Randomised treatment al-
location sequence was generated by a statis-
tician using a random numbers table
Allocation concealment (selection bias) Low risk Quote (page 644): “The codes used in this
random allocation sequence were retained
in a sealed envelope, which was opened
only after the completion of the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both participants and investigators were
unaware of the treatment administered.
Drugs (21 tablets of cetirizine or rupata-
dine) were handed over in identical plastic
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containers to a third person, who was not
directly involved in this study. Drugs were
presented in identical format in terms of
shape, size, texture and packing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Both participants and investigators were
unaware of the treatment administered
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 64/70 completed. 5 participants were lost
to follow-up at end of first week of the
study (3 in cetirizine group and 2 in ru-
patadine group).One fromcetirizine group
was dropped from the study andwas shifted
to another drug because of non-response.
Data for these 6 participants were not in-
tegrated into the analysis
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk None detected. Funder: none
Degonda 2002
Methods Design: double-blind 2-arm randomised controlled trial of fexofenadine vs placebo
Duration: 21 days
Participants Number of participants randomly assigned: 21 (further information obtained from trial
investigator); 13 evaluable participants with 6 in fexofenadine group and 7 in placebo
group
Sex: 38% female
Age of participants, years: 38
Unit of allocation: participant
Country and setting: Switzerland; hospital allergy clinics
Inclusion criteria of the trial
• Chronic urticaria of unknown aetiology, normal ECG, informed consent
Exclusion criteria of the trial
• Pregnancy
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Fexofenadine 180 mg once daily for 21 days
• Placebo once daily for 21 days (1-week washout period, then 3-week run-in, with
all participants taking fexofenadine; then participants were randomly assigned to
fexofenadine or placebo)
Duration of intervention: intermediate-term (21 days)
Length of follow-up: 21 days
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Outcomes Timing of outcome assessment: 21 days
Primary outcomes of the trial
Assessment scores used were as follows:
• Global assessment score: better/unchanged to better/unchanged/worse
• Tiredness: none/mild/moderate/severe
• Itching: none/mild/moderate/severe
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: fexofenadine: headache, sleep disturbance, diarrhoea; placebo:
headache and dizziness, anxiety, dry mouth. Unclear whether or not adverse events led
to dropout. Further information from trial investigator: Of adverse effects reported,
only in 1 case could headache be correlated with fexofenadine intake (reported in 3/21
on fexofenadine and in 1 on placebo); diarrhoea 1/21, 0 in placebo arm
Clinician or participant report: clinician and participant
Notes Study investigators concluded that fexofenadine had a beneficial effect on urticaria
Main report language is German
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Performed by pharmacist who was not in-
volved in the study
Comment: Although randomisation se-
quence was generated offsite, adequacy of
sequence generation is unclear, as no fur-
ther information was provided by trial in-
vestigator
Allocation concealment (selection bias) Unclear risk No details about allocation concealment
available
Comment: Although only allocation num-
ber was visible on sealed medication boxes,
allocation concealment up to the point of
assignment of the intervention is unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs and placebo were identical in
appearance
Comment: Further information from trial
investigators stated that identical small and
white tablet boxes were sealed with a plastic
band (only allocation number could iden-
tify the participant)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study drugs and placebo were identical in
appearance
Comment: Further information from trial
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investigators states that identical small and
white tablet boxes were sealed with a plas-
tic band (only allocation number could
identify the participant). Outcome asses-
sors were unaware of treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 18 commenced active study (Phase II): 3
dropped out from the fexofenadine group
(1 lack of efficacy, 1 worsening of condi-
tion, 1 moved house and lost contact). No
participants dropped out from the placebo
group (i.e. 15/18 completed) (further in-
formation supplied by trial investigator)
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported,
but results were presented in graph format
or as percentages; number of once-daily
treated participants in each group is un-
clear, therefore calculations may be prone
to error
Other bias Unclear risk Funder: Aventis
Odd and unclear trial design by which all
participants were given active drug as run-
in, then were randomly assigned again to
fexofenadine or placebo
Di Lorenzo 2004
Methods Design: randomised parallel-group 4-arm study conducted to compare desloratadine vs
montelukast vs desloratadine plus montelukast vs placebo
Duration: 6 weeks
Participants Number of participants randomly assigned: 160 with 40 in each group
Sex: 31% male, 69% female
Age of participants, years: 18 to 69; mean 43.9 (SD 13.4)
Unit of allocation: participant
Country and setting: Italy; outpatient clinics of university hospitals
Inclusion criteria of the trial
• Chronic idiopathic urticaria
Exclusion criteria of the trial
• Physical, allergic or urticaria vasculitis, NSAID-induced urticaria, positive skin
test to autologous serum or food additive challenge. Pregnancy, breast feeding,
concomitant disease; corticosteroids or LT-RAs for 2 months before start of study (or 1
month oral corticosteroids before start of study)
• Previous unresponsiveness to antihistamine: not stated
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Interventions Interventions, dose, duration
• 5 mg desloratadine every morning plus placebo at night
• 5 mg desloratadine every morning plus 10 mg montelukast at night
• Placebo every morning plus montelukast 10 mg at night; placebo every morning
plus placebo at night
Rescue therapy: loratadine 10 mg allowed (frequency and duration unclear)
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 8 weeks i.e. follow-up extended after cessation of treatment
Outcomes Timing of outcome assessment: baseline, after 3weeks of treatment, after 6weeks, follow-
up at 8 weeks
Primary outcomes of the trial
• 4-point scale of pruritus, number of hives, size of largest hive (cm), interference
with sleep, interference with daily activities, remission of urticaria, excellent response,
no variation, worse data (some of which were supplied as additional data by study
investigator)
• Clinical efficacy of desloratadine alone or combined with montelukast
• Quality of life measures: none
Secondary outcomes of the trial
• Efficacy of montelukast as monotherapy, number of days when rescue therapy not
required
• Adverse events: incidence of emergency discontinuations due to adverse events,
changes in vital signs, laboratory values and ECG
Clinician or participant report: clinician and participant
Notes Study investigators concluded that on average, desloratadine and desloratadine plus
montelukast appear to be more effective than placebo or montelukast alone
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Method of randomisation not stated in
publication. Further information from trial
investigator: “We used the StatsDirect soft-
ware for the list of randomised patients”
Allocation concealment (selection bias) Unclear risk No details given about allocation conceal-
ment; sealed envelopes were used and were
opened after the study had ended. Further
details supplied by study investigator
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 620): ”The pharmacist of the
University Hospital of Verona prepared a
specific set with the treatments to be used
for the study”; ”The investigators and pa-
tients were blinded with respect to the con-
tents of each set”
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Comment: unclear whether tablets were of
identical appearance but probably adequate
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether or how outcome assessors
were blinded
Participants assessed some outcomes and
were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 62/160 initially randomly assigned partic-
ipants dropped out, but this is unclear.
Study investigator states that dropouts re-
sulted from inefficacy and from requests
from participants to discontinue therapy
Dropouts from the study were included in
the analysis
Losses to follow-up: 68% (27/40)in mon-
telukast plus placebo group; 88% (35/40)
in placebo only group. Assumed no drop-
outs in desloratadine monotherapy or in
combined therapy dropped out
Comment: high dropout rates unevenly
distributed between groups
Results presented in graph format or as sta-
tistical significance; raw data not given
Selective reporting (reporting bias) Unclear risk Results obscure; expressed as numbers of
participants not given (mean plus 95% CI
or graphs)
Adverse events: not stated (“low inci-
dence… mild”)
Other bias Unclear risk Funder: Ministero Italiano Universita e
Ricerca; no pharmaceutical industry sup-
port
All data potentially confounded by al-
lowance of rescue medication. Our inter-
pretation suggests that of a possible 1680
patient-days per group in the active study,
Group 1 took rescue medication on aver-
age (median) on all but 90.6 days; Group 2
on all but 91 days; Group 3 on all but 45.
2 days; Group 4 on all but 54 days
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Methods Design: multi-centre double-blind 3-arm placebo-controlled parallel-group study of mi-
zolastine vs loratadine vs placebo
Duration: 1-week placebo run- in period, then participants received therapy for 4 weeks
Participants Number of participants randomly assigned: 247 enrolled: 88 to mizolastine; 79 to lo-
ratadine; 80 to placebo
Sex: 36.8% male, 63.2% female
Age of participants, years: 42 ± 15
Unit of allocation: participant
Country and setting: France, Spain, Italy; secondary care, hospital clinics
Inclusion criteria of the trial
• At least 18 years of age, documented history of CSU (with or without angio-
oedema), at least 2 episodes per week in the absence of treatment
Exclusion criteria of the trial
• Pregnancy, lactation, not using contraception, operating dangerous machinery or
driving as occupation, hereditary angio-oedema or isolated dermographism and or
major systemic disease
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
After 1-week placebo run-in period, participants received 4 weeks:
• Mizolastine 10 mg/d
• Loratadine 10 mg/d
• Placebo
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: 2 weeks and 4 weeks
Primary outcomes of the trial
• Pruritus severity on visual analogue scale (0 = no discomfort, 100 = extreme
discomfort) related to 7 days preceding the visit
• Weekly number of episodes of urticaria, total urticaria score (severity of itching/
size of lesion/number of lesions), intensity of angio-oedema
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: serious leading to study withdrawal: vasculitis (mizolastine group)
, preexisting; appendicitis (loratadine group); other 5 not stated; minor: drowsiness,
headache, fatigue, ‘flu-like’ symptoms, nausea
Clinician or participant report: participant and clinician
Notes Study acronym: ’MILOR’
Study investigators concluded that mizolastine 10 mg daily is an effective and well-
tolerated agent
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Described as randomised, but method of
randomisation not stated
Allocation concealment (selection bias) Unclear risk No methods of allocation concealment
given in the study report, no further infor-
mation available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ”Patients were randomised to a
4-week double-blind treatment...” but no
methods of blinding given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described in the study report
Incomplete outcome data (attrition bias)
All outcomes
Low risk 205/247 completed
Losses to follow-up: total 17%; mizolas-
tine: 13/88 (14.8%); loratadine: 10/79 (12.
9%); placebo: 19/80 (23.7%), with reasons
given
Mizolastine: lack of efficacy 3; adverse
events 4; non-compliance 2; “other” 2; loss
to follow-up 2
Loratadine: lack of efficacy 5; adverse
events 3; non-compliance 0; “other” 2; loss
to follow-up 0
Placebo: lack of efficacy 11; non-compli-
ance 4; “other” 2; loss to follow-up 2
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported,
but data were given asmean scores plus SD;
no participant numbers were given
Other bias Unclear risk Funder: Synthelabo research
Dubertret 2007
Methods Design: randomised double-blind placebo-controlled 4-arm dose-ranging study of ru-
patadine (3 doses) vs placebo
Duration: 28 days
Participants Number of participants randomly assigned: 283 (rupatadine 5 mg n = 68, rupatadine
10 mg n = 73, rupatadine 20 mg n = 67, placebo n = 69)
Sex: 28% male, 72% female
Age of participants, years: range between 12 and 65; average 38.1 ± 13.0
Unit of allocation: participant
Country and setting: France, Romania, Argentina, Hungary; secondary care, hospital
clinics and skin research clinics
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Inclusion criteria of the trial
• CSU at least 3 days per week for 6 weeks
Exclusion criteria of the trial
• Physical urticaria, cholinergic urticaria, urticaria of known aetiology, medications
that are inhibitors of cytochrome P450 isozyme CYP3A4
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Rupatadine 5 mg, 10 mg, 20 mg
• Placebo
(as a single once-daily tablet)
Duration of intervention: intermediate-term (28 days)
Length of follow-up: 28 days
Outcomes Timing of outcome assessment: 14 days and 28 days
Primary outcomes of the trial
• Efficacy assessed by change from baseline in mean pruritus score, mean number of
weals, mean total symptoms score calculated as sum of mean pruritus score and mean
number of weals; mean interference in daily activity score; mean interference with sleep
score over 4-week period
• Quality of life measures not reported
Secondary outcomes of the trial
“All remaining variables,” that is:
• Physician’s global assessment of efficacy at 14 days and 28 days on basis of
symptom severity; change from baseline scored as 0 = worse than at prestudy, 1 = no
change, 2 = slight improvement, 3 = good improvement
• Participants recorded symptoms on daily diary card twice daily. Pruritus: 0 =
none; 1 = mild, not annoying or troublesome; 2 = moderate, annoying/troublesome; 3
= severe, very annoying, substantially interfering with sleep/daily activities; 4 = very
severe, warranting physician visit. For number of weals, scored as follows: 0 (none), 1
(1-5), 2 (6-15), 3 (16-25), 4 (> 25)
• Participants also scored extent of interference with daily activities and sleep: 0 =
none, 1 = mild, 2 = moderate, 3 = severe
• Adverse events: minor only at 4 weeks: somnolence, headache, transient rise in
serum creatine phosphokinase (CPK)
Clinician or participant report: clinician and participant
Notes Study investigators concluded that over the 4-week period, rupatadine 10 mg and 20
mg significantly reduced mean pruritus score compared with placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk No methods of allocation concealment
given in study report
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 224): ”This was a phase II
dose-ranging, randomised, double-blind,
placebo-controlled...”
No details given about method of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 224): ”This was a phase II
dose-ranging, randomised, double-blind,
placebo-controlled...”
No details given about method of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 244/283 completed study according to
protocol
39 participants (14%); 25 (10 given
placebo, 9 given 5 mg, 3 given 10 mg, 3
given 20 mg) withdrew because of lack of
efficacy: 1 for adverse event, 2 for incorrect
treatment allocation, 11 for other or per-
sonal reasons
However, 6 participants were excluded
from analysis without explanation (i.e. 283
randomly assigned); 277 were included in
study ITT analysis
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Unclear risk Funder: Uriach y Compania (Barcelona,
Spain); National Scientific Research Pro-
gram of the Spanish Minister of Science
and Technology
Unclear clinical meaning of primary out-
come (0.5-point drop in mean pruritus
severity score)
Finn 1999
Methods Design: double-blind multi-centre placebo-controlled 5-arm trial to evaluate efficacy
and safety of 4 different doses of fexofenadine vs placebo
Duration: 4 weeks
Participants Number of participants randomly assigned: 476 from 35 centres
Number in each group: placebo 78; 20 mg twice daily 81; 60 mg twice daily 79; 120
mg twice daily 86; 240 mg twice daily 80
Sex: 30% male, 70% female
Ethnicity: 90% white, 4% black, 4% “Asian” and 2% multi-racial
Age of participants, years: 12 to 65
Unit of allocation: participants
Country and setting: USA; setting research clinics
Inclusion criteria of the trial
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• Presence of urticarial weals for at least 3 days per week for 6 consecutive weeks
before entry; minimum of 1 to 5 weals, confirmed by investigator; moderate to severe
itching during the previous 12 hours; informed consent
Exclusion criteria of the trial
• Urticaria associated with underlying disease (e.g. Hodgkin’s disease, vasculitis,
hyperthyroidism, lupus erythematosus, hepatitis); physical urticaria; urticaria due to
medications, insect bites, food or other known aetiology. Dermographism; those
unresponsive to prior antihistamine treatment; malnutrition; drug abuse or alcoholism;
blood dyscrasia; malignancy; renal or hepatic insufficiency; malabsorption; chronic
infection; psychiatric, cardiovascular, hepatic, neurological, endocrine or other major
systemic disease. Not pregnant or lactating
• Previous unresponsiveness to antihistamine: excluded if unresponsive to prior
antihistamine treatment
Interventions Interventions, dose, duration
Single-blind placebo run-in for 24 hours
• Placebo
• 20 mg fexofenadine HCl
• 60 mg fexofenadine HCl
• 120 mg fexofenadine HCl
• 240 mg fexofenadine HCl
Twice a day for 4 weeks
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessments: unclear. Results based on at least 1 postbaseline 12-
hour reflective mean pruritus score (MPS) assessment
Primary outcomes of the trial
• Change in mean pruritus score over 4-week period
• Quality of life measures: none
Secondary outcomes of the trial
• Change events: any adverse events, changes in laboratory values, physical
examination at first and last visits
Clinician or participant report: participant and investigator
Notes Study investigators concluded that fexofenadine HCl was well tolerated and statistically
superior to placebo in treating CSU and in ameliorating interference with sleep and daily
activities. They concluded that doses of 60 mg twice daily or greater were most effective
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
Allocation concealment (selection bias) Unclear risk No methods of allocation concealment
given in the study report
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ”...4 week double blind treatment
period.”Methods of blindingnot described
in the study report
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ”...4 week double blind treatment
period.”Methods of blindingnot described
in the study report
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 439/476 available for analyses (baseline
scores and 1 postbaseline reflectiveMPS as-
sessment). 103 (21.6%) lost to follow-up.
Issues with losses to follow-up with partic-
ipants involved in total discontinuation of
treatment accounting for 21.6%
Reasons for withdrawal:
• Adverse event 19
• Treatment failure 44
• Elected to discontinue 11
• Defaulted from follow-up 3
• Required disallowed medication 7
• Other (not stated) 19
Comment: Table 1 in the study report gives
a full description of reasons for dropout
by group; however as the level of dropout
is high at 21.6%, it is unclear whether
dropout was a significant source of bias in
this study
Selective reporting (reporting bias) High risk Only participants with baseline and at least
1 postbaseline mean pruritus score were in-
cluded in analysis
Other bias Unclear risk Groups comparable at baseline except sig-
nificant differences in interference with
daily activities at baseline
Funder: Hoechst Marion Roussel
Gale 1989
Methods Design: randomised double-blind cross-over 2-arm study comparing the efficacy of
acrivastine vs chlorpheniramine
Duration: 24 days
Participants Number of participants randomly assigned: 20
Sex: 55% male, 45% female
Age of participants, years: mean 39.2 (range 18-27)
Unit of allocation: cross-over (24 days)
Country and setting: Australia; setting unclear
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Inclusion criteria of the trial
• Urticaria of 4 weeks’ duration, daily attacks (or alternate days)
Exclusion criteria of the trial
• No concomitant therapy with tranquillisers or sedatives, other antihistamines,
systemic corticosteroids for at least 4 weeks before entry into the study
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• 8 mg acrivastine
• 4 mg chlorpheniramine maleate
Three times daily for 24 days in this cross-over study. No wash out period reported, but
no participant self-assessments reported in the first 3 days after cross-over to eliminate
carryover effects from previous therapies
Duration of intervention: intermediate-term (24 days)
Length of follow-up: 24 days
Outcomes Timing of outcome assessment: after each 24-day treatment period
Primary outcomes of the trial
• Weals 0-4: 0 (none), 1 (1-5), 2 (6-10), 3 (11-20), 4 (> 20); itching 0-4 (0 = none,
1 = minimal, 2 = mild, 3 = moderate, 4 = severe)
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: no information given
Clinician or participant report: participant and investigator. Participants self-assessed
daily. Participant reviewed by physician after each 24-day treatment period-physician
recorded opinion on which treatment worked best and suited participant best overall
Notes Study investigators concluded that both active drugs were effective, with no significant
differences noted between them
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study states that this is a double-blind
study; no methods of blinding given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of blinding of outcome assessors
not stated
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4/20 participants excluded from analysis
because of protocol violations (20% lost to
follow-up), with no ITT
Selective reporting (reporting bias) High risk Incomplete reporting of data (only means
given); no comment on adverse events
Other bias Unclear risk Definition of disease given but CSU de-
fined as > 4 weeks; however, no included
participants had urticaria < 2 months
Underpowered
Funder: Wellcome Research Laboratories
Garavaglia 1995
Methods Design: randomised double-blind 6-week study of cetirizine vs terfenadine vs placebo
in CSU; parallel 3-arm trial
Duration: 6 weeks
Participants Number of participants randomly assigned: n = 63 took part in the study; however
as participants dropped out, they were replaced, so 47 are presented (number given
cetirizine n = 17; terfenadine n = 16; placebo n = 14)
Sex: cetirizine: 29.41%male, 70.59% female; terfenadine: 18.75%male, 69.23% female;
placebo: 69.23% male, 30.77% female
Age of participants, years: cetirizine 33.8 ± 13.8; terfenadine 35.88 ± 17.3; placebo 37.
8 ± 16.45
Unit of allocation: participant
Country and setting: Argentina; outpatient research clinic
Inclusion criteria of the trial
• Participant’s written consent to study conditions. 6-week history of regular attacks
of idiopathic urticaria: minimum frequency of 3 episodes per week
Exclusion criteria of the trial
• Younger than 18 years of age, pregnant women or women with potential for
pregnancy, serious renal or hepatic dysfunction, dependent on corticosteroids, taking
drugs that interfere with cutaneous reactions unless they had stopped these before entry
into the study; urticaria of known causes (contact, pressure, cold, heat, cholinergic,
dermographism)
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Placebo, cetirizine 10 mg per day, 1 tablet
• Terfenadine 120 mg per day, 2 tablets
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 6 weeks
Outcomes Timing of outcome assessment: 3 visits in total, initial at 3 weeks and final at 6 weeks
from start of study
Primary outcomes of the trial
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• Routine physical examination, including heart rate, blood pressure, height, weight
• Clinician assessed the following: giant papules present or absent, papules present
or absent; if papules present, fewer, or more than 20, erythema present or absent,
oedema present or absent; objective description of lesions including distribution, size,
location.
• Participant report: visits 1 and 2: Participants were asked to complete daily diary
cards to record their assessments of intensity of itching, redness and papules. Symptom
report of mild, moderate or intense based on a visual analogue scale
• Quality of life measures: none
Secondary outcomes of the trial
• Overall efficacy and tolerance assessed at end of study by participant and clinician
• Adverse events: types of adverse events reported. Total adverse events: 2/17 in
cetirizine, 2/16 in terfenadine. Types of adverse events reported: cetirizine: gastritis,
dyspepsia, dry mouth, bitter taste, somnolence; terfenadine: morning sickness,
menstrual alteration (delay, pain), shortening of cycle. No participant abandoned the
study because of intolerable adverse effects
• Participants were withdrawn if they had adverse reactions, interruption of
medication for up to 3 days on more than one occasion, concomitant use of other
active medication, withdrew consent, did not co-operate, violated study protocol, did
not attend follow-up sessions, or there were other reasons (not specified) at the
researcher’s discretion.
Clinician or participant report: clinician and participant
Notes Study report written in Spanish
Study investigators concluded that cetirizine is superior to terfenadine in terms of efficacy
and tolerability; for symptom control, both active drugs were significantly better than
placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote (page 180): “Randomly divided (in
threes) into three equal groups”
However, if participants dropped out, they
were replaced with new participants (14
did not take the medication, 35 did not
return for assessment, 37 did not take the
correct medication. All of these partici-
pants were replaced). As participants who
dropped out were replacedwith newpartic-
ipants, it is unclear whether the trial design
is truly randomised; it is not clear whether
new participants were randomly assigned
de novo or were assigned to the group of
the most recent dropout. The trial report
states: “since the randomisation was per-
formed on groups of 3, it was actually nec-
essary for each loss of a patient [to result in
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resumed] treatment of three patients” (page
182)
(page 186) “9 patients were replaced as
three were withdrawn due to protocol vi-
olations (lost medication, did not attend
tests, did not take correct medication).
Therefore 9 new [participants] were re-
cruited, as randomisation was [done] in
threes”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tablets anddosages prepared to be identical
(boxes of white round tablets), presented so
that each drug or placebo was administered
in a uniform way. A scratch-off label would
reveal the drug type in case of emergency
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors (clinicians and partici-
pants) would not have had indications of
treatment group because of uniform pack-
aging, but methods of blinding are not ex-
plicitly stated
Incomplete outcome data (attrition bias)
All outcomes
High risk 47/63 completed.Droppedout: 3/17 in ce-
tirizine; 3/16 in terfenadine; 9/14 placebo.
15 left the study because of inefficacy and
were not replaced; they were “statistically
computable” (page 186). It is unclear how
results were computed for participants who
dropped out because of inefficacy. Note:
Thismay have introduced bias, as the study
was possibly biased towards positive results
Other reasons for dropout: adverse events:
2/17 in cetirizine; 2/16 in terfenadine due
to adverse events
No participant left the study because of in-
tolerable adverse reactions
Selective reporting (reporting bias) High risk Only results for the cetirizine and terfena-
dine arms of the study were included in the
published report. No results were presented
for the placebo arm
The researcher was able to withdraw par-
ticipants on the basis of his opinion
Other bias Unclear risk Funder: not stated
Analyses were not statistically significantly
different and placebo results were not pre-
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sented; therefore conclusions of the study
as stated in the study report are unreliable
Ghosh 1990
Methods Design: randomised controlled trial of doxepin 10mg thrice daily vs pheniraminemaleate
22.5 mg thrice daily
Duration: 3 weeks
Participants Number of participants randomly assigned: 56
Sex: 67% female in doxepin group, 60% female in pheniramine group
Age of participants, years: 18 to 59
Unit of allocation: participant
Duration of urticaria: 8 weeks to 4 years
Country and setting: India; secondary care
Inclusion criteria of the trial
• CSU; participants refractory to previous treatment
Exclusion criteria of the trial
• < 18 years of age, pregnant and lactating mothers
• Previous unresponsiveness to antihistamine; all participants refractory to previous
treatment
Interventions Interventions, dose, duration
• Doxepin 10 mg thrice daily
• Pheniramine 22.5 mg thrice daily
Length of follow-up: 4 weeks (follow up extended 1 week after cessation of therapy)
Outcomes Timing of outcome assessment: 3 weeks and 4 weeks
Primary outcomes of the trial
• Complete remission; partial remission; no improvement after 3 weeks; recurrence
7 days after cessation of treatment
• Quality of life measures: none
Secondary outcomes of the trial
• Laboratory investigations, blood counts, blood biochemistry
• Adverse events: drowsiness, dry mouth, serum creatinine higher in 1 participant
in doxepin group
Clinician or participant report: both
Notes Study investigators concluded that after 3 weeks of therapy, 8 (28.6%) participants in
doxepin group and 3 (10.7%) in pheniramine group were symptom free (complete
suppression)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants non-responsive to other anti-
histamine treatment excluded
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Allocation concealment (selection bias) Unclear risk Unclear allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Does not appear to be blinded: ”twenty
eight subjects were given doxepin 10 mg
thrice weekly for 3 weeks“...”Another 28
subjects...were treated with pheniramine
maleate 22.5 mg thrice weekly for 3 weeks“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Does not appear to be blinded: ”twenty
eight subjects were given doxepin 10 mg
thrice weekly for 3 weeks“...”Another 28
subjects...were treated with pheniramine
maleate 22.5 mg thrice weekly for 3 weeks
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropouts apparent
Selective reporting (reporting bias) Unclear risk Partial remission/improvement amongst
participants is not defined or specific
Other bias Low risk None detected. Funder: none
Gimenez-Arnau 2007
Methods Design: a randomised multi-centre multi-country double-blind parallel-group placebo-
controlled 3-arm study of rupatadine at 2 different doses
Duration: 6 weeks
Participants Number of participants randomly assigned: 334
Sex: placebo: male 37.8%, female 62.2%; rupatadine 10 mg: 30% male, 70% female;
rupatadine 20 mg: 26.9% male, 73.1% female
Age of participants, years: mean (SD): placebo: 35.8 (13.4); rupatadine 10 mg: 40.2 (3.
6); rupatadine 20 mg: 37.6 (14.6)
Unit of allocation: participant
Country and setting: Spain, Romania, Argentina, Poland, Germany, Italy; multi-centre,
research clinics
Inclusion criteria of the trial
• ECG within normal limits
• Women of child-bearing potential who tested negative for pregnancy
Exclusion criteria of the trial
• Other medication, including specific H1-receptor antagonists for at least 7 days,
and inhibitors cytochrome P450 and isozyme CYP3A4. Acute urticaria, physical
urticaria (cholinergic, cold/heat pressure, etc.) and chronic urticaria associated with
some underlying disease (e.g. Hodgkin’s disease, vasculitis, lupus erythematosus,
hepatitis)
• Previous unresponsiveness to antihistamine: not stated
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Interventions Interventions, dose, duration
• Rupatadine 10 mg
• Rupatadine 20 mg
• Placebo
Once daily for 6 weeks
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: up to 6 weeks
Outcomes Timing of outcome assessment: after 2, 4 and 6 weeks of treatment
Primary outcomes of the trial
• Change from baseline in mean pruritus score (MPS) over 4-week treatment period
• Quality of life measures: none
Secondary outcomes of the trial
• Change from baseline in mean number of weal score (MNW), mean total
symptoms score (MTSS = MPS + MNW); DLQI; visual analogue scale over 4 and 6
periods (VAS 0: no discomfort; to 100: extreme discomfort)
• Pruritus was assessed by scoring on a 5-point scale of 0 to 4 (0 = none; 1 = mild,
not annoying or troublesome; 2 = moderate, annoying or troublesome; 3 = severe, very
annoying, substantially interfering with sleep/daily activities; 4 = very severe,
warranting doctor visit). Similarly, the number of weals was scored on a 5-point scale: 0
(0), 1 (1-5), 2 (6-15), 3 (16-25), 4 (> 25)
• Overall efficacy was assessed after 2, 4 and 6 weeks of treatment; investigator-
assessed global efficacy 0 to 4 (0 = worse, 1 = no change, 2 = slight improvement, 3 =
good improvement, 4 = excellent improvement)
• Adverse events: any adverse events recorded (no serious adverse events recorded)
Clinician or participant report: participant and investigator (patient daily diary cards)
Adverse events: any adverse events; headache; somnolence; hypertension; “metrorrhagia”
Notes Investigators conclude that rupatadine 10 mg is a fast long-acting treatment with a better
safety profile than rupatadine 20 mg
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”...according to a centralized com-
puter-generated randomisation code pro-
vided by the sponsor of the study”
Further information from the study inves-
tigator
“The randomisation procedures were car-
ried out at J. Uriach y Compañía, S.A. The
Production Quality Management Depart-
ment of J. Uriach y Compañía, S.A. drew
up a randomisation list for the treatments.
Afterwards, the Quality Assurance Unit of
J. Uriach y Compañía S.A. randomly as-
signed a treatment to each code. Two copies
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of the randomisation code and two of the
randomised list of patients were obtained”
Allocation concealment (selection bias) Low risk Quote: “A duly closed and sealed copy of
each document was kept in the Quality As-
surance Unit and in the Production Qual-
ity Management Department of J. Uriach
y Compañía S.A. A third closed and sealed
copy randomised list was prepared for the
CRO MDS PS Pharma Services. In addi-
tion, once the study was concluded, all the
individual envelopes were returned to the
monitor, who checked that none of them
had been opened for an unjustified reason.
After the lock of study database, the copy
kept by the Quality Assurance Unit was
opened and filed in the master file of the
study” (further information obtained from
study investigator)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote from study: ”... double-blind,
placebo-controlled... study..”
Further information from study investi-
gator: “This was a double-blind study so
that neither the investigator nor the patient
knew treatment assignation. To preserve
double blinding, medication was packaged
identically for both types of treatments,
with identical outside appearance of the
strips andboxes. Individual envelopes iden-
tified with the patient assignation num-
ber were prepared. Each one included the
identity of the treatment assigned to each
patient. These envelopes, duly closed and
sealed, were submitted to the investigator”
“All medication was given in a two tablets
scheme, that is, the 10 mg dose was given
in two (10 mg plus placebo) tablets, the 20
mg dose was given in two (10 mg plus 10
mg) tablets, and the placebo was given in
two (placebo plus placebo) tablets”
Further information from study investiga-
tor
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”... double-blind, placebo-controlled...
study..”
Comment: as above
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No ITT; no actual scores given for DLQI,
even at baseline
41/334 lost to follow-up (12.2%) with 293
evaluable participants
Reasons for withdrawal: rupatadine 10 mg:
participant decision n = 4; loss to follow-
up n = 1; exclusion criteria n = 2; treatment
failure n = 7; non-attendance at scheduled
visits n = 2; other n = 1
Rupatadine 20 mg: loss to follow up n = 1;
exclusion criteria n = 3; treatment failure n
= 4; lack of compliance n = 1
Placebo: participant decision n = 2; loss to
follow-up n = 1; serious adverse event n =
1; treatment failure n = 11
Selective reporting (reporting bias) Low risk SAF population stands for safety popula-
tion (i.e. all randomly assigned participants
who received any study drug). Figure 2 in
the study report is done with the ITT pop-
ulation, as 5 patients did not present the
efficacy variables; this is why the intention-
to-treat analysis was performed in 329 par-
ticipants
In Figure 1, the number of participants
completing the trial from the placebo group
is 98, not 88 (as confirmed by study inves-
tigator)
DLQI scores not stated in published report
(percentages only)
Other bias Unclear risk Funder: J Uriach y Compania, Spain
Go 1989
Methods Design: double-blind randomised 3-arm RCT comparing cetirizine, terfenadine and
placebo in a cross-over study
Duration: cross-over study lasting for 6 weeks, subdivided into 3 periods of 2 weeks
Participants Number of participants randomly assigned: 30
Sex: not stated
Age of participants, years: 15 to 69 (mean 48.8), but included at least 1 participant
ineligible by age according to exclusion criteria
Unit of allocation: cross-over
Country and setting: Netherlands, Belgium; setting not stated
Inclusion criteria of the trial
• Chronic CSU of at least 6 weeks’ duration with at least 1 daily episode of weals
and pruritus
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Exclusion criteria of the trial
• Younger than 16 years, pregnancy, lactation, impaired renal or hepatic function,
angioneurotic oedema, glaucoma pressure or aspirin-sensitive urticaria. Washout of up
to 14 days if other medication taken before study commenced
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Cetirizine 10 mg at night for 2 weeks plus placebo every morning
• Terfenadine 60 mg twice daily
• Placebo twice daily for 2 weeks
No washout between treatments
Participants could elect to finish particular treatment before 2 weeks was up and to move
to next treatment in sequence
Duration of intervention: short-term (2 weeks per intervention)
Length of follow-up: 6 weeks (i.e. follow-up extended beyond cessation of therapy)
Outcomes Timing of outcome assessment: at 2 weeks
Primary outcomes of the trial
• Investigator-recorded presence/absence of “giant” (undefined) or other weals: 0
(0), 1 (< 20), 2 (> 20), erythema and oedema (baseline, plus at end of each treatment)
• Participant daily diaries-itching, erythema and weals (0 = none, 1 = mild, 2 =
moderate, 3 = severe)
• Also VAS for overall condition
Secondary outcomes of the trial
• Reasons for discontinuation
• Adverse events: incidence of side effects. Serious adverse events unclear for all 3
treatments. Minor adverse events: cetirizine: sedation; headache; dizziness; nausea.
Terfenadine: sedation; headache; malaise. Placebo: sedation; headache; dizziness;
nausea; other GI disturbance. Quality of life measures: none
• Serious adverse events unclear for all 3 treatments
• Minor adverse events: cetirizine: sedation; headache; dizziness; nausea;
terfenadine: sedation; headache; malaise; placebo: sedation; headache; dizziness;
nausea; other GI disturbance.
Clinician or participant report: both
Notes Study investigators concluded as follows: By investigatormeasures, cetirizine significantly
was better than placebo in all outcomes; terfenadine findings were only borderline or
were not significant
By participant measures, both drugs were equally (and statistically) superior to placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
102H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Go 1989 (Continued)
Allocation concealment (selection bias) Unclear risk No allocation concealment methods de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study states that it was double-blind
Quote: ‘products were given as identical
capsules bid, with placebo as the morning
intake in the cetirizine sequence’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study states that it was double-blind. Un-
clear how outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2/30 were excluded after placebo sequence
(refusal to participate) (6%)
Serious adverse events were unclear for all
3 treatments
10/30 early withdrawals from treatment:
inefficacy in placebo group n = 3; adverse
events: cetirizine n = 1; placebo n = 1; terfe-
nadine n = 3; unspecified reason: placebo:
n = 2. No ITT (although low dropout rate)
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported.
Mixed dichotomous and continuous out-
come reporting
Other bias Unclear risk Funder: UCB (makers of cetirizine)
Godse 2007
Methods Design: randomised double-blind placebo-controlled parallel multi-centre study com-
paring efficacy of fexofenadine and levocetirizine
Duration: up to 1 month
Participants Number of participants: 40 (20 in each group)
Sex: 50% male, 50% female
Age of participants, years: 14 to 70
Unit of allocation: participant
Country and setting: India; setting hospital clinic
Inclusion criteria of the trial
• Described as having CSU; criteria for diagnosis not described. No infection or
underlying cause of diagnosis. Blood count, urine and sugar analysed before treatment
began
• Informed consent
Exclusion criteria of the trial
• Other than pregnancy or lactation, not stated
• Previous unresponsiveness to antihistamine: not stated
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Interventions Interventions, dose, duration
• Fexofenadine HCl 180 mg once daily
• Levocetirizine 5 mg daily
For relief of symptoms up to 1 month
Duration of intervention: intermediate-term (up to 1 month)
Length of follow-up: up to 4 weeks
Outcomes Timing of outcome assessment: 2 week and 4 weeks
Primary outcomes of the trial
• Mean change in Urticaria Activity Score (defined in paper) at 2 weeks and 4
weeks (compared with baseline)
Secondary outcomes of the trial
• Adverse events: fexofenadine: headache; levocetirizine: drowsiness
• Quality of life measures: none
Clinician or participant report: clinician
Notes Study investigators concluded that fexofenadine was superior to levocetirizine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”All participants were divided into
two groups,” described as randomised but
no details given
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk 2/20 participants in levocetirizine group
were lost to follow-up (no reasons given)
and were replaced by 2 new participants.
No ITT
Selective reporting (reporting bias) High risk Small study; no rawdata;means and SDs of
scores only; results not expressed as partic-
ipant numbers. States placebo controlled,
but no placebo results reported
Other bias Unclear risk Sponsor: Sanofi-Aventis and Systopic Lab-
oratories (provided drugs)
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Methods Design: cross-over study comparing cetirizine with placebo
Duration: 1 week
Participants Number of participants randomly assigned: 32
Sex: 50% female
Age of participants, years: range 18 to 46 (mean 30.4 ± 8.2)
Unit of allocation: cross-over
Country and setting: Singapore; secondary care
Inclusion criteria of the trial
• Chronic idiopathic urticaria
Exclusion criteria of the trial
• Angio-oedema, liver or renal disease, steroids in last 28 days
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Cetirizine 10 mg at night for 1 week
• Placebo at night for 1 week and crossed over
Length of follow-up: 1 week
Duration of intervention: short-term (1 week per intervention)
Outcomes Timing of outcome assessment: 1 week
Primary outcomes of the trial
• Visual analogue scale of baseline urticaria severity (unclear over what period this
related to): 0 = very bad, 100 = excellent
• Daily diary for itching and weals: 0 = none, 1 = mild, 2 = moderate, 3 = severe
• Initial mean severity on VAS by investigators: 45.5 out of 100 (range 21-94)
• Cetirizine yielded significantly better scores than placebo on physician and
participant VAS and on participant diaries for itch and weals
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: minor adverse events: cetirizine: drowsiness; placebo: drowsiness
Clinician or participant report: both
Notes Study investigators concluded that cetirizine yielded significantly better scores than
placebo on physician and participant VAS and in participant diaries for itch and weals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) High risk No allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Probably done
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Investigators’ assessment of severity onVAS
Incomplete outcome data (attrition bias)
All outcomes
High risk No ITT. No mention of serious adverse
events or dropouts due to them. 4 partici-
pants (12.5%) lost to follow-up
Selective reporting (reporting bias) High risk Results derived from visual analogue scales;
not statedwhether groupswere comparable
at baseline
Other bias Unclear risk Funder: none
No washout between treatments, but no
sequential effect shown
Grant 1988
Methods Design: double-blind multi-centre 3-arm trial of terfenadine, chlorpheniramine and
placebo
Duration: 6 weeks
Participants Number of participants randomly assigned: 136
Age group and gender: not stated
Unit of allocation: participant
Country and setting: USA; setting recruited from medical practices of principal investi-
gators at 10 university research clinics (assumed that the practices were the settings)
Inclusion criteria of the trial
• Pruritic weals of unknown cause for 3 days per week for 6 consecutive weeks
Exclusion criteria of the trial
• Participants previously unresponsive to antihistamines were excluded: pregnant,
lactating or not using effective contraception, concomitant medications, abnormality
in laboratory values, medical history or physical examination findings
Interventions Interventions, dose, duration
Participants entered a single-blind placebo period for a week, and if hives of moderate
severity were present for 3 days during the week, participants were assigned to
• Terfenadine 60 mg twice daily
• Chlorpheniramine 4 mg 3 times a day
• Placebo for 6 weeks (frequency of placebo not stated)
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: up to 6 weeks
Outcomes Timing of outcome assessment: weekly for 6 weeks
Primary outcomes of the trial
• Mean symptom scores recorded by participants during baseline single-blind phase
and double-blind 6-week period
• Number of hives: none, 1 to 5, 6 to 15, 16 to 25, > 25
106H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Grant 1988 (Continued)
• Redness: absent, slight, definite, extreme
• Itching: absent, mild, moderate, severe
• Waking with hives: none, < 1 hour, 1 to 6 hours, > 6 hours
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: including drowsiness, fatigue/tiredness, headache, nausea
Clinician or participant report: investigators and participants
Notes Study investigators concluded that chlorpheniramine was not statistically significantly
different from placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation: Quote (page
575): ”participantswere randomly assigned
to one of three groups of equal size...”
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method of blinding unclear: Quote (page
575): ”Acceptable participants entered the
first phase of the study and were adminis-
tered placebo in a single-blind fashion for
a week. Those who developed moderately
severe hives for at least 3 days that were
actually observed by the investigators were
then enrolled in the double-blind phase”
Also, unclear if blinding adequate: quote:
“In order to limit the number of drop-outs,
diphenhydramine 25mg capsules were of-
fered as relief medication”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear method of blinding outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk 122/136 who were randomly assigned
completed the study (of an undisclosed
number, ’more than half ’ were initially
screened but excluded)
14 (10.2%) were lost to follow-up
Withdrawals due only to treatment failure:
terfenadine n = 1; chlorpheniramine n = 4;
placebo n = 9. Unbalanced between groups
but unlikely to introduce bias
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Selective reporting (reporting bias) High risk Results presented graphically only, no par-
ticipant numbers or means with SD
Other bias Unclear risk Participants allowed a different antihis-
tamine if uncontrolled: 22/42 (52%) of
placebo group took diphenhydramine; 12/
46 (26%) of chlorpheniramine group and
4/46 (9%) of terfenadine group already a
subgroup, as participants unresponsive to
antihistamines were excluded
Funder: none stated
Gu 2002
Methods Design: multi-centre (4 centres) randomised double-blind parallel 2-arm study of deslo-
ratadine vs loratadine
Duration: 28 days
Participants Number of participants randomly assigned: 158
Sex: male 45%, female 64%
Age of participants, years: 18 to 65, desloratadine mean 38.6; loratadine mean 39.1
Unit of allocation: participant
Country and setting: China; secondary care
Inclusion criteria of the trial
• Mean age 16 to 65 male or female
• Known CSU
• Classical weal (not longer than 24 hours)
• Chronic idiopathic urticaria > 6 weeks
• Weal seen on day of assessment
• Participants able to consent to study
Exclusion criteria of the trial
• Other form of urticaria due to insect-, food- and drug-induced urticaria, cold
urticaria, pressure urticaria, solar urticaria, cholinergic, etc., urticaria vasculitis, SLE,
thyroid-induced urticaria
• Occupation pilot, driver
• Cardiac disease and cardiac arrhythmia, liver disease, peptic ulcer and other
chronic disease
• Pregnant women, breast feeding and any women who plan to have pregnancy
• Known allergies to desloratadine and loratadine, multi-drug allergies
• Participated in another clinical trial within last 3 months
• Using cardiac medications, morphine and sedatives
• Non-compliant with medications, unable to attend follow-up, unforeseen
circumstances (e.g. accident), not willing to consent
• Previous unresponsiveness to antihistamine: not mentioned
Duration of disease in desloratadine group 26.9 weeks; loratadine group 26.1 weeks
Groups comparable at baseline with t value and P value in Chart 2
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Interventions Interventions, dose, duration
• Desloratadine 5 mg/d by mouth once daily, 28 days
• Loratadine 10 mg/d once daily by mouth, 28 days
Duration of intervention: 28 days (intermediate)
Length of follow-up: seen before treatment, at 14 days, at 28 days
Concomitant/rescue treatment: not mentioned
Outcomes Timing of outcome assessment: 14 days and 28 days
Primary outcomes of the trial
• Total symptoms scores, number and size of weals
• Symptom improvements, weal number, weal size, redness, itching intensity
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: including severity of adverse events
◦ Mild: not requiring intervention
◦ moderate: obvious but can continue with the trial
◦ Severe: symptoms needing medication
◦ Adverse events that may be/may not be/obviously related to trial drugs
Timing of outcome assessment: seen before treatment, at 14 days and at 28 days
Clinician or participant report: clinician and participant
Notes Study investigators concluded that desloratadine is safe and effective in the treatment
of CSU. No significant differences between the 2 groups, no serious adverse events.
Desloratadine safe and effective
Main study report in Chinese
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants and personnel were blinded to
treatment group
Not mentioned clearly
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors were blinded to treat-
ment group
Not mentioned clearly
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, no details about dropout in trans-
lation of published report. ITTanalysis car-
ried out: unclear
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Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported,
but reporting of adverse events is unclear.
Severity of adverse advents and whether or
not these were likely to have been caused by
trial medication were specified as an out-
come, but reported results are unclear and
state only that no serious adverse events oc-
curred
Other bias Unclear risk Funder: not stated
Assessment of compliance undertaken but
not clearly stated, apart from exclusion cri-
teria
Guo 2003
Methods Design: randomised double-blind parallel-group comparison ofmizolastine vs loratadine
Duration: 4 weeks
Participants Number of participants randomly assigned: 47; n = 24 mizolastine, n = 23 loratadine
Sex: 36% male, 55% female
Age of participants, years: 17 to 53, mizolastine mean 34.9; loratadine mean 33.0
Unit of allocation: participant
Country and setting: China; secondary care
Inclusion criteria of the trial
• CSU over 16 years of age
• Fulfilled criteria for chronic Idiopathic urticaria; mean duration 1.5 month to 144
months
• Symptoms within 24 hours before entry into the study
Exclusion criteria of the trial
• On medications, pregnant or lactating women; other types of urticaria, other skin
diseases (not specified); patients with severe liver, kidney and haematological diseases;
known allergies to H1-antagonists and allergic to mizolastine; taking astemizole < 8
weeks or another antihistamine fewer than 7 days; known to have heart disease, cardiac
arrhythmia, prolonged QT interval; known to have cancer; in high-intensity profession
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Mizolastine 10 mg
• Loratadine 10 mg once daily for 4 weeks
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: 7, 14 and 28 days
Primary outcomes of the trial
• Symptoms: itching severity (VAS score), diameter of largest weal, number of weals
per day, duration of weals (hours)
• Clinical improvements: complete suppression/significant improvements/
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improvements/no changes using SSRI score (symptom scores reduction index)
• Quality of life measures: not stated
Secondary outcomes of the trial
• Adverse events: dry mouth, sleepiness, lethargy, no differences in side effects
between the 2 groups
Clinician or participant report: clinician and participant
Notes Study investigators concluded that no difference in side effects was found between the
2 groups. Findings indicated that the effect of mizolastine was much better than that of
loratadine, and it could be selected as the priority treatment for CSU
Main study reported in Chinese
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Double-blind randomisation stated.Quote
(page 482): “divided into two groups by
randomised method”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 482): “double-blind,” but no
further details given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 482): “double-blind,” but no
further details given
Incomplete outcome data (attrition bias)
All outcomes
High risk Stated 47 cases, but analyses include 23 in
each group; data analysis was based on 46
cases; no reason given for this dropout
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk None detected
Funder: not stated
Handa 2004
Methods Design: randomised 2-arm double-blind study of cetirizine vs fexofenadine
Duration: 28 days
Participants Number of participants randomly assigned: 116; n = 59 cetirizine; n = 57 fexofenadine
Sex: not stated
Age of participants, years: range of 17 to 65
Unit of allocation: participant
Country and setting: India; dermatology institute clinic
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Inclusion criteria of the trial
• CSU (weals for at least 2 days per week for consecutive weeks before study)
Exclusion criteria of the trial
• Other forms of urticaria, dermatographism, pregnant, lactating
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Cetirizine 10 mg/d
• Fexofenadine 180 mg/d
Duration of intervention: intermediate-term (28 days)
Length of follow-up: 28 days
Outcomes Timing of outcome assessment: days 14 and 28
Primary outcomes of the trial
• Final response: symptom-free: no signs or symptoms; partial improvement, no
improvement (judged by physician)
• Participant evaluation by “analogue scale”: itching: 0 = none; 1 = mild, not
annoying; 2 = moderate, annoying and troublesome; 3 = severe, interfering with sleep
and daily activities
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: minor adverse events (not requiring treatment withdrawal):
included drowsiness, constipation, epigastric pain, cough, headache plus swollen feet
Clinician or participant report: participant and investigator
Notes Study investigators concluded that cetirizine seemed to have therapeutic advantage over
fexofenadine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Method of randomisation not stated, de-
scribed as randomised. Further informa-
tion from study investigator states: “For the
study we generated a randomisation list us-
ing a random number table”
Allocation concealment (selection bias) Low risk Study investigator states: “The code was
kept with the central authority-not directly
involved with the study and assessment of
endpoints. Both the investigators and pa-
tientswere blinded since the central author-
ity provided the patients with similar look-
ing sealed envelopes containing the medi-
cation and labelled only as A or B”
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study investigator states: “Both the inves-
tigators and patients were blinded since the
central authority provided the patientswith
similar looking sealed envelopes containing
the medication and labelled only as A or
B. The blinding was opened after assessing
the results and the statistical analysis of the
two groups A and B. It was done by inquir-
ing from the central authority which was
dispensing the drugs to the patient”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study investigator states: “Both the inves-
tigators and patients were blinded since the
central authority provided the patientswith
similar looking sealed envelopes containing
the medication and labelled only as A or
B. The blinding was opened after assessing
the results and the statistical analysis of the
two groups A and B. It was done by inquir-
ing from the central authority which was
dispensing the drugs to the patient”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk High dropout rate, no ITT (no ITT con-
firmed by study investigator); 19/116 lost
to follow-up in total (13%): 7 in cetirizine
group and 12 in fexofenadine group within
2 weeks, ”the most common reason be-
ing treatment failure.” Unclear if this con-
tributes to bias
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported,
but other outcomes were reported as well
(e.g. duration of weals, diurnal variation,
intensity of itching, presence of weals).
Symptoms during the day were not re-
ported by groups
Other bias Low risk Funder: not stated. No indication of com-
parability of groups at baseline
Hao 2003
Methods Design: randomised multi-centre double-blind 2-arm parallel-group comparison of
desloratadine vs loratadine
Duration: 28 days
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Participants Number of participants randomly assigned: 217; desloratadine n = 108; loratadine n =
109
Sex: male 43.8%, female 56.2%
Age of participants, years: 18 to 65
Unit of allocation: participant
Country and setting: China, secondary care, Southern Hospital, 3rd Military Medical
University. Chongqing, China
Inclusion criteria of the trial
• CSU by clinical signs, chronic Idiopathic urticaria > 6 weeks, urticaria not due to
other causes
• Consented, agreed for clinical study, not on antibiotics or other agents
Exclusion criteria of the trial
• Known allergies to desloratadine and loratadine
• Taking immunosuppressants (and other medications, type not stated), taking
desloratadine or loratadine within 4 weeks of start of study
• Previous unresponsiveness to antihistamine: unclear, washout period-treatment
commenced after 4-week washout period from previous antihistamines or
immunosuppressants (type not stated)
• Taking medication that prolonged QT interval; high-intensity profession
• Previous unresponsiveness to antihistamines not stated
Interventions Interventions, dose, duration
• Desloratadine 5 mg per day
• Loratadine 10 mg per day in once-daily doses
Duration of intervention: intermediate-term (28 days)
Length of follow-up: 28 days
Outcomes Timing of outcome assessment: 7, 14 and 28 days
Primary outcomes of the trial
• Effectiveness and safety. Symptoms: itching severity; diameter of largest weal;
number of weals per day; degree of weal swelling; duration of weals (hours)
• Clinical improvements: complete suppression/significant improvement/
improvement/no change
• Quality of life measures: none
Secondary outcomes of the trial
• Safety of medications (blood pressure, heart rate/FBC/U/E LFT)
• Adverse events: dry mouth, sleepiness, lethargy, no details were given about why
participants with severe adverse effects required withdrawal
Clinician or participant report: clinician and participant
Notes Main study report in Chinese
Study investigators concluded that desloratadine is an effective and safe agent for CSU
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Stated to be randomised
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind, no further de-
tails given about blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind, no further de-
tails given about blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3/105 dropped out or were lost from the
desloratadine group; 3/106 dropped out or
were lost from the loratadine group; no rea-
sons given
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk None detected. Funder: not stated
Harvey 1981
Methods Design: double-blind randomised cross-over study in which participants were treated
sequentially (5-arm comparison of hydroxyzine plus placebo, hydroxyzine plus terbu-
taline, hydroxyzine plus chlorpheniramine, hydroxyzine plus cimetidine)
Duration: 7 to 10 days
Participants Number of participants randomly assigned: 23
Sex: 79% female
Age of participants, years: mean 37 (range 24-64)
Unit of allocation: cross-over participants
Country and setting: USA; setting University of Colorado Health Sciences Center
Inclusion criteria of the trial
• Chronic urticaria refractory to treatment, normal physical examination findings
and laboratory values
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: population was selected as refractory
to treatment
Interventions Interventions, dose, duration
Cross-over study in which participants were treated sequentially with 5 regimens in
double-blind random sequence
• Hydroxyzine plus terbutaline (beta agonist) = 25 mg 4 times a day plus 2.5 mg 4
times a day for 7 to 10 days
• Hydroxyzine plus cyproheptadine = 25 mg 4 times a day plus 4 mg 4 times a day
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for 7 to 10 days
• Hydroxyzine plus chlorpheniramine = 25 mg 4 times a day plus 4 mg 4 times a
day for 7 to 10 days
• Hydroxyzine plus cimetidine (H2-antihistamine) = 25 mg 4 times a day plus 300
mg 4 times a day for 7 to 10 days
• Hydroxyzine plus placebo = 25 mg 4 times a day for 7 to 10 days (details of
placebo not stated)
Duration of intervention: short-term (7-10 days each intervention)
Length of follow-up: unclear
Outcomes Timing of outcome assessment: 7 to 10 days
Primary outcomes of the trial
• Participants selected which regimen they believed was most effective; symptom
diary recorded twice daily (for final 5 days of each treatment regime)-hive count: 0
(none), 1 (1-6), 2 (7-12), 3 (> 12); itching: 0 = none, 1 = mild, 2 = moderate, 3 = severe
• Suppression of skin weals following intradermal histamine
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: extreme tremulousness (n = 2) in terbutaline necessitated
abbreviated treatment course
Clinician or participant report: participant and investigator
Notes Study investigators concluded that hydroxyzine plus cimetidine was significantly better
than other combinations. Hydroxyzine had transient soporific effects but was well tol-
erated. Unclear whether soporific effects were due to hydroxyzine and not to one of the
other sedating antihistamines
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated: ”par-
ticipants were treated orally in a double-
blind randomised serial fashion...”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk ”participants were treated orally in a
double-blind randomised serial fashion...”
Method of blinding unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ”participants were treated orally in a
double-blind randomised serial fashion...”
Method of blinding unclear
Incomplete outcome data (attrition bias)
All outcomes
High risk 19/23 completed. 4 removed because of
non-compliance (17% lost to follow-up).
One participant not accounted for
Extreme tremulousness (n = 2) in terbu-
116H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Harvey 1981 (Continued)
taline necessitated ”abbreviated treatment
course”
ITT unclear (some terbutaline participants
did not complete the course, but non-
compliant participants were excluded from
analysis)
Selective reporting (reporting bias) High risk Adverse events not clearly reported
Other bias Unclear risk Funder: NIH Allergic Disease Center
Grants
Study duration not clearly defined (”7-10
days”)
No stated exclusions, and physical ur-
ticariamay have been included.Twogroups
were given a combination of 2 first-gen-
eration antihistamines; concomitant treat-
ment with hydroxyzine allowed in all
groups
Hjorth 1988
Methods Design: double-blind randomised 2-arm cross-over study of terfenadine vs clemastine
Study 1: clemastine vs placebo
Study 2: terfenadine vs placebo
Duration: 2 weeks
Participants Number of participants randomly assigned: 60; 30 per group in each cross-over phase
Sex: 33% male, 67% female
Age of participants, years: 18-72 (mean 37)
Unit of allocation: cross-over, no washout period described
Country and setting: Denmark; setting unclear
Inclusion criteria of the trial
• CSU (no definition stated), may include participants with atopic dermatitis
Exclusion criteria of the trial
• None stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Clemastine 1 mg twice daily for 2 weeks
• Placebo twice daily for 2 weeks
• Followed by cross-over to terfenadine 60 mg twice daily for 2 weeks
Duration of intervention: short-term (2 weeks per intervention)
Length of follow-up: 14 days
Outcomes Timing of outcome assessment: 14 days
Primary outcomes of the trial
• Participants kept written record of number of weals, itch severity and side effects
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• Physicians’ overall rating: none, moderate, excellent
• Efficacy rated according to number of weals, as symptom score used in results was
not defined
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: only drowsiness reported
Clinician or participant report: participant and clinician
Notes Study author concluded that terfenadine was more efficacious than clemastine or placebo
No review outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”in random order, participants were as-
signed...”; no further details given
Allocation concealment (selection bias) Unclear risk Unclear, no details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study is stated to be double-blind; unclear
how this was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study is stated to be double-blind; unclear
how this was achieved, as only 1 study au-
thor/single investigator was involved
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants who dropped out
from each group not stated. Withdrawals
not mentioned
Selective reporting (reporting bias) High risk Results incompletely reported, no numer-
ical data (graphs only); able to rate effi-
cacy only according to number of weals, as
symptom score used in results was not de-
fined
Other bias Unclear risk Funder: not stated
Diagnosis of CSU not clearly defined; un-
clear whether concomitant medications al-
lowed; single study author
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Methods Design: double-blind randomised controlled 3-arm study comparing levocetirizine vs
desloratadine vs placebo
Duration: not stated
Participants Number of participants randomly assigned: 107; levocetirizine group: 37; desloratadine
group: 34; placebo: 36
Sex: not stated
Age of participants, years: 18 to 60
Unit of allocation: participant
Country and setting: Albania; tertiary centre
Inclusion criteria of the trial
• CSU symptoms at least 6 weeks
Exclusion criteria of the trial
• Not specified
Interventions Interventions, dose, duration
• 5 mg levocetirizine and
• 5 mg desloratadine
(each increasing weekly to 10 mg, then 20 mg)
Duration of intervention: unclear
Length of follow-up: not stated
Outcomes Primary outcomes of the trial
• Timing of outcome assessment: not stated
• Number of participants symptom free
• Adverse events: no serious adverse events with either drug
• Quality of life measures: Increasing doses improved quality of life
Notes Study investigators concluded that Increasing the dosage of levocetirizine and deslorata-
dine up to 4-fold improved chronic urticaria symptoms without compromising safety
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study states randomly assigned, but not
clear how done
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study says double-blind but no other de-
tails
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants accounted for, but 9 from
active arms left the study (reasonnot stated)
, and all participants fromplacebo arm (36)
dropped out from the study
Selective reporting (reporting bias) Unclear risk No timing of assessment stated
Other bias Unclear risk Funder: not specified
This study was available as a short confer-
ence abstract only; we were unable to iden-
tify a published report or to obtain further
information from the study investigator
Juhlin 1987
Methods Design: randomised double-blind 3-arm cross-over placebo-controlled study of acrivas-
tine and clemastine
Duration: 5 days each cross-over period
Participants Number of participants randomly assigned: 18
Sex: 33% male, 67% female
Age of participants, years: 14 to 75 (mean 43.2)
Unit of allocation: cross-over
Country and setting: UK; setting unclear
Inclusion criteria of the trial
• Informed consenting adults, with CSU
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Cross-over: All participants had acrivastine 8 mg 3 times daily for 5 days, then
• Clemastine 1 mg 3 times daily for 5 days, then
• Placebo 3 times daily for 5 days
Cycle through each regimen with 2-day breaks in between with no relevant treatment
Duration of intervention: short-term (5 days per intervention)
Length of follow-up: unclear (at end of each 5-day treatment period?)
Outcomes Timing of outcome assessment: 5 days
Primary outcomes of the trial
• Questionnaire: itching/wealing/caused drowsiness/suited participant/best overall
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: no withdrawals/serious adverse events. Minor adverse events:
drowsiness
Clinician or participant report: investigator and participant questionnaire
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Notes Study investigators concluded no significant differences in efficacy were noted between
acrivastine and clemastine; both were significantly preferred by participants over placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but randomisa-
tion method was unclear
Allocation concealment (selection bias) Unclear risk No allocation concealment described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk ”A double-blind, placebo-controlled study.
” Mentioned only in title; no other details
given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ”A double-blind, placebo-controlled study.
” Mentioned only in title; no other details
given
Incomplete outcome data (attrition bias)
All outcomes
Low risk 18/18 completed. None lost to follow-up
Selective reporting (reporting bias) High risk Although both doctor questionnaire and
participant self-assessment were carried
out, only simple participant perceptions re-
ported; no objective data provided
Other bias Unclear risk Funder: Sponsorship: Wellcome Founda-
tion Ltd
Nomention of whether concomitant treat-
ments were permitted
Underpowered
Juhlin 1991
Methods Design: randomised double-blind cross-over 3-arm trial comparing 10or 20mgcetirizine
vs placebo
Duration: 15 days
Participants Number of participants randomly assigned: 30
Sex: 27% male, 63% female
Age of participants, years: range 15 to 70 (mean 43)
Unit of allocation: cross-over
Country and setting: Sweden; setting unclear
Inclusion criteria of the trial
• In the first study, participants had severe CSU (daily eruptions of weal) for mean
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of 4 years’ duration
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: reported as ’variably effective,’ but
non-responders were not excluded from this study
Interventions Interventions, dose, duration
• Cetirizine 10 mg/d for 15 days
• Placebo once daily for 15 days
After 15 days, participants were allowed to cross over with no washout period. Non-
responders were allowed to increase to twice-daily dosing
Duration of intervention: short-term (15 days)
Length of follow-up: end of each 15-day treatment period
Outcomes Timing of outcome assessment: 15 days. Visits at baseline and at end of each treatment
phase
Primary outcomes of the trial
• Participant daily diary for weals, erythema, pruritus and oedema: 0 = absent, 1 =
mild, 2 = moderate, 3 = severe
• VAS by participants for evaluation of condition: 0 to 100 mm
• Global evaluation of improvement judged on % basis: 91% to 100% = excellent;
30% or less = poor
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: minor adverse events: dry mouth, diarrhoea, heaviness of the
head, sedation. No serious side effects noted
Clinician or participant report: participant
Notes Study investigators concluded that cetirizine was significantlymore effective than placebo
in reducing incidence of erythema, weals and pruritus
Study 2 in the published report was a laboratory study on the effects of certain agonists;
the results were not included in this analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear method of randomisation. Partic-
ipants ’randomly assigned’
Allocation concealment (selection bias) Unclear risk Unclear. Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind study. Unclear how this was
done
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind study. Unclear how this was
done
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants who dropped out
from the study (if any) unclear
Selective reporting (reporting bias) High risk Extensive laboratory tests were carried out
(for adverse effects) but were not reported.
Measures of incidence and severity of weals
were reported
Other bias Low risk None detected. Funder: not stated
Kalivas 1990
Methods Design: randomised multi-centre parallel-group 3-arm double-blind placebo-controlled
study of cetirizine vs hydroxyzine vs placebo
Duration: 4 weeks
Participants Number of participants randomly assigned: 219; cetirizine: 69, hydroxyzine: 69, placebo:
73
Sex: not stated
Age of participants, years: 12+, no further details
Unit of allocation: participant
Country and setting: USA; centres included medical and science centres and private
practice
Inclusion criteria of the trial
• Clinically documented CSU
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Cetirizine 5 mg once daily (increasing to max 20 mg once daily in 2 steps “as
necessary”) for 4 weeks
• Hydroxyzine 25 mg once daily (increasing to twice daily, then 3 times daily “as
necessary”) for 4 weeks
Intermediate dose of cetirizine not stated
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: baseline, 3 days, 1 week, 2 weeks, 3 weeks, 4 weeks
Primary outcomes of the trial
• Daily diary with 4-point scale: measured number, size, duration of lesions and
number of urticarial episodes, degree of pruritus; same scale used by investigator at
baseline, after 3 days’ treatment, 1 week, 2 weeks, 4 weeks. Scale as follows: number of
lesions: 0 (0), 1 (1-10), 2 (11-20), 3 (> 20); number of episodes: 0 (0), 1 (1), 2 (2-3), 3
(> 3); average lesion size in inches: 0 (0), 1 (< 0.5), 2 (0.5-1), 3 (> 1); duration of lesions
in hours: 0 (0), 1 (1-4), 2 (4-12), 3 (12-24); pruritus: none/mild/moderate/severe
• Adverse events (serious adverse events requiring treatment withdrawal): minor
adverse events (not requiring treatment withdrawal): headache, somnolence, nausea,
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dizziness, fatigue, dry mouth, dyspepsia
• Quality of life measures: none
Secondary outcomes of the trial
• Global evaluation of treatment efficacy, sedation. After 4 weeks, investigator made
global assessment on 5-point scale: 0 = no improvement/worse, 1 = slight
improvement, 2 = definite improvement, 3 = highly effective, 4 = complete
disappearance of symptoms
Clinician or participant report: participant
Notes Investigator concludes that cetirizine and hydroxyzine have equivalent efficacy, and both
are superior to placebo; no significant differences in adverse effects were noted, except
for somnolence and nausea; no significant differences between cetirizine and placebo
were observed in terms of somnolence
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants “randomly assigned”; quote
(page 1015), no further information
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Stated to be double-blinded but unclear
how this was achieved; in addition, partici-
pants and personnel do not appear blinded
Quote (page 1015): ”All patients receiv-
ing active drugs began by taking the low-
est daily dose... The dose was titrated up as
necessary in two steps to respective allow-
able maximums...“
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Stated to be double-blinded but unclear
how this was achieved; in addition, partici-
pants and personnel do not appear blinded
Quote (page 1015): ”All patients receiv-
ing active drugs began by taking the low-
est daily dose... The dose was titrated up as
necessary in two steps to respective allow-
able maximums...”
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up not clearly described
31/219 randomly assigned lost to follow-
up (14%)
Each table provides different numbers of
included participants; not clear why and
when participants were lost to follow-up;
study authors note in discussion that 10%
of cetirizine group, 7% of hydroxyzine
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group and 24% of placebo group withdrew
because of lack of efficacy
Adverse events (serious adverse events re-
quiring treatment withdrawal):
• Cetirizine group: 1 withdrawal due
to adverse effects (ns)
• Hydrozyzine group: 3 withdrawals
due to adverse effects (ns)
• Placebo group: 1 withdrawal due to
adverse effects (ns)
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk None detected. Funder: not stated
Kaplan 2005
Methods Design: multi-centre randomised double-blind parallel-group placebo-controlled 2-arm
study of fexofenadine vs placebo
Duration: 4 weeks
Participants Number of participants randomly assigned: 259
Sex: 26% male, 74% female
Age of participants, years: 247 younger than 65; 8 older than 65
Unit of allocation: participant
Country and setting: US; setting secondary care
Inclusion criteria of the trial
• Chronic idiopathic urticaria
Exclusion criteria of the trial
• < 12 years, inactive urticaria at baseline, less than moderate severity of pruritus,
pregnancy or lactation, mental illness, malnutrition, blood dyscrasia, renal/hepatic
insufficiency, chronic infection, drug abuse, alcoholism, cancer, malabsorption,
previous hypersensitivity to fexofenadine, other major systemic disease
• Previous unresponsiveness to antihistamine: excluded those unresponsive to
antihistamine treatment
Interventions Interventions, dose, duration
• Fexofenadine 180 mg once daily for 28 days
• Placebo once daily for 28 days
Single-blind placebo run-in phase for 2 to 5 days
At next visit, participants had to qualify for entry into randomised portion of study, then
were randomly assigned 2:1 to fexofenadine:placebo
Duration of intervention: intermediate-term (28 days)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: seen weekly for 4 weeks
Primary outcomes of the trial
• Efficacy assessment: change from baseline scores, participants’ mean daily number
of weals, pruritus severity scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 =
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warrants physician)
• Complete suppression of urticaria (from patient global assessment scores)
• Proportion with good/excellent response (decreased mean daily number of weals
and pruritus severity; mean pruritus severity)
• Secondary efficacy assessment: number, frequency, size, duration of lesions;
severity of pruritus according to modified total symptoms score: 0 (0 weals), 1 (1-10
weals), 2 (11-20 weals), 3 (> 20 weals); number of total weal episodes longer than 1
hour apart, average size of lesions, pruritus severity
• Participant and investigator global evaluation of overall efficacy at final visit or
early termination visit (0 = no improvement/worsening, 1 = slight but insufficient
improvement, 2 = definite improvement, 3 = substantial improvement, 4 = complete
disappearance of symptoms)
• Quality of life measures (from Spector 2007): mean total DLQI score from
baseline to 4 weeks compared with placebo in 2 individual domains (symptoms and
feelings; personal relationships)
Secondary outcomes of the trial
• Adverse events: asthma requiring hospitalisation, headache. Not stated whether
these required treatment withdrawal
• WPAI (work productivity and activity impairment)
• Pharmokinetic variables were reported elsewhere
Notes Same study as Spector 2007
Study investigators concluded that fexofenadine at 180 mg once daily offered effective
well-tolerated relief of the symptoms of urticaria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 662): ”Randomisation in a 2:
1manner to receive either fexofenadine hy-
drochloride,180mg, or placebo once daily”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study stated as double-blind. Initial single-
blind run-in with placebo for 2 to 5 days
Quote (page 663): “Patients received dou-
ble blind study medications packaged in
bottles with 40 tablets” (enough for course
of treatment)
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study stated as double-blind. Initial single-
blind run-in with placebo for 2 to 5 days.
Participants received study medication in
bottles with 40 tablets (enough for course
of treatment)
Comment: probably done, but unclear how
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outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Did not include participants lacking post-
baseline result. Unclear howmany dropped
out at each time point along with reasons
for dropout
Losses to follow-up of 259 randomly as-
signed: fexofenadine 12/167 (7%); 13/92
(14%): 7% dropped out of fexofenadine
group, 14% from placebo group (lack of
efficacy)
Adverse events: Most common reason for
loss to follow-up was lack of efficacy (6
of 13 from placebo group, and 1 of 12
from fexofenadine group). Other reasons
not stated
Asthma requiring hospitalisation: n = 1
in fexofenadine group; headache occurred
in 5% of fexofenadine group and 3% of
placebo group; not stated whether any of
these required treatment withdrawal
Numbers of participants in each study were
very unclear at each time point
Selective reporting (reporting bias) High risk Study authors combined unadjusted mean
DLQI scores from 2 weeks and 4 weeks
Other bias Unclear risk Funder: Aventis Inc (Sanofi-Aventis
Group)
Kint 1989
Methods Design: double-blind randomised multiple (3)-arm cross-over study comparing ceti-
rizine, terfenadine and placebo
Duration: 6 weeks
Participants Number of participants randomly assigned: 30 in sequence
Sex: 44% male, 56% female
Age of participants, years: 41.2 ± 14.7 (range 21-74)
Country and setting: Belgium; secondary care
Unit of allocation: cross-over
Inclusion criteria of the trial
• Not stated
Exclusion criteria of the trial
• 16 years; pregnancy/lactation; renal/hepatic dysfunction; glaucoma; angio-oedema
• Previous unresponsiveness to antihistamine: not stated
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Interventions Interventions, dose, duration
• Cetirizine 10 mg at night plus placebo every morning for 2 weeks
• Terfenadine 60 mg twice daily for 2 weeks
• Placebo twice daily for 2 weeks in random order (multiple cross-over using Latin
square design)
Unclear which treatments were compared at each phase
Duration of intervention: short-term (2 weeks)
Length of follow-up: 2 weeks (for each phase)
No washout between treatments; if intolerable, symptoms due to lack of response could
progress early to next in sequence (after clinic visit). Seen at each change in treatment
5 instances of rescue medications used in placebo group only (antihistamines n = 4,
dexamethasone n = 1) (against protocol)
Outcomes Timing of outcome assessment: end of weeks 1 and 3 at each phase
Primary outcomes of the trial
• At each visit, investigator noted presence or absence of weals or giant weals,
erythema, oedema; also VAS for overall assessment 0 to 100 (extremely poor to
excellent)
• Daily diary cards to record itching, erythema and weals; VAS weekly
• At last visit, participant and investigator stated which treatment they preferred
Secondary outcomes of the trial
• Compliance and protocol violations
• Quality of life measures: none
• Adverse events: minor sedation, headache, dry mouth, malaise, dizziness, GI
symptoms
Notes Study investigators concluded that no significant differences in efficacy were found be-
tween the 2 active treatments; both were better than placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Random sequence”; multiple sequence
defined by Latin square design
Allocation concealment (selection bias) Unclear risk Unclear, no apparent allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear how outcome assessors were
blinded to treatment allocation
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/30 participants lost to follow-up (10%)
. 2 dropouts due to lack of efficacy during
first sequence (cetirizine n = 1 and terfena-
dine n = 1); 1 dropout in second sequence
for same (cetirizine)
Selective reporting (reporting bias) High risk Results not clearly reported; placebo se-
quence had rescuemedication. Study inves-
tigators conclude... ”thus only for wheals
were borderline or significant differences
from placebo recorded by investigator”
5 instances of rescue medication used in
placebo group only (antihistamines n = 4,
dexamethasone n = 1) (against protocol)
Other bias Unclear risk Funder: UCB Braine-L’Alleud
Leyh 1989
Methods Design: randomised double-blind 4-armcross-over study to investigate efficacy of acrivas-
tine at 2 doses vs clemastine and placebo
Duration: 5 days in each arm
Participants Number of participants randomly assigned: 20
Sex: 60% female
Age of participants, years: 18 to 72 (mean 41.3)
Country and setting: Lubeck; secondary care
Unit of allocation: cross-over
Inclusion criteria of the trial
• Allowed participants with acute urticaria (longer than 2 weeks), although none
included with urticaria < 2 months
Exclusion criteria of the trial
• Systemic steroids in last 2 weeks, concurrent sedatives/antihistamines
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Acrivastine 4 mg 3 times daily for 5 days
• Cross-over acrivastine 8 mg 3 times daily for 5 days
• Clemastine 1 mg 3 times daily for 5 days
• Placebo 3 times daily for 5 days in random order
Unclear which treatments were compared at each phase
3-day washout initially, then 2-day break between treatments
Duration of intervention: short-term (5 days per intervention)
Length of follow-up: 5 days
Outcomes Timing of outcome assessment: 5 days
Primary outcomes of the trial
• Participants self-assessed daily: weals 0 to 4 (0 (0), 1 (1-5), 2 (6-10), 3 (11-20), 4
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(> 20)); itching 0 to 4 (0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe)
• Investigator at end of study recorded in his opinion which treatment worked best
and suited participant best overall
• Quality of life measures: none
Secondary outcomes of the trial
• Minor adverse events (not requiring treatment withdrawal): drowsiness
Clinician or participant report: investigator and participant (self-assessment form)
Notes Study investigators concluded that assessment showed all 3 active drugs were better than
placebo; no statistically significantly difference was noted between them
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study stated to be double-blind, but no de-
tails given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if blinded. As investigators appear
to have made subjective decision on best
treatment, it is possible that they were not
blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only 20 participants; no dropouts; no se-
rious adverse events noted. Raw figures not
shown (means only)
Selective reporting (reporting bias) Unclear risk Incomplete reporting of data (mean scores
only, without SD of self-assessment for
wealing, itching and overall discomfort).
Percentage scores of physician assessment
and overall improvement
Other bias Unclear risk Funder: Wellcome Research Laboratories
Leynadier 2000
Methods Design: randomised double-blind parallel-group 2-arm study ofmizolastine vs loratadine
Duration: 28 days
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Participants Number of participants randomly assigned: 61
Sex: 64% male, 46% female
Age of participants, years: 40 ± 13
Country and setting: France; secondary care
Unit of allocation: participant
Inclusion criteria of the trial
• Chronic idiopathic urticaria, < 2 episodes of urticaria during 3- to 7-day run-in
with symptom score < 2; age < 18 years
Exclusion criteria of the trial
• No exclusions stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Mizolastine 10 mg once daily for 4 weeks
• Loratadine 10 mg once daily for 4 weeks; 3 to 7 single-blind run-in
Not stated whether this was with placebo (although placebo seems likely)
Duration of intervention: short-term (28 days)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: 4 visits in total: at screening (day 3 or 7), at inclusion
(day 10), after 14 and 28 days of treatment
Primary outcomes of the trial
• Principal criteria included number of episodes of urticaria per week as evaluated
by investigator and evaluation by participant of the discomfort caused by urticaria
during the week before the visit. Investigator evaluated symptoms at baseline and at 2
and 4 weeks; number of urticaria episodes during the week before the visit, as recorded
in the participant’s self-evaluation notebook (SEN); whether the participant had an
urticaria episode at the time of the visit; number and size of weals; number of weals
and/or plaques: 0 (absent), 1 (10), 2 (> 10), 3 (body covered in plaques and/or weals);
size of plaques: 1 (1.5 cm), 2 (> 1.5 cm and ≤ 2.5 cm), 3 (> 2.5 cm); severity of
itching: 0 (absent), 1 (present, but mild), 2 (moderate), 3 (severe); and severity of any
associated angio-oedema. The severity of each symptom was scored using a 4-point
scale from 0 (symptom absent) to 3 (severe symptom), as was the clinical global
impression for angio-oedema (0 = absent; 1 = mild; 2 = moderate with tight feeling; 3 =
severe, disfiguring)
• Participants used the same scale to complete a daily diary; at baseline and at weeks
2 and 4, participants used a visual analogue scale (0 = no discomfort to 100 = extreme
discomfort) (related to that day). Overall mean daily score defined as sum of scores
evaluating severity of itching and number and size of weals was recorded daily by the
participant
• Quality of life measures: none
Secondary outcomes of the trial
• Signs and symptoms of urticaria episodes at time of visit, as evaluated by
investigator, tolerance to pharmacological effect, participant’s evaluation of signs and
symptoms of urticaria (mean overall daily score) and mean total duration of episodes
• Adverse events: serious leading to withdrawal: mizolastine: painful erythema of
hands
• Minor events: fatigue, drowsiness, dizziness, rhinitis
Clinician or participant report: investigator and participant
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Notes Study investigators concluded that no statistically significant differences in efficacy were
found between drugs, as measured by number of urticarial episodes and discomfort from
symptoms; duration of episodes shorter with mizolastine (not statistically significant)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Patients were randomly allocated...”; no
details given about method of randomisa-
tion
Allocation concealment (selection bias) Unclear risk Allocation concealment not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind study. Unclear how blinding
was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind study. Unclear how blinding
was achieved
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of participants completing the
study and evaluable does not match cor-
responding information given about non-
completers
7/61 lost to follow-up (11%): mizolastine
group: 3/26, loratadine group: 4/35
Withdrawals: adverse events: serious lead-
ing to withdrawal: mizolastine: painful ery-
thema of hands n = 1
Minor events: mizolastine: fatigue n = 2;
drowsiness n = 1; loratadine: drowsiness n
= 1; dizziness n = 1; rhinitis n = 1
A figure of n = 56 is given as the number
of evaluable participants in the published
report, but after withdrawals and losses to
follow-up, the number of participants re-
maining in the trial is 54
Selective reporting (reporting bias) Unclear risk All outcomes reported but presented only
as number of participants free of symp-
toms, which decreased significantly in both
groups (numbers not given; results ex-
pressed graphically and related to num-
ber of participants free of individual symp-
tom (e.g. pruritus), but not possible to tell
how many participants were symptom-free
overall
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Other bias Unclear risk Number of participants free of symptoms
decreased significantly in both groups, but
numbers not given; figures given relate to
numbers of participants free of individual
symptom (e.g. pruritus), but not possible to
tell how many participants were symptom-
free overall
Funder: none
Liu 2003
Methods Design: 5-centre double-blind parallel-group randomised trial of mizolastine vs lorata-
dine
Participants Number of participants randomly assigned: 213 enrolled: 104 mizolastine, 102 lorata-
dine, 206 completed the trial
Sex: mizolastine: male 46 (42.6%), female 62 (57.4%); loratadine: male 50 (47.6%),
female 55 (52.4%)
Age of participants, years: mizolastine 39.32; loratadine 37.9
Unit of allocation: participant
Country and setting: Beijing, China; multi-centre secondary care
Inclusion criteria of the trial
• CSU confirmed, age > 16 years, duration of disease > 6 weeks, frequency at least
twice/wk or occurrence 2 days/wk, symptoms less than 24 hours, urticaria within 24
hours before randomisation, signed and consented
Exclusion criteria of the trial
• Pregnant and lactating women, other types of urticaria (not chronic idiopathic
urticaria), hypersensitivity to H1-antagonist or known mizolastine allergies, known
serious liver dysfunction, kidney failure, ischaemic heart disease, endocrine
dysfunction, taking steroid/immunosuppressant (stopping medication within 4 weeks),
stopping astemizole less than 8 weeks before; reference is made in the study report to
participants stopping antibiotics within 7 days, but this is unclear
• Previous unresponsiveness to antihistamine: not stated
• Astemizole previously used; at least 8 weeks washout
Interventions Interventions, dose, duration
• Mizolastine 10 mg
• Loratadine 10 mg, once daily at night for 28 days
Duration of intervention: intermediate-term (28 days)
Length of follow-up: 28 days
Outcomes Timing of outcome assessment: 7, 14, 28 days
Primary outcomes of the trial
• Efficacy assessment based on symptom score reducing index (SSRI)
• Score of diameter of largest weal, weekly urticarial episodes
• Visual analogue score
• Quality of life measures: none
Secondary outcomes of the trial
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• Itching score, number of weals, diameter of largest weal, duration of urticaria
(weals), frequency of attacks per week, VAS score (participants rated severity of itch by
visual analogue scale)
• Adverse events: no serious adverse event. Other adverse events included sleepiness,
lethargy, dry mouth, headache, abdominal pain, constipation, nausea, diarrhoea,
anxiety and palpitations. One participant from the mizolastine group withdrew
because of severe diarrhoea
Clinician or participant report: participant and clinician.Outcomes reported by clinician
apart from VAS score (participant rated severity of itch by visual analogue scale)
Notes Study investigators concluded that mizolastine is quicker in action than loratadine, with
similar efficacy. The incidence of adverse effects is similar in the 2 groups
Main study report is written in Chinese
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 306): “randomly divided”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 306): “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 306): “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 206/213 completed, but study stated that
12 participants dropped out; it is unclear
if they dropped out from the number en-
rolled or the number completing
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported
Other bias Low risk None detected. Funder: not stated
Liu H-N 1990
Methods Design: double-blind 2-arm cross-over trial comparing nifedipine (calcium channel
blocker) with chlorpheniramine
Duration: 4 weeks
Participants Number of participants randomly assigned: 22
Sex: 13% male, 27% female
Age of participants, years: 36 (range 21-54)
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Unit of allocation: cross-over
Country and setting: Taiwan; secondary care
Inclusion criteria of the trial
• CSU for at least 6 weeks, with no underlying cause
Exclusion criteria of the trial
• > 18 years of age, pregnant or lactating
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
Washout of at least 12 hours, then randomised:
• Group 1: nifedipine 10 mg 4 times a day for 4 weeks, placebo for 2 days and
chlorpheniramine 4 mg 4 times a day for 4 weeks
• Group 2: chlorpheniramine 4 mg 4 times a day for 4 weeks, placebo for 2 days
and nifedipine 10 mg 4 times a day for 4 weeks
Participants had one or another active drug, then 2 days of placebo, then the other active
drug; all capsules identical in appearance
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: unclear (daily scores)
Primary outcomes of the trial
• Degree of itching (scale 0-3); frequency of episodes (scale 0-4); number of hives
per episode (scale 0-4, where 0 = 0 hives; 1 = 1 to 6 hives; 2 = 7 to 12 hives; 3 = 13 to
18 hives; and 4 = ≥ 19 hives); size of the hives (scale 0-4, where 0 = 0 mm, 1 = 0 to 10
mm, 2 = 11 to 20 mm, 3 = 21 to 30 mm, 4 = > 30 mm) and duration of the hives
(hours) (scale 0-4, where 0 = 0 hours, 1 = 0 to 6 hours, 2 = 7 to 12 hours, 3 = 13 to 24
hours, 4 = > 24 hours)
• Quality of life measures: none
Secondary outcomes of the trial
• Blood pressure
• Adverse events: nausea, dizziness, drowsy, mild hypotension
• No minor adverse effects stated for chlorpheniramine
Clinician or participant report: investigator and participant
Notes Study investigators concluded that nifedipine not a first-line drug for chronic urticaria,
and that it is helpful for only some selected patients
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method unclear
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind study. All medication in cap-
sules and identical in appearance; partici-
pants blinded. Probably done but no de-
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tails given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind study. All medication in cap-
sules and identical in appearance; partici-
pants blinded. Probably done but no de-
tails given
Incomplete outcome data (attrition bias)
All outcomes
Low risk 18/22 participants completed the study
(18% lost to follow-up): n = 3military per-
sonnel posted elsewhere, n = 1 severe nau-
sea on nifedipine ×1
Minor adverse events: nifedipine: n = 3
dizziness, n = 1 drowsiness, n = 2 mild hy-
potension
Comment: Substantial losses to follow-up
may have introduced a source of bias to the
study. No ITT
Selective reporting (reporting bias) High risk Duration of follow-up not clearly defined
Unclear whether concomitant medications
were permitted or whether participants
were compliant
Blood pressure results not reported in full,
only in terms of adverse events
Other bias Unclear risk Underpowered
Funder: none
Locci 1991
Methods Design: topical treatment of urticaria; randomised controlled 2-arm study of oxatomide
gel vs dechlorpheniramine cream
Duration:15 days
Participants Number of participants randomly assigned: 27; 12 in oxatomide group and 15 in dechlor-
pheniramine group
Sex: 50% female oxatomide group, 33% female dechlorpheniramine group
Age of participants, years: oxatomide group:mean39.6±5.2; dechlorpheniramine group:
mean 38.3 ± 2.6
Country and setting: Italy; secondary care
Unit of allocation: participant
Inclusion criteria of the trial
• CSU (not clearly defined)
Exclusion criteria of the trial
• Eczema, skin infection or infestation; pregnancy/lactation; children
• Previous unresponsiveness to antihistamine: not stated
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Interventions Interventions, dose, duration
• Oxatomide gel 5% twice daily
• Dechlorpheniramine cream twice daily to affected sites
Duration of intervention: short-term (15 days)
Length of follow-up: 15 days
Outcomes Timing of outcome assessment: 15 days
Primary outcomes of the trial
• Progress of itching (severity, site, duration), appearance of lesions with reference
to presence of erythema (intensity, site), weals (size, site, number), lesions due to
scratching
• Severity 0 to 4 scale on participant daily diary
• Quality of life measures: not stated
Secondary outcomes of the trial
• Adverse events: transitory erythema after application
Clinician or participant report: clinician and participant
Notes Study investigators concluded that similar statistically significant improvements were ob-
served in erythema and number of weals. Study authors concluded that both treatments
worked
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”According to a controlled experi-
mental design completely randomised be-
tween patients, half were treated with ox-
atomide (O) and half with dechlorpheni-
ramine (D)”; no details about method of
randomisation
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding described
Comment: open to bias as 2 different for-
mulations (gel and cream preparations)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding described
Comment: open to bias as 2 different for-
mulations (gel and cream preparations)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No ITT; 2/27 (13%) lost to follow-up (did
not attend) in dechlorpheniramine group
(2/15). No reasons given
Comment: unclear whether this degree of
loss to follow-up in a small study intro-
duced a source of bias
137H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Locci 1991 (Continued)
Selective reporting (reporting bias) Unclear risk All outcomes reported but presented
graphically; improvement in symptoms ex-
pressed as percentage (change inmean score
and SD), not by participant number
Included some participants with localised
urticaria. No measurement of actual dose
applied
Comment: unclear
Other bias Low risk None detected. Funder: not stated
Maiti 2011
Methods Design: randomised single-blinded single-centred parallel-group 2-arm trial comparing
rupatadine with levocetirizine
Duration: 4 weeks
Participants Number of participants randomly assigned: 70 (rupatadine n = 35; levocetirizine n = 35)
Sex: rupatadine group: male 15 (43%), female 20 (57% ); levocetirizine group: male 16
(45%), female 19 (60%)
Age of participants, years: 12 to 60
Unit of allocation: participant
Country and setting: India; secondary care
Inclusion criteria of the trial
• Unclear
Exclusion criteria of the trial
• Significant concomitant illness, pregnancy or lactation, oral contraceptive pills,
antihistamines within 72 hours, oral steroids within a month, physical urticaria, cold
urticaria, cholinergic urticaria
• Previous unresponsiveness to antihistamine: unclear
Interventions Interventions, dose, duration
• Rupatadine 10 mg once daily or
• Levocetirizine 5 mg once daily
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: 4 weeks
Primary outcomes of the trial
• Pruritus, size of weals, number of weals and number of separate urticarial episodes
• Differential and absolute eosinophil count, serum IgE
• Aerius Quality of Life Questionnaire (AEQLQ), based on DLQI (not validated)
• Physician or investigator assessment of global efficacy based only on participant
symptom scores
Secondary outcomes of the trial
• Adverse events: drowsiness, headache, dry mouth, gastric irritation
Clinician or participant report: both
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Notes Study investigators concluded that the incidence of adverse drug reactions was found to
be less in the rupatadine group. Rupatadine is a better choice in CSU in comparison
with levocetirizine because of a better efficacy and safety profile
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear which group was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear which group was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 54/70 completed (10 did not report for fol-
low-up, 6 were non-compliant). No partic-
ipant stopped treatment because of adverse
effects
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported
Other bias Low risk None detected. Funder: not stated
Makino 2012
Methods Design: randomised 3-arm open study
Duration: 4 weeks
Participants Number of participants randomly assigned: 97 (olopatadine 10mggroup35; olopatadine
5 mg group 30; no medication group 32)
Sex: olopatadine 10 mg group: male 31.4%, female 68.6%; olopatadine 5 mg group:
male 16.7%, female 83.3%; no medication group: male 28.1%, female 71.9%
Age of participants, years (mean): olopatadine 10 mg group 55.2 ± 14.9; olopatadine 5
mg group 55.0 ± 13.5; no medication group 59.1 ± 15.1
Unit of allocation: participant
Washout period: none, but run-in phase of 4 to 6 weeks with all participants receiving
10 mg olopatadine; no cross-over
Country and setting: Japan; secondary care
Inclusion criteria of the trial
• Chronic urticaria > 6 weeks with no causes
Exclusion criteria of the trial
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Makino 2012 (Continued)
• Patients with physical urticaria, pregnant females and lactating mothers; urticaria
with VAS score less than 50 out of maximum 100
At least moderate to severe disease
Duration of disease greater than 6 weeks
Interventions Interventions, dose, duration
All participants with CSU with a VAS itch score higher than 50 were treated with 10 mg
olopatadine hydrochloride daily for 4 to 6 weeks. Of these, participants having a VAS
itch score less than 20 were randomly allocated to 1 of 2 groups:
• Group 1: 10 mg olopatadine hydrochloride daily
• Group 2: 5 mg olopatadine hydrochloride daily
• Group 3: stopped taking medication
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Concomitant/rescue treatment not permitted
Outcomes Timing of outcome assessment: Efficacy end point was defined as length of time the
VAS itch score remained less than 50 with no additional treatment and ongoing up to 4
weeks
Primary outcomes of the trial
• Number of participants whose VAS score went above 50
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: No participants reported adverse effects
Clinician or participant report: clinician
Notes Study investigators concluded that both 10 mg olopatadine and 5 mg olopatadine were
effective and were better than no treatment but were not significantly different from each
other
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, but no details
Allocation concealment (selection bias) High risk Allocation not apparently concealed, as the
trial was open
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals noted were 12 out of 35 in
10 mg group, 6 out of 30 in 5 mg group
and 22 out of 32 in no medication group.
Reasons for all withdrawals were unclear.
ITT analysis was carried out
Selective reporting (reporting bias) Low risk Outcomes reported
Other bias Unclear risk Funder: not stated
Marks 1980
Methods Design: randomised double-blind 3-arm cross-over study of chlorpheniramine vs placebo
Duration: not stated
Participants Number of participants randomly assigned: 24. Numbers in each group not stated
Sex: not stated
Age of participants: not stated
Unit of allocation: cross-over, chlorpheniramine vs placebo arm data used in this review
Country and setting: Australia; secondary care
Inclusion criteria of the trial
• CSU
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Chlorphenamine 4 mg 4 times a day
• Chlorphenamine plus cimetidine
• Chlorphenamine 4 mg 4 times a day plus cimetidine 400 mg 4 times a day (H1 +
H2 antagonist)
• Placebo: frequency not clear
Duration of intervention: for all 3 interventions, duration of treatment was not stated
Length of follow-up: not stated
Outcomes Timing of outcome assessment: not stated
Primary outcomes of the trial
• Improvement in urticaria
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: not stated
Clinician or participant report: investigator
Notes Study investigators concluded that significant improvement in urticaria was seen with
chlorpheniramine and with chlorpheniramine plus cimetidine compared with placebo;
no difference was noted between efficacy of active treatments
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not stated
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear, no details given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear, no details given
Incomplete outcome data (attrition bias)
All outcomes
High risk Numbers in each group not stated. No ad-
verse events described; 2/24 randomly as-
signed (8%) lost to follow-up because of ir-
regular tablet intake
Selective reporting (reporting bias) Unclear risk Write-up published as item of correspon-
dence, unclear whether all prespecified out-
comes were reported
Other bias Unclear risk Funder: none
Very short report, no further information
available
Monroe 1988
Methods Design: double-blind randomised multi-centre 2-arm trial of loratadine vs placebo
Duration: 4 weeks
Participants Number of participants randomly assigned: unclear; 169 evaluated for safety, 153 eval-
uated for efficacy, numbers randomly assigned to each group unclear
Sex: not stated
Unit of allocation: participant
Age of participants: not stated
Country and setting: USA (primary and secondary)
Inclusion criteria of the trial
• CSU (not specified)
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Loratadine 10 mg daily for 4 weeks
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• Placebo daily for 4 weeks
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: at baseline, then weekly for 4 weeks
Primary outcomes of the trial
• Proportion with good/excellent response (itching erythema and number and size
of hives), overall condition and therapeutic response
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events (minor): loratadine: sedation and dry mouth
Clinician or participant report: investigator
Notes Study investigators concluded that loratadine is efficacious and safe
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method unclear
Allocation concealment (selection bias) Unclear risk No allocation concealment described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details given about blinding, described
as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details given about blinding, described
as double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Numbers randomly assigned and num-
ber in each group unclear (not stated).
169 evaluated for safety, 153 for efficacy.
Treatment failure: loratadine group n = 1;
placebo group n = 10; other numbers of
and reasons for withdrawal not stated
Selective reporting (reporting bias) High risk Rawfigures not given-only percentages and
P values.Outcomemeasures unclear; statis-
tics not specified. Raw figures not stated;
origin of P values not stated (i.e. appropri-
ateness of statistical methods unclear)
Other bias Unclear risk Funder: none
Very short report
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Methods Design: randomised double-blind 3-arm trial of loratadine vs hydroxyzine vs placebo
Duration: 1 week
Participants Number of participants randomly assigned: 59 total, 18 for urticaria (disaggregated data
obtained from study authors for CSU and atopic dermatitis participants)
Sex: 29% male, 71% female
Age of participants, years: 18 to 63
Unit of allocation: participant
Country and setting: USA; secondary care
Inclusion criteria of the trial
• CSU in an active state for at least 3 weeks before study commencement
Exclusion criteria of the trial
• Steroids in previous 10 days (or depot steroid in last 28 days)
• Pregnant (pregnancy test administered before start of study)
• Previously unresponsive to antihistamine excluded
Interventions Interventions, dose, duration
• Loratadine 10 mg every morning plus placebo twice daily for 1 week
• Hydroxyzine 25 mg 3 times daily for 1 week
• Placebo 3 times daily for 1 week
Duration of intervention: short-term (1 week)
Length of follow-up: 1 week
Outcomes Timing of outcome assessment: 1 week
Primary outcomes of the trial
• Proportion with good/excellent response (“marked or complete relief ”): pruritus,
erythema, hives
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: included with dermatitis group in same study: somnolence,
hydroxyzine more sedative than loratadine
Clinician or participant report: investigator andparticipant (diary).Diary cards including
size and number of weals, erythema and pruritus; scored between 0 and 3; summed for
total symptoms score plus global estimation of effect at end
Notes Study investigators concluded that loratadine is as effective as hydroxyzine in the treat-
ment of urticaria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not clear; ”ran-
domly assigned”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
Low risk No details about blinding given, described
as double-blind
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All outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No details about blinding given, described
as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of dropouts from 18 randomly as-
signed with urticaria not stated. Results ex-
pressed as percentages with P values. No
outcomes expressed as participant num-
bers; no baseline values. Unclear howmany
withdrew with reasons
Comment: The report does not contain
sufficient information to allow a judgement
about whether incomplete outcome data
introduced a source of bias
Selective reporting (reporting bias) Unclear risk Laboratory tests conducted at start, unclear
whether these were monitored as an out-
come. Erythema not reported as an out-
come (but included in overall symptom
score) Comment: unclear whether out-
comes were fully reported. No further in-
formation was available from investigators
Other bias Unclear risk Funder: none. Short report with insuffi-
cient information to allow a judgement
about risk of other bias
Monroe 2003
Methods Design: randomised double-blind multi-centre parallel 2-arm placebo-controlled study
of desloratadine 5 mg vs placebo
Duration: 6 weeks
Participants Number of participants randomly assigned: 226 (116 desloratadine; 110 placebo)
Sex: 27% male, 73% female desloratadine group; 24% male, 76% female placebo
Age of participants, years: desloratadine 41.8 (range 13-80); placebo 39.2 (range 13-84)
Unit of allocation: participant
Country and setting: US, Chile, Canada, Venezuela, Germany, Norway, Sweden, Bel-
gium; setting unclear
Inclusion criteria of the trial
• CSU for at least 6 weeks before entry into study with at least 1 flare in previous 3
weeks
• Normal physiological and laboratory values
• Informed consent
• Use of adequate contraception method is appropriate
Exclusion criteria of the trial
• < 12 years old, patients with urticaria < 3 days/wk in preceding 3 weeks, <
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moderate severity, no weals at time of screening, pruritus score < 14 over last 3 days
and on morning of baseline visit
• Pregnancy/lactation
• Concomitant illness
• Other urticaria medication
• Previous intolerance of antihistamines
• Participants deemed unable to keep accurate symptom diary
• Excluded if previously non-responsive to antihistamines
Interventions Interventions, dose, duration
• Desloratadine 5 mg for 6 weeks
• Placebo daily
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 6 weeks
Outcomes Timing of outcome assessment: 1, 2, 4 and 6 weeks (visits at screening, at baseline (day
1), on day 4, at weeks 1, 2, 4 and 6. Efficacy and safety assessments made at visit day 4
and weeks 1, 2, 4 and 6)
Primary outcomes of the trial
• Proportion with good/excellent response (“marked or complete relief ”): pruritus,
erythema, hives
• Global assessment at visits agreed by participant and physician: 0 = none, 1 =
mild (signs/symptoms minimally aware and easily tolerated), 2 = moderate (definite
awareness of signs/symptoms but tolerable), 3 = severe (signs/symptoms difficult to
tolerate and interfering with daily activities or sleep)
• Therapeutic response agreed on by participant and physician (visit day 4 and
weeks 1, 2, 4 and 6): 1 = complete relief, virtually no signs/symptoms; 2 = marked
relief, signs/symptoms greatly improved, causing little trouble; 3 = moderate relief,
signs/symptoms present and troublesome but noticeably improved; 4 = slight relief,
minimal improvement in signs/symptoms; 5 = treatment failure, signs/symptoms
unchanged or worse than baseline
• Quality of life measures: none
Secondary outcomes of the trial
• Participants given diary cards, completed twice daily. Symptom score in diary on
4-point scale: pruritus, number of hives, size of largest hive, interference with sleep,
interference with daily activities
• Compliance assessed by study diary, tablet count, questioning
• Adverse events: serious (requiring withdrawal): bronchitis/sinusitis URTI, nausea)
; vomiting, sedation; minor adverse events: headache, nausea, dry mouth
Clinician or participant report: investigator and participant
Notes Study investigators concluded that at week 1: mean improvement from baseline in re-
flective pruritus score significantly greater in desloratadine group; overall more effective
than placebo; significant improvement in total symptoms score and interference in sleep
and daily activities in desloratadine group; reduction in number and size of largest hive
significantly better in desloratadine group
Statistically significant improvements noted by day 2 of study
Week 6: statistically significant improvement in pruritus from baseline in desloratadine
group comparedwith placebo; desloratadine-treated participants had significantly greater
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control of morning instantaneous total symptoms score compared with placebo patients.
Overall, desloratadine was statistically significantly better than placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 536): “1:1 ratio according to
computer generated schedule”
“Blocks of 4 using random numbers gen-
erated by SAS function UNIFORM with
seed based on clock-time”
Comment: adequate randomisation
Allocation concealment (selection bias) Low risk Quote (page 537): “A set of sealed en-
velopes containing the identification of test
drug corresponding to each subject was
provided to each center. This enabled the
investigator to identify the treatment as-
signment of individual subjects in the event
of an emergency without compromising
the blinding of other subjects. The ran-
domisation schedule for blinding of treat-
ments was disclosed only after study com-
pletion”
Comment: Sealed envelopes indicate that
this was probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 537): “Desloratadine, in 5 mg
tablets, and placebo were identical in ap-
pearance and packaged identically in sealed
coded envelopes. All study personnel were
blinded to the identity of medication. A
set of sealed envelopes containing the iden-
tification of test drug corresponding to
each subject was provided to each center.
This enabled the investigator to identify the
treatment assignment of individual sub-
jects in the event of an emergency with-
out compromising the blinding of other
subjects. The randomisation schedule for
blinding of treatments was disclosed only
after study completion”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (page 537): “Desloratadine, in 5 mg
tablets, and placebo were identical in ap-
pearance and packaged identically in sealed
coded envelopes. All study personnel were
blinded to the identity of medication. A
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set of sealed envelopes containing the iden-
tification of test drug corresponding to
each subject was provided to each center.
This enabled the investigator to identify the
treatment assignment of individual sub-
jects in the event of an emergency with-
out compromising the blinding of other
subjects. The randomisation schedule for
blinding of treatments was disclosed only
after study completion”
Incomplete outcome data (attrition bias)
All outcomes
High risk Lost to follow-up: desloratadine 19/116
(19%); placebo 35/110 (31%)
Treatment failure: desloratadine n = 14,
placebo n = 29; other adverse events: deslo-
ratadine n = 3, placebo n = 2, non-compli-
ance each group n = 1, loss to follow-up:
desloratadine n = 1, placebo n = 2, lack of
desire to continue placebo n = 1
Adverse events: serious (requiring with-
drawal): desloratadine: 3 (1 bronchitis/si-
nusitis, 1 URTI, 1 nausea); placebo: 2
(1 vomiting, 1 sedation); minor adverse
events: desloratadine: headache n = 18,
nausea n = 7, dry mouth n = 6; placebo:
headache n = 11, nausea n = 2, dry mouth
n = 5
Actual participant numbers missing from
results (percentages of improvement in
scores and statistical significance only
given); ITT stated by authors but unclear
because of lack of provided data
Comment: judged as high risk because of
high dropout rate
Selective reporting (reporting bias) Unclear risk Prespecified outcomes were reported, other
than compliance
Excluded participants previously non-re-
sponsive to antihistamines; may involve se-
lective reporting of positive results
Other bias Unclear risk Funder: Schering-Plough Research Insti-
tute
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Methods Design: randomised double-blind parallel-group study; desloratadine 5 mg, 10 mg, 20
mg
Duration: 4 weeks
Participants Number of participants randomly assigned: 314
Country and setting: Germany; setting unclear
Inclusion criteria of the trial
• Males and females with CSU 18 to 75 years of age
• Willingness to participate in the study. Participant must be 18 to 75 years of age,
of either gender and of any race. Participant must have had this episode of chronic
idiopathic urticaria for at least 6 weeks and must have been dosing with a second-
generation antihistamine for 2 weeks or longer
• Current episode of urticaria is sufficiently symptomatic at the screening visit to
qualify for this study
• Baseline week (entry period) UAS between 10 and 30 inclusive. Participants must
understand and be willing to assess and record symptom scores; must have voluntarily
signed a written informed consent
• Must confirm that all prior medication washout times have been observed
• Female volunteers of childbearing potential (including women who are less than 1
year postmenopausal and women who will be sexually active during the study) must
agree to use a medically accepted method of contraception or must be surgically
sterilised before screening
• Must be free of any clinically relevant disease other than chronic idiopathic
urticaria (CIU) that would, in the principal investigator’s and/or sponsor’s opinion,
interfere with conduct of the study or study evaluations. Participants must be able to
adhere to dosing and visit schedules and must agree to record symptom severity scores,
medication times, concomitant medications and adverse events (AEs) accurately and
consistently in a daily diary
Exclusion criteria of the trial
• Female who is pregnant or intends to become pregnant during the study, is
nursing or intends to be nursing during the study or within 90 days after study
completion
• Has not observed designated washout periods for any of the prohibited
medications. Has used any investigational product within 30 days before enrolment
• Symptomatic seasonal or perennial allergic rhinitis
• Asthma not controlled by short-acting beta-2 agonists used as necessary
• Severe diseases, especially those affecting the immune system, except urticaria.
Presence of a permanent gastrointestinal condition that may influence oral therapy
(chronic diarrhoea diseases, congenital malformations or surgical mutilations of
gastrointestinal tract)
• History of/or presence of epilepsy, significant neurological disorders,
cerebrovascular attacks or ischaemia. History of/or presence of myocardial infarction or
cardiac arrhythmia that requires drug therapy. Evidence/history of significant renal
disease
• Significant hepatic disease. Presence of cancer, which requires chemotherapy or
radiation therapy
• Glaucoma
• Urinary bladder neck obstruction with emptying difficulties
• Acute urticaria
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• Body mass index (BMI) > 35. Has any clinically significant deviation from
appropriate reference range in the physical examination, or another clinical evaluation
that, in the investigator’s judgement, may interfere with the study evaluation or may
affect participant safety. Is in a situation or condition that, in the opinion of the
investigator, may interfere with optimal participation in the study
• Participating in any other clinical study
• Is on the staff or is affiliated with or a family member of staff personnel directly
involved with this study. Is allergic to or has a history of hypersensitivity to the study
drug (desloratadine), to any of its excipients or to loratadine
• Galactose intolerance, lactase deficiency or glucose-galactose malabsorption
Interventions Interventions, dose, duration
• Desloratadine 5, 10, 20 mg
• 20 mg for 4 weeks
Intermediate duration of intervention (4 weeks)
Outcomes Timing of outcome assessment: 4 weeks
Primary outcomes of the trial
• Change in Urticaria Activity Score (UAS) from baseline to final week for
desloratadine 5 mg versus desloratadine 20 mg (time frame: baseline and 4 treatment
weeks)
• UAS is a composite diary-recorded score. Diary-recorded scores included weal
score and pruritus score, with numerical severity intensity ratings of 0 = none to 3 =
intense. Scoring was to be done twice daily within 1 hour of arising and in the evening,
approximately 12 hours later. Scoring was reflective, covering the 12-hour period since
the previous recording. Daily UAS is the average of morning and evening scores. Final
week by definition was the terminal week. It was the last week that participants stayed
for the treatment period
• Quality of life measures: none
Clinician or participant report: UAS participant reported
Notes Study investigators provided no conclusions
Study number P04849; also indexed as EudraCT: 2006-001449-33. Results available
online
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel were blinded to
treatment group
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded to treat-
ment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Group 5 mg 12/106
• 2 withdrawals unrelated to study
drug
• 7 withdrawals related to study drug
• 3 non-compliance with protocol
Group 10 mg: 9/104
• 2 adverse events
• 5 withdrawals related to study drug
• 2 non-compliance with protocol
Group 20 mg: 10/104
• 2 adverse events
• 1 loss to follow-up
• 1 withdrawal unrelated to study drug
• 2 withdrawals related to study drug
• 2 non-compliance with protocol
• 1 did not meet eligibility
• 1 administrative
Withdrawal and losses accounted for and
balanced between groups
ITT analysis carried out
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Underpowered because of poor recruit-
ment; thus study is inconclusive
Funder: Schering-Plough
Nelson 2000
Methods Design: multi-centre double-blind randomised placebo-controlled 5-arm parallel study
with 4 different doses of fexofenadine vs placebo
Duration: 4 weeks
Participants Number of participants randomly assigned: 468
Sex: 30% male, 70% female placebo; 31% male, 69% female 20 mg; 29% male, 71%
female 60 mg; 33% male, 68% female 120 mg; 27% male, 73% female 240 mg
Age of participants, years: range 12 to 65
Country and setting: USA; secondary care
Unit of allocation: participant
Inclusion criteria of the trial
• CSU of at least 6 weeks’ duration for at least 3 days per week
Exclusion criteria of the trial
• Urticaria associated with underlying disease (e.g. Hodgkin’s, vasculitis,
hyperthyroid, lupus, hepatitis, malnutrition, drug abuse, alcoholism, blood dyscrasia,
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malignancy, renal/hepatic insufficiency, malabsorption, chronic infection;
psychological, heart, neurological or other systemic diseases) excluded if previously
non-responsive to antihistamines
Interventions Interventions, dose, duration
• Placebo
• 20 mg, 60 mg,120 mg or
• 240 mg fexofenadine HCl twice daily
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: 1, 2, 3, 4 weeks
Primary outcomes of the trial
• Participants’ twice-daily diaries recording pruritus severity (0-4; 0 = none; 1 =
mild; 2 = moderate, may interfere with sleep/activities; 3 = severe, very annoying,
substantially interfering with sleep/activities; 4 = needs physician)
• Number of weals over previous 12 hours; also assessed interference with sleep and
daily activities
• Efficacy measures reported as average daily means.
• Quality of life measures: none
Secondary outcomes of the trial
• Efficacy measures: change in average mean pruritus score from baseline to 4 weeks
• Weals: change from baseline; 0 to 4 (0 = none, 1 = 1-5, 2 = 6-15, 3 = 16-25, 4 = >
25)
• Interference with sleep/daily activities (0 = none, 1 = mild, 2 = moderate, 3 =
severe)
• Participants recorded scores for pruritus severity and number of weals (over the
previous 12 hours) in a daily diary. Efficacy variables included mean daily changes from
baseline in pruritus severity, number of weals and interference with sleep and daily
activities due to urticaria
• Adverse events: withdrawals: 4 in 20 mg group, 5 in 60 mg group, 4 in 120 mg
group, 1 in 240 mg group and 2 in placebo group
Clinician or participant report: investigator and participant
Notes Study investigators concluded that all fexofenadine groups were significantly better than
placebo groups re pruritus, reduction in weal score and reduced interference with sleep/
activities
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation unclear, no de-
tails given; described as randomised
Allocation concealment (selection bias) Unclear risk No details given
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as 24-hour single-blind lead-
in, followed by 4-week double-blind treat-
ment, but no details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as 24-hour single-blind lead in,
followed by 4-week double-blind treat-
ment, but no details given about blinding
of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk 186/468 randomly assigned lost to follow-
up as follows: 437 had at least 1 postbase-
line adverse event assessment; 418 had at
least 1 postbaseline 12-hour mean pruri-
tus score assessment (i.e. for safety analysis,
losses of n = 31 (6%); for efficacy assess-
ments, losses of n = 50 (10.6%))
In text, study authors state that only 282
participants completed the study (losses n
= 186 (40%))
Serious adverse events present in all groups
but not specified. Most common adverse
events reported (not specified which led to
withdrawal of treatment) were as follows:
headache ~ 25%, URTI ~ 8%, nausea 5%,
dyspepsia 5%, diarrhoea 2%, gastroenteri-
tis 2%, “pain” 4%, abdominal pain 2%,
myalgia 4%
Frequencies similar across all groups in-
cluding placebo
Incorrectly stated ITT; large number of
withdrawals not accounted for
Table implies that figures states 325 were
evaluated at end of study (4 weeks). This is
not resolved in text
Study authors state ITT analysis but did
not include all participants randomly as-
signed at the beginning of the study (31
with no data and not included in the anal-
ysis)
Comment: Discrepancies in number of
dropouts and large number of withdrawals
suggest that attrition bias could have been
introduced
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported
but excluded persons known to be unre-
sponsive to antihistamines; serious adverse
events present in all groups but not speci-
fied
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Comment: unclear whether selective re-
porting and participant selection intro-
duced a source of bias
Other bias Unclear risk Funder: Hoechst Marion Roussel
Nettis 2004
Methods Design: randomised double-blind placebo-controlled 3-arm study of desloratadine alone
vs desloratadine with montelukast (H1- and H2-antagonists) vs placebo
Duration: 6 weeks
Participants Number of participants randomly assigned: 81 (27 in each group)
Sex: 24% male, 76% female desloratadine; 15.4% male, 84.6% female desloratadine
plus montelukast; 40% male, 60% female placebo
Age of participants, years: 37.5 ± 10.9 (desloratadine plus placebo); 35.6 ± 12.8 (deslo-
ratadine plus montelukast); 36.8 ± 10.7 (placebo)
Country and setting: Italy; secondary care
Unit of allocation: participant
Inclusion criteria of the trial
• CSU
Exclusion criteria of the trial
• Atopic disease; concomitant illness including hepatic, endocrine, psychological
disorder; cancer; other major symptoms; delayed pressure urticaria excluded by test
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Desloratadine 5 mg once daily and placebo for 6 weeks, desloratadine 5 mg once
daily and montelukast 10 mg for 6 weeks
• Placebo daily for 6 weeks
1-week single-blind placebo run-in ended with 1-week single-blind placebo washout.
Concomitant medications not allowed during course of trial
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 6 weeks
Outcomes Timing of outcome assessment: baseline, 3 weeks and 6 weeks (participants examined by
physician 4 times over 8-week period: first after 1-week placebo run-in, second after 3
weeks’ active treatment, third at end of treatment, final at end of placebo washout week)
Primary outcomes of the trial
• Complete suppression of urticaria. Efficacy measures were scored according to the
following scales: pruritus: 0 (none), 1 (mild), 2 (moderate) and 3 (severe); number of
weals: 0 (none), 1 (1-10 weals), 2 (11-20 weals) and 3 (> 20 weals); average size of
weals: 0 (no lesion), 1 (< 1.27 cm), 2 (1.27-2.54 cm) and 3 (> 2.54 cm); number of
separate urticarial episodes: 0 (no episodes), 1 (1 episode), 2 (2-3 episodes) and 3 (> 3
episodes). The maximum value of the total symptoms score (TSS) was 12. At each
clinical visit, participants also completed a 10-cm visual analogue scale (VAS) indicating
overall severity of their urticaria over the previous days from 0 (none) to 10 (worst)
• Quality of life measures: 5-item questionnaire administered (using part of DLQI)
at each visit (0-3, no problems to severe problems)
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Secondary outcomes of the trial
• Adverse events: no major or minor events in all 3 groups
Clinician or participant report: investigator and participant
Notes Study investigators concluded that both treatments were significantly more effective than
placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation unclear
Allocation concealment (selection bias) Unclear risk Methods of allocation concealment not
stated. Sealed envelopes in pharmacy
Comment: Not entirely clear whether
sealed envelopes related to blinding ofmed-
ication or allocation concealment, judged
as unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk 1-week single-blind placebo run-in and
run-out. Double-blind study, adequately
blinded
Quote (page 1402): ”Patients were not in-
formed that the treatment would be di-
vided into specific periods”
“The tablets were encapsulated in double
blind fashion and sealed in envelopes by
a pharmacist along with the instruction
sheets at the beginning of the trial. All treat-
ments were dispensed by a third party”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded as above
Comment: probably done, inferred from
text
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5/81; 5 lost to follow-up (6%)
Number and reasons for withdrawal:
• Desloratadine plus placebo n = 2
• Desloratadine plus montelukast n = 1
• Placebo n = 2
• Non-compliance n = 3, lack of desire
to continue n = 1, need to take steroids for
acute angio-oedema n = 1
Comment judged as low risk, as with-
drawals with reasons were given and were
balanced between the 2 groups
No ITT; most results reported as number
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of participants showing any improvement,
with no indication of effect size
Selective reporting (reporting bias) Unclear risk Attempt at QoL measurement, but DLQI
into non-validated scale; HRQoL results
unclear-presented only graphically; y-axis
(if consistent with other graphs) indicates
only % participants showing any improve-
ment (no indication of effect size)
Baseline data unclear: Symptom severity
scale appears to be out of 12, yet at baseline,
mean is stated as about 60 in each group
Other bias Unclear risk Funder: none
Nettis 2006
Methods Design: randomised double-blind 2-arm placebo-controlled study of levocetirizine 5 mg
vs placebo
Duration: 6 weeks
Participants Number of participants randomly assigned:106, n = 53 levocetirizine, n = 53 placebo
Sex: 33% male, 67% female levocetirizine; 41% male, 59% female placebo
Age of participants, age: mean 41.1 (SD 22-71) levocetirizine; mean 39 (SD 22-69)
placebo
Country and setting: Italy; secondary care
Unit of allocation: participant
Inclusion criteria of the trial
• CSU
Exclusion criteria of the trial
• Atopics, concurrent disease (malignancies or hepatic, psychiatric, endocrine or
other major systemic diseases)
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Levocetirizine 5 mg once daily for 6 weeks
• Placebo once daily for 6 weeks
1-week placebo run-in (single-blind), then treatment for 6 weeks, then 1-week placebo
washout at end of study
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 8 weeks i.e. follow-up extended after cessation of therapy
Outcomes Timing of outcome assessment: screening, after placebo run-in, after 3 weeks of active
treatment, after 1 week of washout (at 6 weeks)
Examined by physician 4 times over 8-week period: first after placebo run-in (1 week);
second after 3 weeks’ active treatment; third after 6 weeks’ active treatment; fourth after
final week of placebo-participants complete visual analogue scale for overall severity of
urticaria since last visit (0 = none, 10 = worst)
Primary outcomes of the trial
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• Complete suppression of urticaria
• Quality of life measures: a 5-question urticaria quality of life questionnaire
administered, evaluating cutaneous symptoms, emotions, practical problems: “over the
last week, how itchy, sore, painful or stinging has your skin been? How embarrassed or
self-conscious have you been because of your skin? How much has your skin influenced
the choice of clothes that you wear? How much has your skin affected any social or
leisure activities? Has your skin prevented you from working or studying? If no, how
much of a problem has your skin been at work or studies?” Answered on 4-point scale
(0 = no problems to 3 = severe). Participants used daily diary: pruritus (0 = none, 1 =
mild, 2 = moderate, 3 = severe); number of weals (0 = none, 1 = 1-10, 2 = 11-20, 3 = >
20); size of weal (mean diameter) (0 = none, 1 = < 1.27 cm, 2 = 1.27-2.54 cm, 3 = > 2.
54 cm); number of separate urticarial episodes (0 = none, 1 = 1 episode, 2 = 2-3
episodes, 3 = > 3 episodes)
Secondary outcomes of the trial
• Adverse events: no serious or minor adverse events in either group
• Proportion relapsing within 1 month of cessation of drug
Clinician or participant report: both
Notes Study investigators concluded that mean total symptoms score decreased by 81% vs 1%
by end of study period in levocetirizine vs placebo group, respectively
Treatment group had statistically significant decrease in number of weals at all visits
(overall 79%reduction in score); also statistically significant decrease in urticarial episodes
and size of weals (75% reduction); pruritus also (85% reduction)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation unclear (”ran-
domly assigned”)
Allocation concealment (selection bias) Unclear risk Sealed envelopes in pharmacy.
Comment: not entirely clear whether
sealed envelopes related to blinding ofmed-
ication or allocation concealment, judged
as unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study; participants not in-
formed that treatments would be divided
up into specific periods: 1-week placebo
run-in (single-blind), then treatment for
6 weeks, then 1-week placebo washout at
end of study. Double-blind study: ”tablets
were encapsulated in a double blind fash-
ion and sealed in envelopes by a pharmacist
together with instruction sheets.” 1-week
placebo run-in (single-blind), then treat-
ment for 6 weeks, then 1 week placebo
washout at end of study. Medications dis-
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pensed by third party
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded as above
Comment: probably done, inferred from
text
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100/106 randomly assigned participants
completed
Withdrawals: levocetirizine n = 2, n = 4
in placebo group, dropped out in placebo
run-in phase because of non-compliance n
= 2, heart attack n = 1, needed to take oral
steroids for aggravated urticaria n = 3 (2
in placebo group and 1 in levocetirizine
group)
No ITT
Comment: lownumber of dropouts, evenly
balanced between groups, not thought to
contribute bias
Selective reporting (reporting bias) Unclear risk Results not clearly reported. Attempt at
measuring quality of life, but not with val-
idated scale; results of this inadequately re-
ported. Quality of life scores statistically
significantly improved frombaseline in lev-
ocetirizine group but not in placebo group
(no scores given)
Other bias Low risk Funder: none
Ollert 1999
Methods Design: randomised 2-arm multi-centre (10 centres) parallel-group comparison of mi-
zolastine vs placebo
Duration: 4 weeks
Participants Number of participants randomly assigned: 78 (39 each in mizolastine and placebo)
Sex: 40% male, 60% female
Age of participants, years: 40 ± 13
Unit of allocation: participant
Country and setting: Germany; research clinic
Inclusion criteria of the trial
• CSU with or without angio-oedema for at least 6 weeks, with at least 2 urticarial
episodes per week
Exclusion criteria of the trial
• Pregnant, not using effective contraception (in women of childbearing age), use of
machinery at work, abnormal physiological values, serious concomitant illness
including psychiatric illness and alcoholism, taking other medications concomitantly
with mizolastine
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• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
Placebo run-in periods (i.e. variable washout period of any othermedications (depending
on previous medication type) before study commenced)
• 10 mg mizolastine a day
• Identical placebo
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: at days 0, 14 and 28
Primary outcomes of the trial:
• Mean total symptoms score (participant report); number of urticarial episodes per
week
• Visual analogue scale parameters ranged from no reduction in symptoms (0%) to
very strong reduction in symptoms (100%)
• Response to treatment (responder) was defined by a score decrease > or = 50%
between day 0 and day 28, and by reduced frequency of urticaria episodes/wk
• Evaluation was done with reference to the study protocol and to participant
diaries of all symptoms the week before
• VAS: 4-point scale for itching (0 = absent, 1 = mild, 2 = moderate, 3 = severe) and
weal and erythema (0 = none, 1 = < 10, 2 = > 10, 3 = generalised outbreak)
• Quality of life measures: none
Secondary outcomes of the trial
• Cardiovascular measures and body weight
• Adverse events: reported, 14 adverse events in 13 participants in the mizolastine
group; asthenia, fatigue, headache and influenza-like symptoms were reported, whereas
rhinitis and bronchitis were reported more frequently in the placebo group. Drowsiness
or sedation not reported in either group
Clinician or participant report: clinician and participant
Notes Study report written in German
Study investigators concluded that mizolastine demonstrates clinical and statistical su-
periority over placebo in the treatment of CSU, and showed a good safety profile
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised, unclear asmethod
not stated
Allocation concealment (selection bias) Unclear risk Unclear, no details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind, identical place-
bos given
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind, but no details
given
Incomplete outcome data (attrition bias)
All outcomes
Low risk Stated to be ITT analysis. 19 partici-
pants dropped out: 11/39 mizolastine, 8/
39 placebo. Reasons given: 2 in total for
undesirable effects, 12 in total for lack of ef-
fect, 5 in total for other reasons (page S26,
table 2)
Selective reporting (reporting bias) Unclear risk Unclear; not all physiological measures
were reported in full in the study report
Other bias Low risk None detected. Funder: not stated
Ortonne 2004
Methods Design: randomised parallel-group 2-arm study of desloratadine vs placebo
Duration: 42 days
Participants Number of participants randomly assigned: 137 (desloratadine n = 65, placebo n = 72)
Sex: gender not stated
Age of participants, years: 18, mean age not stated
Unit of allocation: participant
Country and setting: France (multicentre), research clinics
Inclusion criteria of the trial
• CSU history for ≥ 6 weeks and active disease at enrolment (pruritus score ≥ 2
(screening); AM/PM pruritus sum score (days -3 to 1) ≥ 14; global CSU severity ≥ 2
(screening/randomisation))
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: unclear
Interventions Interventions, dose, duration
• Desloratadine 5 mg
• Placebo once daily
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 42 days
Outcomes Timing of outcome assessment: 14 days and 42 days
Primary outcomes of the trial
• Change from baseline in mean reflective pruritus score at day 14
Secondary outcomes of the trial
• Therapeutic response and changes in individual CSU signs/symptoms scores
• Adverse events were rated according to severity/relation to treatment
• Therapeutic response and changes in individual CSU signs/symptoms scores
Clinician or participant report: participant and clinician
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Notes Study investigators concluded that desloratadine was effective from the first dose and
throughout 6 weeks in CSU
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated, described as randomised
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many out of 137 randomly
assigned participants completed the study
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Unclear risk Funder: Schering-Plough. Short confer-
ence abstract
Ortonne 2007
Methods Design: multi-centre 2-arm randomised double-blind trial of desloratadine vs placebo
Duration: 42 days
Participants Number of participants randomly assigned: 142 (desloratadine n = 65, placebo n = 77)
Age, years: > 18; desloratadine 41.2 ± 15.4; placebo 41.5 ± 15.2
Gender: desloratadine 36.9% male, 63.1% female; placebo 40.3% male, 59.7% female
Unit of allocation: participant
Country and setting: France; set in 40 dermatology centres
Inclusion criteria of the trial
• Active moderate to severe CSU, pruritic weals of unknown cause for 3 days per
week for 6 consecutive weeks and a flareup before visit 1
• > 18 years of age, good general health
• Female participants using contraception
• Other entry criteria included a pruritus score of 2 (at least moderate pruritus), a
weal score of 1 (at least 1-6 weals) and a global CSU severity score of 2 (at least
moderate severity) at screening and at baseline
• Participants were also required to show an AM/PM reflective pruritus score of 14
for the 3 consecutive days before baseline and the morning of day 1
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Exclusion criteria of the trial
• Pregnant or lactating, asthma requiring inhaled or systemic corticosteroids, had
been injected with corticosteroids within 90 days of screening
• Had been hospitalised for CSU for 3 months of screening, had antihistamine-
resistant CSU
• Skin reactions due to drug- or food-related allergies, hypersensitivity to
desloratadine
• Concomitant disease
• Unable to give informed consent
• Prior unresponsiveness to antihistamines, history of “poor motivation, non-
compliance with medications or treatment protocols”
Interventions Interventions, dose, duration
• Desloratadine 5 mg daily
• Placebo
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: up to 6 weeks
Outcomes Timing of outcome assessment: days 7, 14, 42 (patient diaries collected at these times
or at time of early termination, if applicable)
Primary outcomes of the trial
• Pruritus evaluated at visits and reflectively (last 12 hours)
• Primary efficacy measure was variation in mean AM/PM reflective pruritus scores
over first 2 weeks of treatment, expressed as change from baseline to day 14 and area
under curve of reflective pruritus score vs time from baseline to day 14
• Quality of life measures: See primary outcomes above
Secondary outcomes of the trial
• Disruption of sleep and daily activities. Variation in mean AM/PM reflective
pruritus scores after 1 and 6 weeks of treatment (0 = none; 1 = mild, noticeable but
discreet, easy to tolerate; 2 = moderate, obvious, unpleasant presence but bearable; 3 =
severe, hard to bear), instantaneous pruritus scores on days 1 to 4 and change in
number of weals (0 = none, 1 = 1-6, 2 = 7-12, 3 = > 12) and maximum size of weals (0
= none, 1 = < 1 cm, 2 = 1-5 cm, 3 = > 5 cm) after 1, 2, 6 weeks’ treatment; global
response to treatment defined as % with complete response, marked or moderate (after
6 weeks); safety profile
• Also global severity score (0 = no signs/symptoms; 1 = signs/symptoms clearly
present but associated with minimal awareness, easily tolerated; 2 = definite awareness
of signs/symptoms that are bothersome but tolerable; 3 = signs/symptoms hard to
tolerate, causing interference with daily activities/sleep) appears to have been measured,
but not stated to be a specific endpoint. Variation of the scores of 2 QoL dermatology-
specific tools measured between baseline and day 42, the French translation version of
the Dermatology Life Quality Index (DLQI) and the VQ-Dermato (a French language
scoring instrument)
• Adverse events: serious events requiring withdrawal: desloratadine group:
pregnancy (not treatment-related)
• Other adverse events: similar incidence in both groups, greater in placebo group.
One participant in placebo group withdrew because of exacerbation of urticaria
Clinician or participant report: participant diaries, general (non-directive) questions by
investigators, or clinical examination
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Notes Study investigators concluded that desloratadine was shown to be significantly superior
to placebo in improving severity of pruritus as measured by reflective pruritus scores
measured between days 0 and 14
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 39): “following screening
(visit 1), a computer-generated allocation
code was used to randomly assign patients”
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind, medication was
provided to participants in a numbered
container based on their randomisation
code
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double-blind but method of
investigator blinding not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 85/142 randomly assigned participants
completed the study
Figure 1 of the study report provides an ac-
count of dropouts from each group. 142
randomly assigned (65 desloratadine, 77
placebo). 5 withdrawn as received no treat-
ment or had no baseline data. Of remain-
ing 137 (65 desloratadine, 72 placebo), 85
completed (49 desloratadine, 36 placebo)
. 16 withdrew from desloratadine group
(12 lack of efficacy, 1 adverse event (preg-
nancy, not treatment-related), 1 withdrew
consent, 1 was lost to follow-up, 1 other
reason). 36 withdrew from placebo group
(34 lack of efficacy, 2 lost to follow-up de-
scribed as ’loss of sight’ in fact lost to fol-
low-up)
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported,
but results are presented as percentages or
as graphs with statistical significance
Comment: endpoint at 6 weeks is not clear
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Other bias Unclear risk Funder: Schering-Plough Research Insti-
tute
Patel 1997
Methods Design: randomised double-blind 2-arm parallel-group study of loratadine vs cetirizine
Duration: 2 weeks
Participants Number of participants randomly assigned: 46 (22 loratadine, 18 cetirizine)
Sex: not stated
Age of participants: not stated
Unit of allocation: participant
Country and setting: not stated; investigators located in USA and Canada
Inclusion criteria of the trial
• CSU with moderate to severe pruritus and hives
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• 10 mg of loratadine
• Cetirizine once daily (mornings for 2 weeks)
Duration of intervention: short-term (2 weeks)
Length of follow-up: 2 weeks
Outcomes Timing of outcome assessment: baseline and days 7 and 14
Primary outcomes of the trial
• Pruritus, number and size of hives and erythema. Primary efficacy parameter was
physician-evaluated change in pruritus between baseline and day 7. Pruritus and
erythema were rated as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe. Number
of hives was evaluated on a 3-point scale (0 = none, 1 = 1 to 6, 2 = 7 to 12, 3 = > 12).
Diameters of the largest hives were measured and rated as 0 = none, 1 = < 1.5 cm, 2 =
1.5 to 2.5 cm, 3 = > 2.5 cm. The overall condition of chronic idiopathic urticaria was
graded as 0 = none, 1 = mild, 2 = moderate, 3 = severe. Ratings of therapeutic response
to study drug were 1 = complete relief, 2 = marked relief, 3 = moderate relief, 4 = slight
relief, 5 = treatment failure
• Quote (page 319): “Histamine skin-prick challenge was performed before therapy
was initiated and 2 hours after the last dose on the last study day after all clinical
evaluations”. Results were transferred onto clear tape; planimetry was used to measure
areas
• Quality of life measures: not stated
Secondary outcomes of the trial
• Adverse events: recorded by participants, sedation recorded by 2 in the cetirizine
group
Clinician or participant report: clinician and participant diary card
Notes Study investigators concluded that loratadine and cetirizine were well tolerated with
comparable efficacy
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised, methods not de-
scribed
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind, no details given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind, no details given
Incomplete outcome data (attrition bias)
All outcomes
Low risk 40/46 complete (22 loratadine, 18 ceti-
rizine). These non-completers had fewer
than 7 days of therapy or lack of valid fol-
low-up visit or both
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Unclear risk Funder: Schering-Plough, USA
Paul 1998
Methods Design: multi-centre double-blind randomised parallel-group study comparing fexofe-
nadine 60 mg, 120 mg, 180 mg, 240 mg or placebo, each once daily
Duration: 6 weeks
Participants Number of participants randomly assigned: 222 (details unclear)
Age of participants, years: placebo 43 ± 13; fexofenadine 60 mg 44 ± 17; fexofenadine
120 mg 45 ± 12; fexofenadine 180 mg 43 ± 15; fexofenadine 240 mg 44 ± 14
Overall age, years: 44 ± 14
Sex (% female): placebo 54%, fexofenadine 60 mg 58%, fexofenadine 120 mg 47%,
fexofenadine 180 mg 68%, fexofenadine 240 mg 59%
Total female: 58%
Duration of symptoms: 3 years ± 5
Severity of urticaria: unclear
Unit of allocation: participant
Country and setting: France, UK, Germany; secondary care
Inclusion criteria of the trial
• CSU symptoms at least once a week
Exclusion criteria of the trial
• “Predominantly” physical urticaria, urticarial vasculitis, hypersensitivity to
terfenadine or not responsive to antihistamine treatment; topical and systemic
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treatment for CSU
Interventions Interventions, dose, duration
• Fexofenadine 60 mg
• Fexofenadine 120 mg
• Fexofenadine 180 mg
• Fexofenadine 240 mg
• Placebo
(each once daily)
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 6 weeks
Outcomes Timing of outcome assessment: weekly assessment
Total symptoms score (TSS) (0-4 for number of weals; 0-3 for itching intensity; 0-7
combined TSS)
Primary outcomes of the trial
• Mean daily TSS and weekly TSS
• Quality of life measures: none
Secondary outcomes of the trial
• Sleep interference (0-3), daily activity (0-3), global participant score for
effectiveness (0-4)
• Physician assessments: intensity of erythema, lesion size, number and extent
• Adverse events: headache 12% in active group, 14% in placebo group
Clinician or participant report: both
Notes Study investigators concluded that good or excellent response in 60 mg group = 63%,
120 mg group 50%, 180 mg group 64%, 240 mg group 55% and placebo group 41%;
not clear whether timing for this result but may be 6 weeks
Fexofenadine is effective at 120 mg and above from week 1 as compared with placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants non-responsive to other anti-
histamine treatment excluded
Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated how
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated how
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No ITT. 76 participants withdrew before
completion: 30 lost from placebo, 14 from
120 mg group, 16 from 180 mg group and
8 from 240 mg group
Treatment group reason for withdrawal:
lack of effect 13%, adverse events 7%, pa-
tient request 6%
Placebo group: lack of effect 33% and ad-
verse events 20%
Selective reporting (reporting bias) Unclear risk No ITT; study says weekly as well as fort-
nightly; all active drug groups put together
and reported only selectively
Other bias Unclear risk Funder: Hoechst Marion Roussel
Peyri 1991
Methods Design: randomised double-blind multi-centre placebo-controlled 2-arm study of ebas-
tine 10 mg daily vs placebo
Duration: 14 days
Participants Number of participants randomly assigned: 204 (ebastine 100, placebo 104)
Sex: not stated
Age of participants: not stated
Unit of allocation: participant
Country and setting: Spain; secondary care (outpatient clinics)
Inclusion criteria of the trial
• CSU, of at least 3 months’ duration, cutaneous eruptions, active disease
Exclusion criteria of the trial
• Angio-oedema, neoplasia, steroids in last 2 weeks (topical or systemic)
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Ebastine 10 mg once daily for 14 days
• Placebo once daily for 14 days
Duration of intervention: short-term (14 days)
Length of follow-up: 14 days
Outcomes Timing of outcome assessment: baseline, 7 days, 14 days
Primary outcomes of the trial
• Participants assessed itching severity and number/size of weals on 4-point scale:
nil/mild/moderate/severe
• Investigator recorded number of weals
• Joint assessment of mean weekly duration of symptoms
• Both scored overall treatment efficacy at end of trial period: no change/moderate
improvement (improvement in approximately half of symptoms)/good (improvement
in most or all of symptoms), but reported as ’cure, improvement, no change, or
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worsening’
• Tolerability assessed by physician and participant as good/moderate/poor
Secondary outcomes of the trial
• Side effects rated as absent/mild/moderate/severe
• Adverse events (serious, requiring withdrawal)
Clinician or participant report: both
Notes Study investigators concluded that a significantly greater reduction in weal size and weal
number was seen in ebastine group over placebo. Pruritus significantly less in ebastine
group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind study; matching placebo
capsules; unclear whether blinding was ad-
equate for both participants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear, no details given
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up: 27/204 (13%), ebas-
tine 9/100 (9%), placebo 18/104 (17%)
Withdrawals due to lack of efficacy: ebas-
tine n = 3 and placebo n = 13; poor toler-
ability: ebastine n = 1; lack of efficacy plus
poor tolerability: ebastine n = 1, placebo
n = 3; other reasons not due to treatment:
ebastine n = 4, placebo n = 2
Withdrawals with reasons stated and bal-
anced between the 2 groups
No ITT
Selective reporting (reporting bias) Unclear risk No clear definition of outcomes, unclear
howoutcome assessmentswere used to gen-
erate assessments of (Quote) (page 52):
“cure, improvement, no change, worsen-
ing” Age and sex of participants not known
Other bias Unclear risk Funder: Almirall
Note: Groups were well matched for age,
sex, duration of urticaria, previous treat-
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ment and response to prior antihistamine
therapy
Phanuphak 1987
Methods Design: double-blind randomised placebo-controlled 2-arm study of ketotifen (mast cell
stabiliser) vs placebo
Duration: 2 weeks
Participants Number of participants randomly assigned: 30 (16 ketotifen and 14 placebo)
Sex: 25% male, 75% female ketotifen; 26% male, 64% female placebo
Age of participants, years: mean 30.4
Unit of allocation: participant
Country and setting: Thailand; secondary care
Inclusion criteria of the trial
• CSU for longer than 6 weeks
Exclusion criteria of the trial
• Pregnancy, lactation, < 15 years old
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Ketotifen 1 mg twice daily
• Placebo twice daily
2-week run-in: participants allowed to take chlorpheniramine 4 mg prn up to 6-hourly;
then randomly assigned to ketotifen or placebo and still allowed to take chlorpheniramine
concomitantly; numbers of chlorpheniramine tablets taken recorded
Duration of intervention: short-term (2 weeks)
Length of follow-up: 2 weeks
Outcomes Timing of outcome assessment: baseline and 2 weeks
Primary outcomes of the trial
• Proportion with good/excellent response: scored as 0 = no lesion or no symptoms,
1 = mild symptoms, 2 = moderate symptoms, 3 = severe symptoms
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: minor and serious
Clinician or participant report: investigator and participant diaries
Notes Study investigators concluded that ketotifen was significantly better than placebo. Chlor-
phenamine requirement was dropped in significantly more participants taking ketotifen
than placebo (94% vs 7%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned to 2
groups, method not described
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Allocation concealment (selection bias) Unclear risk Third party sealed envelopes with code
number, containing active treatment or
placebo prepared and sealed by a third per-
son, but unclear if this refers to blinding or
to concealment of allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study; identical white tablets
provided to participants, blinded to partici-
pants, as supplied in sealed coded envelopes
prepared by a third party
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors were
blinded and how
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up: 30 (16 ketotifen
and 14 placebo)
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported
Comment: The ’slightly effective’ and ’in-
effective’ evaluation of patient score put to-
gether as ineffective
Other bias Unclear risk Funder: Sandoz
Allowed concomitant treatment with
chlorpheniramine such that positive results
of ketotifen group might be due to this
alone or to the combination of ketotifen
plus chlorpheniramine; very small num-
bers; sponsored by manufacturer
Pons-Guiraud 2006
Methods Design: randomised double-blind multi-centre 2-arm trial comparing emedastine and
loratadine
Duration: 4 weeks
Participants Number of participants randomly assigned: 192 (emedastine n = 84, loratadine n = 77)
Sex: loratadine: 34.5% male, 65.5% female; emedastine: 25% male, 75% female
Age of participants, years: loratadine: 42.6 ± 14.7; emedastine:43.4 ± 13.3
Country and setting: Italy, France, Hungary, Czech Republic; secondary care
Unit of allocation: participant
Inclusion criteria of the trial
• Other skin/systemic disease that could affect efficacy evaluation; concomitant
antihistamines, sedatives, steroids
• Hypersensitivity to loratadine or emedastine or excipient pregnancy or lactation
• Premenopausal women not on contraceptive; profession requiring driving/
operation of machinery
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• Raised liver enzymes/creatinine; drug/alcohol abuse
• < 75% compliance during placebo run-in
• Lack of co-operation; “previous enrolment into the trial”; non-Caucasians < 18 or
> 64
• Those with history of failure to respond to antihistamine
• Included only if at least moderate itching for at least 3 days during 7-day run-in
Interventions Interventions, dose, duration
• Emedastine difumarate 2 mg twice daily
• Loratadine 10 mg once daily (plus placebo once daily)
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 weeks (plus optional visits 2 weeks after cessation of therapy)
Outcomes Timing of outcome assessment: 1, 2 and 4 weeks (plus optional visits at week 2 and 2
weeks after discontinuation of treatment)
• Complete suppression of urticaria, proportion with good/excellent response, good
or excellent response but not completely suppressed
• Primary endpoint (from daily symptom diary): total urticaria symptoms score:
sum of itching intensity score + hive number score (measured twice daily)
• Erythema intensity score, largest hive score, extension of involved skin score, final
overall effectiveness scores (participant and investigator)
• Itching: 0 = none; 1 = mild, symptom present but not annoying/troublesome; 2 =
moderate, frequently troublesome, not interfering with sleep/activities; 3 = severe,
sufficient to interfere with sleep/activities
• Number of weals (0 = none, 1 = 1-6, 2 = 7-12, 3 = > 12)
• Intensity of erythema (0 = absent, 1 = slight/pale, 2 = definite or red, 3 = extreme/
bright red)
• Extent of skin involved (0 = weals absent; 1 = 1%-10% body involved; 2 =
moderate amount of body involved, 11%-30%; 3 = large amount of body involved, >
30%)
• Overall effectiveness of medication (0 = no improvement/worse, 1 = slight
improvement, 2 = moderate improvement, 3 = marked improvement, 4 = complete
disappearance of symptoms)
• Quality of life measures: none
Secondary outcomes of the trial
• Size of largest hive (0 none, 1 = < 1.5 cm, 2 = 1.5-2.5 cm, 3 = > 2.5 cm)
• Adverse events: Safety analysis included all 192 randomly assigned participants
(96 in each group)
• Serious: loratadine: attempted suicide; emedastine: bilateral calcaneum fractures
following fall
• Minor adverse events: sleepiness, nausea, constipation, palpitations, dry mouth;
emedastine: sleepiness, headache, fatigue, increased liver enzymes
Clinician or participant report: both
Notes Study investigators concluded that no significant differences between treatments were
noted at 4 weeks according to investigator and participant scores; mean symptom scores
improved significantly from baseline in both groups
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer list prepared by sponsor
Allocation concealment (selection bias) Low risk Sealed envelopes containing code breaks
were given to each centre
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy study; 2
identical capsules; placebo run-in
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy study; 2
identical capsules; placebo run-in, but
unclear whether outcome assessors were
specifically blinded to allocation
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 152/192 completed
12 participants excluded after randomi-
sation, as they took prohibited antihis-
tamines. 19 more excluded after randomi-
sation, as they failed to report scores for
hives/itching during placebo run-in pe-
riod. Only the remaining 161 participants
were included in ITT. 31 lost to follow-up
(16%). Per-protocol (PP) analysis included
only 153 participants-8 had major proto-
col violations or dropped out
Two were withdrawn because of serious ad-
verse events: 1 suicide attempt, 1 fracture
following a fall in emedastine group
No ITT
Comment: All dropouts accounted for but
not clearly by group
Selective reporting (reporting bias) Low risk No selective reporting
Comment: excluded participants unre-
sponsive to antihistamines
Other bias Unclear risk Funder: Saluc-Pharma S.A. Study drug
manufactured and packaged by sponsor; no
power calculation
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Methods Design: randomised multi-centre randomised parallel-group double-blind 2-arm study
comparing levocetirizine 5 mg and desloratadine 5 mg
Duration: 4 weeks
Participants Number of participants randomly assigned: 886 (levocetirizine n = 438, desloratadine n
= 448)
Sex: levocetirizine 35.2%male, 64.8% female; desloratadine 36.2%male, 68.3% female
Age of participants, years (range): levocetirizine 43.36 (18-79.2); desloratadine 42.85
(18.1-81.3)
Unit of allocation: participant
Country and setting: multi-centre Germany and UK; secondary
Inclusion criteria of the trial
• Male and female outpatients 18 years of age and older, with a clinical history of
CSU (i.e. episodes of hives of characteristic weal and flare appearance, occurring
regularly, at least 3 times a week) for a period of at least 6 weeks during last 3 months
without an identifiable cause were recruited into the study
• All participants were additionally required to have a pruritus severity score (over
last 24 hours) ≥ 2 and number of weals score ≥1 for at least 3 days in the week before
randomisation
Exclusion criteria of the trial
• Physical urticaria, drug-induced urticaria, vasculitis, senile pruritus, hereditary
angio-oedema, other dermatological or clinically significant disease; steroids in last 4
weeks; desloratadine, loratadine, levocetirizine, cetirizine in last 10 days; astemizole in
last 12 weeks; ketotifen in last 2 weeks; leukotriene antagonists in last 3 days; CNS
acting agents
• Pregnant/breastfeeding
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Levocetirizine 5 mg once daily
• Desloratadine 5 mg once daily
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 5 weeks i.e. follow up extended after cessation of therapy
Outcomes Timing of outcome assessment: 4 scheduled visits over a period of 5 weeks: screening
visit 1 (V1; week -1), randomisation visit (V2; week 0), control visit (V3; week 1) and
final visit (V4; week 4)
Primary outcomes of the trial
• Mean pruritus severity score, mean pruritus duration, number and size of weals,
mean CSU composite score (sum of pruritus severity score and score for number of
weals)
• Participants evaluated and recorded severity of pruritus and duration of pruritus
over last 24 hours (reflective) and number and size of weals (at the time of evaluation)
in DRCs on 4-point scales of 0 to 3, once a day in the evening over entire duration of
the trial
• Pruritus severity was scored (0 = none; 1 = mild (present but not disturbing); 2 =
moderate (disturbing but not hampering daytime activities and/or sleep); and 3 =
severe/intense (disturbing and hampering daytime activities and/or sleep)), and
duration of pruritus was scored (0 = no pruritus; 1 = < 1 hour; 2 = 1-6 hours; and 3 = >
173H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Potter 2009 (Continued)
6 hours)
• Similarly, number of weals was scored (0 = none; 1 = mild (< 20 weals/24 h); 2 =
moderate (21-50 weals/24 h); and 3 = severe/intense (> 50 weals/24 h)), as was size of
weals (diameter of the greatest weal) (0 = no weal; 1 = 1-1.5 cm; 2 = 1.5-3.0 cm; and 3
= > 3.0 cm)
• Quality of life measures: self-administered DLQI; QoL and participant’s and
investigator’s global satisfaction with treatment were evaluated as secondary efficacy
measures
Secondary outcomes of the trial
• Adverse events: “Safety and tolerability of treatment was evaluated according to
the frequency, severity, nature and duration of adverse events reported by the patients
during the entire study period. Any abnormalities noted during the physical
examinations were also evaluated”
Clinician or participant report: participant and clinician
Notes Study investigators concluded that levocetirizine 5 mg was significantly more efficacious
than desloratadine 5 mg in the treatment of CSU symptoms
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 597): “Randomization to the
study drug was achieved by allocation of a
unique study number to each subject and
a computer-generated
sequential randomisation number pro-
vided by the Biostatistics Department of
the study sponsor (UCBS.A., Brussels, Bel-
gium)”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (page 597): “capsules identical in
shape, size and colour to allow a double-
blind design”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear how outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 832/886 completed
• Levocetirizine group: lack of efficacy
n = 10; “other” n = 6; adverse events n =
4; loss to follow-up n = 3; withdrawal of
consent n = 2
• Desloratadine group: lack of efficacy
n = 13; ”other” n = 7; adverse event n = 3;
loss to follow-up n = 3; withdrawal of
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consent n = 3
• Comment: numbers balanced
between groups, reasons for losses stated
In NCT00264303, reasons for withdrawal
were given but do not correspond with
the number of participants analysed-n =
25 levocetirizine and n = 29 desloratadine-
because of adverse event, lack of efficacy,
loss to follow-up, participant preference to
withdraw, other reasons. However, number
of participants analysed was n = 434 in le-
vocetirizine group and n = 443 (877 total)
in desloratadine group (only 9 losses out of
886 specified, reasons unclear). Judged as
unclear risk
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Unclear risk Funder: UCB
Ring 2001
Methods Design: randomised double-blind placebo-controlled parallel-group 2-arm study of
desloratadine vs placebo
Duration: 6 weeks
Participants Number of participants randomly assigned: 190 (95 in each group)
Sex: 29% male, 71% female desloratadine; 22% male, 78% female placebo
Age of participants, years: 12 to 79
Country and setting: USA and Germany; secondary care
Unit of allocation: participant
Inclusion criteria of the trial
• CSU, men and women > 12 years of age, minimum 6-week history of CSU and
active flare
• CSU for longer than 3 weeks before screening, with weals visible for > 3 days per
week
• Overall moderate disease severity at screening and baseline, moderate pruritus and
presence of weals at screening
• At baseline, participants also had to have a total reflective pruritus score > 14 (at
least moderate) over the previous 3 days and on the morning of the baseline visit
• Normal laboratory and physiological values
Exclusion criteria of the trial
• Significant concomitant illnesses (e.g. malignancy) or pharmacological agents that
could interfere with study drug, asthma with leukotriene inhibitors or required long-
term inhaled or systemic corticosteroid therapy
• Previous unresponsiveness to antihistamine: not stated
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Interventions Interventions, dose, duration
• Desloratadine 5 mg
• Placebo
Once daily for 6 weeks (sufficient time for washout of any medications before study was
employed)
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 6 weeks
Outcomes Timing of outcome assessment: days 1 and 4, then weeks 1, 2, 4, 6
Primary outcomes of the trial
• Participants used 4-point scale (reflective related to previous 12 hours-scored twice
daily; instantaneous related to immediate time of assessment on all study days) for
pruritus, number of weals, size of largest weal; summed to give total symptoms score
• Recorded interference with sleep and interference with daily activities
• Severity assessed by physician and participant at days 1 and 4, then at weeks 1, 2,
4 and 6 (0 = none, 1 = mild, 2 = moderate, 3 = severe)
• Therapeutic response jointly assessed on 5-point scale (1 = complete relief to 5 =
treatment failure)
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: serious adverse events (requiring treatment withdrawal):
desloratadine n = 3, placebo n = 2 (not specified but not life threatening)
• Minor adverse events: desloratadine: n = 53 headache, fatigue, pharyngitis, URTI,
dizziness; placebo n = 41: headache, fatigue, pharyngitis, URTI, dizziness, viral
infection
Clinician or participant report: investigator and participant
Notes Study investigators concluded that results from week 1 were maintained throughout
study duration
Desloratadine significantly superior to placebo in reducing average mean reflective pru-
ritus score (56% vs 21%) and total symptoms score (51.6% vs 19.3%). Interference with
sleep and daily activities, number of weals, size of largest weal all significantly reduced
by desloratadine vs placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated schedule, randomly
assigned
Allocation concealment (selection bias) Unclear risk Unclear, no details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study; matched placebo
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind study; unclear how outcome
assessors were blinded to treatment alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up: desloratadine: 19/95
(20%); placebo: 32/95 (34%)
Treatment failure: desloratadine n = 13,
placebo n = 21; non-compliance: deslorata-
dine n = 3, placebo n = 6; adverse events:
desloratadine n = 3, placebo n = 2; other
losses to follow-up: desloratadine n = 0,
placebo n = 2; did not wish to continue:
placebo n = 1
Adverse events: serious adverse events (re-
quiring treatment withdrawal): deslorata-
dine: 3 not specified (not life threatening);
placebo: 2 not specified (not life threaten-
ing)
Comment: high level of loss to follow-up;
more losses in the placebo group; unclear
whether this contributed to bias
Selective reporting (reporting bias) Unclear risk Desloratadine significantly superior to
placebo in reducing averagemean reflective
pruritus score (74% vs 49%). Numbers for
total symptoms score not given at 6 weeks,
but said to be significant. Actual reductions
in scores not stated, only percentages; un-
clear how clinically significant these reduc-
tions are
Other bias Unclear risk Funder: Schering-Plough Research Insti-
tute
Salo 1989
Methods Design: randomised double-blind cross-over 3-arm study comparing acrivastine vs hy-
droxyzine vs placebo
Duration: 5 days each treatment
Participants Number of participants randomly assigned: 21
Sex: 47% female
Age of participants, years: 18-70, mean 38.3
Country and setting: Finland and UK; secondary
Unit of allocation: cross-over participants
Inclusion criteria of the trial
• Defined CSU as > 4 weeks; however, no participants included with urticaria < 2
months; adults over 18 years
Exclusion criteria of the trial
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• Systemic steroids in last 4 weeks, concurrent sedatives, other antihistamines
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Acrivastine 8 mg 3 times daily
• Hydroxyzine hydrochloride 20 mg 3 times daily
• Placebo 3 times daily during three 5-day periods
3-day washout initially; then 2-day washout period between treatments
Duration of intervention: short-term (5 days per intervention)
Length of follow-up: 5 days for each treatment
Outcomes Timing of outcome assessment: at 5 days for each treatment
Primary outcomes of the trial
• Participants self-assessed daily (weals 0-4; 0 = none, 1 = 1-5, 2 = 6-10, 3 = 11-20,
4 = > 20) (itching 0-4; 0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe)
• Investigator at end of study recorded in his opinion which treatment worked best
and suited participant best overall
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: reasons for 3 withdrawals not stated. Minor events not stated
Clinician or participant report: investigator and participant (daily diary)
Notes Study investigators concluded that participant data showed no differences between active
treatments; both better than placebo (P value < 0.05)
Physician data showed active treatment better than placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation unclear, de-
scribed as randomised
Allocation concealment (selection bias) Unclear risk Unclear. Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind study. Method of blinding
not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind study. Method of blinding
not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Incomplete reporting of data; reasons for
withdrawal not stated. No ITT
3/21 lost to follow-up (34%)
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Selective reporting (reporting bias) High risk Investigators appear to have made sub-
jective decision on best treatment. No
raw data-mean scores only. Adverse effects
of drowsiness significantly more prevalent
with hydroxyzine than with placebo, but
numbers of participants experiencing this
not stated
Other bias Unclear risk Funder: Wellcome Research Laboratories
Sener 1999
Methods Design: randomised 2-arm parallel-group study comparing ketotifen and fluoxetine
Duration: 6 weeks
Participants Number of participants randomly assigned: 60 (30 in each group)
Sex: 41% female, 59% male
Unit of allocation: participant
Age of participants, years (SD): 19-74 (42.08 ± 19.24)
Country and setting: Turkey, research clinic
Inclusion criteria of the trial
• CSU
Exclusion criteria of the trial
• None
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Ketotifen (H1-antihistamine first generation) 1 mg twice daily for 6 weeks
• Fluoxetine (SSRI) 20 mg 4 times a day for 6 weeks (not a cross-over)
Duration of intervention: intermediate-term (6 weeks)
Length of follow-up: 6 weeks
Outcomes Timing of outcome assessment: baseline, weekly and at 6 weeks
Primary outcomes of the trial
• Number of lesions
• Degree of itching and discomfort
• Amount of angio-oedema graded 0 to 4 for each participant
• Quality of life measures: not stated
Secondary outcomes of the trial
• Adverse events: not stated
Clinician or participant report: unclear
Notes Study investigators concluded that significantly greater improvement in symptom score
was seen in the ketotifen group (P value < 0.001); fluoxetine led to significant improve-
ment in number of lesions, degree of itch and angio-oedema
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation unclear (“ran-
domly divided”)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding (1 treatment twice daily and
the other treatment 4 times daily)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding (1 treatment twice daily and
the other treatment 4 times daily)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No rawdata; adverse events notmentioned,
nor withdrawals from study
Selective reporting (reporting bias) Unclear risk Limited report of outcomes, as reported
only as abstract for poster presentation
Other bias Unclear risk Funder: not stated. Very short poster ab-
stract
Staevska 2014
Methods Design: prospective randomised double-blind cross-over trial
Duration: 5 days
Participants Number of participants randomly assigned: 24
Sex: 75% female
Age of participants, years: mean 45, range 19 to 68
Unit of allocation: cross-over (first phase only considered)
Country and setting: Bulgaria; tertiary care
Inclusion criteria of the trial
• ≥ 18 years of age
• 6-week documented history of urticaria with intake of 15 to 30 mg prednisolone
Exclusion criteria of the trial
• Participants with physically induced urticaria
• Pregnancy and lactation
• Any chronic disease requiring daily other drug treatment including
antihypertensives, antipsychotics and antidepressants
• Other skin disease
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
Initial in-hospital treatment, assessment of effectiveness and tolerability of levocetirizine
10 and 20 mg vs hydroxyzine 100 and 200 mg. This was done in a double-blind fashion
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on alternate-day regimens
• Levocetirizine 20 mg per day and levocetirizine 15 mg plus hydroxyzine 50 mg as
evening dose for 5 days. After 5 days, participants from arm 1 and arm 2 were crossed
over to the alternative treatment. No washout
Length of follow-up: 5 days on each treatment
Short duration of intervention (5 days)
Length of follow-up: 5 days
Outcomes Timing of outcome assessment: day 5
Primary outcomes of the trial
• Urticaria-specific quality of life
Secondary outcomes of the trial
• Effect of the 2 regimens on urticaria symptoms
• To compare the effects of the 2 regimens on urticaria symptoms (number of
weals, pruritus severity)
• Effect on nighttime sleep
• To compare the effects of the 2 regimens on quality of nighttime sleep
• Effects on daytime somnolence
• To compare the effects of the 2 regimens on daytime somnolence
• Effects on blood eosinophil numbers, Na2+, K+, ALAT, ASAT, ECG
• To document the effects of treatment with higher doses of levocetirizine or
hydroxyzine on blood eosinophil numbers, Na+(sodium ion), K+(potassium ion),
ALAT (alanine transaminase), AST (aspartate transaminase), ECG (electrocardiogram)
• To assess adverse events
• To investigate safety by assessing the nature, incidence and severity of adverse
events within treatment groups
• Adverse events: not mentioned
Quality of life measures: median CU-Q2oL scores
Clinician or participant report: physicians calculated weal scores and severity of pruritus
Notes Study investigators concluded that higher than standard doses of cetirizine can improve
quality of life in participants discontinuing steroid treatment. Addition of hydroxyzine
does not seem to provide benefit but causes increased daytime somnolence
Study ID NCT01250652
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised. Randomisation,
ensuring balanced numbers of cases in the 2
treatment arms, was performed pair-wise at
a specialised website (http://www.random-
izer.org/)
Comment: Exposure to study medication
after randomisation to determine tolera-
bility of medications on alternate-day reg-
imens may have compromised randomi-
sation through a potential carry-over ef-
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fect (insufficient washout period between
phases)
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: “Medication was given
morning and evening in opaque gelatine
capsules that were prepared by a technician
who was not aware of the clinical work”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The investigators, whowere blinded to the
treatment groups”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 25 participants were initially randomly
assigned. 24 participants completed the
study-1 withdrawal after randomisation
(personal reasons)
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Unclear risk Funder: UCB Pharma. Short report, con-
ference abstract
Thompson 2000 Study 1
Methods Design: randomised multi-centre double-blind 2-arm placebo-controlled parallel study
of fexofenadine vs placebo
Duration: 4 weeks
Participants Number of participants randomly assigned: 160
Sex, fexofenadine: 18% male, 72% female; placebo: 30% male, 70% female
Age of participants, years: fexofenadine: 40 ± 11; placebo: 38 ± 13
Country and setting: US; secondary care
Unit of allocation: participant
Inclusion criteria of the trial
• CSU, 1 to 5 weals confirmed by investigator and moderate to severe itching in last
12 hours
Exclusion criteria of the trial
• Drug/alcohol abuse, blood dyscrasia, malabsorption, malignancy, chronic
infection, pregnancy/lactation, psychological disorder; cardiac, hepatic,
immunological, endocrine, other major systemic disease; participants with less than
moderate to severe itching in previous 12 hours, inactive urticaria
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Fexofenadine 60 mg twice daily for 4 weeks
• Placebo twice daily for 4 weeks
Duration of intervention: intermediate-term (4 weeks)
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Length of follow-up: 4 to 6 weeks i.e. follow-up extended after the cessation of therapy
Outcomes Timing of outcome assessment: 4 or 6 weeks
Primary outcomes of the trial
• Average change from baseline in overall DLQI score for 4- to 6-week study,
percentage work or classroom productivity, percentage work/classroom time missed
• Quality of life measures: significant improvement in DLQI in fexofenadine
groups in both studies compared with placebo (over “4-6 week period”); in individual
domains of DLQI (symptoms/feelings, daily activities, leisure, work or school, personal
relations, treatment), significantly better improvement in fexofenadine achieved in
both studies in symptoms/feelings, daily activities, work or school and personal
relations for leisure and treatment
Secondary outcomes of the trial
• Adverse effects: not stated
• Average change from baseline in individual DLQI domains, daily activity/
productivity, overall work/classroom productivity, percentage work/classroom
productivity (i.e. 100%-percentage work/class time missed)
• Pruritus severity scale (0 = none; 1 = mild, not annoying or troublesome; 2 =
moderate, annoying/troublesome, may interfere with daily activities/sleep; 3 = severe,
very annoying, substantially interfering with sleep/daily activities; 4 = very severe,
warrants physician visit
Clinician or participant report: Participants completed self-administered questionnaire,
DLQI (score range 0-30), work productivity and activity impairment questionnaire
(WPAI-0-100%, high = greater productivity) at entry, interim visit (15 ± 2 days’ treat-
ment), final visit (30 ± 4 days) or early termination
Notes Study investigators concluded that significant differences were demonstrated in only 1
study out of 2. Increase in “work productivity,” “overall work productivity,” regular daily
activities significantly higher in fexofenadine group compared with placebo group (both
studies); no differences between groups re time missed from class/work
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Patients were randomised to re-
ceive 60 mg fexofenadine HCl twice daily
or placebo twice daily...”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ”24 hour single-blind placebo lead-
in, and a subsequent 4-week double blind
treatment period.” Unclear how blinding
was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ”24 hour single-blind placebo lead-
in, and a subsequent 4-week double blind
treatment period.” Unclear how blinding
183H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Thompson 2000 Study 1 (Continued)
was achieved
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of whether there were drop-
outs; therefore unable to corroborate ITT
analyses as reported in Study 1
Selective reporting (reporting bias) Unclear risk Ambiguity re duration of trial, as reported
methods say 4 weeks and results say 4 to
6 weeks. DLQI measures reported but not
as proportions of participants with 50%
or greater improvement in quality of life
measurements whilst taking H1-antihis-
tamines; therefore not possible to include
DLQI data
Other bias Unclear risk Funder: Hoechst Marion Roussel. Study
investigators report 2 identical studies in
this paper; if studies identical, unclear why
not combined as a single study
Thompson 2000 Study 2
Methods Design: randomised multi-centre double-blind 2-arm placebo-controlled parallel study
of fexofenadine vs placebo
Duration: 4 weeks
Participants Number of participants randomly assigned: 165
Sex: fexofenadine: 26% male, 74% female; placebo: 27% male, 77% female
Age of participants, years: fexofenadine: 38 ± 13; placebo:40 ± 13
Country and setting: USA; secondary care
Unit of allocation: participant
Inclusion criteria of the trial
• CSU, 1 to 5 weals confirmed by investigator and moderate to severe itching in last
12 hours
Exclusion criteria of the trial
• Drug/alcohol abuse, blood dyscrasia, malabsorption, malignancy, chronic
infection, pregnancy/lactation, psychological disorder; cardiac, hepatic,
immunological, endocrine, other major systemic disease; participants with less than
moderate to severe itching in previous 12 hours, inactive urticaria
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Fexofenadine 60 mg twice daily for 4 weeks
• Placebo twice daily for 4 weeks
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: 4 to 6 weeks i.e. follow-up extended after the cessation of therapy
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Outcomes Timing of outcome assessment: 4 or 6 weeks
Primary outcomes of the trial
• Average change from baseline in overall DLQI score for the 4- to 6-week study,
percentage work or classroom productivity, percentage work/classroom time missed
• Quality of life measures: significant improvement in DLQI in fexofenadine
groups in both studies compared with placebo (over “4-6 week period”); in individual
domains of DLQI (symptoms/feelings, daily activities, leisure, work or school, personal
relations, treatment)
Secondary outcomes of the trial
• Average change from baseline in individual DLQI domains, daily activity/
productivity, overall work/classroom productivity, percentage work/classroom
productivity (i.e. 100%-percentage work/class time missed)
• Pruritus severity scale (0 = none; 1 = mild, not annoying or troublesome; 2 =
moderate, annoying/troublesome, may interfere with daily activities/sleep; 3 = severe,
very annoying, substantially interfering with sleep/daily activities; 4 = very severe,
warrants physician visit
• Participants completed self-administered questionnaire, DLQI (0-30), work
productivity and activity impairment questionnaire (WPAI-0-100%, high = greater
productivity) at entry, interim visit (15 ± 2 days’ treatment), final visit (30 ± 4 days) or
early termination
Clinician or participant report: participant (for QoL questionnaires) and clinician
Notes Study investigators reported that significantly better improvement in fexofenadine was
achieved in both studies in symptoms/feelings, daily activities, work or school and per-
sonal relations; for leisure and treatment, significant difference was demonstrated in 1
study out of 2
Increase in “work productivity,” “overall work productivity,” regular daily activities sig-
nificantly higher in fexofenadine group compared with placebo group (both studies); no
difference between groups re time missed from class/work
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Patients were randomised to re-
ceive 60 mg fexofenadine HCl twice daily
or placebo twice daily...”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ”24 hour single-blind placebo lead-
in, and a subsequent 4-week double blind
treatment period.” Unclear how blinding
was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ”24 hour single-blind placebo lead-
in, and a subsequent 4-week double blind
treatment period.” Unclear how blinding
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was achieved
Incomplete outcome data (attrition bias)
All outcomes
High risk Study 2: number randomly assigned stated
in text to be 165; in tables, total number
adds up to 167; no mention of whether
there were dropouts. Unable to confirm
ITT numbers in study report for Study 2
Selective reporting (reporting bias) Unclear risk Ambiguity regarding duration of trial
methods: says 4 weeks; results say 4 to 6
weeks. DLQI measures reported but not
as proportions of participants with 50%
or greater improvement in quality of life
measurements whilst taking H1-antihis-
tamines; therefore not possible to include
DLQI data
Other bias Unclear risk Funder: Hoechst Marion Roussel
Study authors report 2 identical studies in
this paper; if studies identical, unclear why
not combined as a single study
Wan 2009
Methods Design: randomised single-blind 4-arm trial comparing a combination of sedating H1-
antihistamine and non-sedating H1-antihistamine (hydroxyzine plus cetirizine); combi-
nation of H1-antihistamine and H2-antihistamine (hydroxyzine plus famotidine); and
combination of H1-antihistamine and LRA (hydroxyzine plus montelukast) vs placebo
Duration: 4 weeks
Participants Number of participants randomly assigned: 120
Sex: 38% male, 62% female
Age of participants, years: 31 (18-45); 36.4 (20-52); 34.8 (20-54); 33.2 (18-48)
Unit of allocation: participant
Country and setting: Taiwan; secondary care
Inclusion criteria of the trial
• Newly diagnosed CSU patients
Exclusion criteria of the trial
• Recent use of systemic corticosteroids or immunosuppressants
• Previous unresponsiveness to antihistamine: unclear
Interventions Interventions, dose, duration
1-week ‘run-in’ period to wash out previous antihistamine used for treatment. Randomly
assigned to receive:
• Oral hydroxyzine 25 mg plus cetirizine 5 mg twice a day
• Oral hydroxyzine 25 mg plus famotidine 20 mg twice a day
• Oral hydroxyzine 25 mg twice a day plus montelukast 5 mg twice a daily
• Oral placebo twice a day
Duration of intervention: intermediate-term (4 weeks)
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Length of follow-up: 4 weeks
Outcomes Timing of outcome assessment: baseline and after 4 weeks of treatment
Primary outcomes of the trial
• Participant completed a daily record for the preceding 24 hours of the numbers of
small (diameter < 3 cm) and large (> 3 cm) skin weals, according to a specific
classification number, and with scoring as follows: 0 = < 10 weals; 1 = 10 to 15 small
weals or < 10 large weals; and 3 = almost entirely covered with weals. Relative severity
of itch was scored as follows: 0 = none; 1 = mild; 2 = moderate; 3 = severe. The possible
weekly aggregate urticaria activity score (UAS) therefore ranged from 0 to 42
• Participants also provided a 10-cm visual analogue scale score from 0 (none) to 10
(worst) during each outpatient clinic visit, which indicated the overall severity of their
urticaria over the previous 2 weeks. (A response to medication was defined as a
reduction in weekly UAS to < 25% of baseline, and a relapse as a return to > 75% of
baseline UAS)
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: serious adverse events (none reported), sedation
Clinician or participant report: participant and clinician
Notes Study investigators concluded that the combination of H1- and H2-receptor antagonists
provided the greatest treatment efficacy according to the measures used in this small
study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (page 195): ”The same investigating
physicianwhowas blinded to the treatment
regimens saw the patient”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 107/120 randomly assigned completed the
study (13 of 30 participants from placebo
group dropped out after experiencing no
real benefit following therapy for 1-2
weeks)
Comment: All dropouts were from the
placebo group, but as the reasons for this
are given, we have judged the risk of bias as
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low
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported
Other bias Unclear risk Funder: Montelukast provided by manu-
facturer Merck Sharp Dohme
Wang 2012
Methods Design: randomised controlled trial of mizolastine 10 mg daily for 4 weeks followed by
10 mg every other day for 4 weeks and followed by 10 mg per 3 days in the last 4 weeks
for comparison with long-term mizolastine 10 mg daily for 12 weeks
Duration: 12 weeks
Participants Number of participants randomly assigned: 100 (experimental decremental dose group)
; control n = 50, long-term 10 mg mizolastine n = 50
Sex: intervention: men 27, women 23 (46% female); control group: men 28; women 22
(44% female)
Age of participants, mean in years: experimental group 32.66; control group 30.86
Unit of allocation: single participants
Country and setting: China; secondary care
Inclusion criteria of the trial
• Chronic Idiopathic urticaria > 6 weeks, urticaria not due to other causes, age 12
to 65 years; no history of ischaemic heart disease, liver, lung or renal dysfunction; no
consumption of medication within 4 weeks or antihistamine within 1 week
Exclusion criteria of the trial
• Other type of urticaria, known to be allergic to mizolastine, pregnant or lactating
women, taking other medications
• Previous unresponsiveness to antihistamine: not mentioned
Interventions Interventions, dose, duration
• Mizolastine 10 mg daily for 4 weeks
• 10 mg alternate days for 4 weeks
• 10 mg every third day for 4 weeks
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: not mentioned
Concomitant/rescue treatment permitted: not mentioned
Outcomes Timing of outcome assessment: 4, 8, 12 weeks
Primary outcomes of the trial
• Measurement of plasma level of antihistamine (EIA), symptoms: itching severity,
diameter of largest weal, number of weals per day, duration of weals (hours); clinical
improvement: complete suppression, significant improvement, improvement, no
change
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: dry mouth, sleepiness, lethargy
Clinician or participant report: clinician
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Notes Study investigators concluded that long-term decrement in mizolastine therapy is effec-
tive, safe and convenient in the treatment of chronic urticaria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/50 participants in each group were lost
to follow-up, no reasons given
No ITT analysis carried out
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk Funder: not stated
Weller 2013
Methods Design: randomised double-blind parallel-group single-dose study of desloratadine 5 mg
vs 20 mg desloratadine
Duration: 5 hours (short-term)
Participants Number or participants randomly assigned: n = 29 (5 mg desloratadine n = 13, 20 mg
desloratadine n = 16)
Sex: 5 mg desloratadine group: 9 women/4 men (64% female); 20 mg desloratadine
group: 7 women/9 men (43% female)
Age of participants, mean years: 5 mg desloratadine group 43.5 ± 12.9; 20 mg deslo-
ratadine group: 41.7 ± 11.3
Unit of allocation: selected body area in single participants
Country and setting: Germany; Allergie-Centrum-Charité, a tertiary referral centre for
allergies and urticaria
Inclusion criteria of the trial
• Chronic idiopathic urticaria > 6 weeks, outpatients, age 18 to 75 years; eligible for
the study if they had moderate to severe CSU according to their clinical history, if they
exhibited spontaneous urticaria lesions at the second visit for a baseline assessment (as
explained below) and if they had a history of beneficial effect derived from
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antihistamine treatment
Exclusion criteria of the trial
• Presence of acute urticaria/acute angio-oedema, intake of corticosteroids or other
immunosuppressive therapy within 14 days before the beginning of the study, use of
depot corticosteroids or long-term systemic corticosteroids within 21 days before the
beginning of the study, presence of permanent severe disease (especially disease
affecting the immune system); presence of galactose intolerance, lactase deficiency or
glucose galactose malabsorption; history of adverse reactions including hypersensitivity
to desloratadine or loratadine
• Intake of medication that could cause changes in QT interval (drugs listed on
www.qtdrugs.org)
• Met any criteria from a typical list of exclusion criteria for pharmacological
studies: presence of a permanent gastrointestinal condition that may influence oral
therapy, history or presence of epilepsy; significant neurological disorders,
cerebrovascular attacks or ischaemia; history or presence of myocardial infarction or
cardiac arrhythmia that requires drug therapy, evidence of severe renal dysfunction,
evidence of significant hepatic disease, presence of active cancer that requires
chemotherapy, presence of alcohol abuse or drug addiction, participation in any
clinical trial within 4 weeks before enrolment, pregnancy or breastfeeding and existing
or planned placement in an institution after ruling according to §40AMG
(Arzneimittelgesetz)
Mild to severe disease, duration of disease longer than 6 weeks
Interventions Interventions, dose, duration
• 5 mg vs
• 20 mg desloratadine
short-term (5 hours)
Length of follow-up: after 5 hours
Outcomes Timing of outcome assessment (state which time points): 5 hours
Primary outcomes of the trial
• Primary efficacy parameter of the study was assessment of the reduction in size of
spontaneous urticaria lesions by thermography (hyperthermic skin area) before and
during treatment with study medication
• Quality of life measures: none
Secondary outcomes of the trial
• Additional parameters of efficacy included assessment of the reduction in size of
spontaneous urticarial lesions by planimetric analysis of digital time-lapse photography,
volumetric analysis of selected weals and evaluation of weal numbers
• Adverse events: no serious adverse events reported
Clinician or participant report: clinician
Notes Study investigators concluded that a direct comparison between 5 mg and 20 mg of
desloratadine showed no difference in weal area, weal volume or number of weals. “In
contrast, a comparison of the reduction in the total weal number after 5 hours during
treatment with 5 mg desloratadine minus no treatment versus treatment with 20 mg
minus no treatment showed significant differences (p < 0.01)”
Risk of bias
190H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Weller 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
scheme
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants and clinical staff, for exam-
ple, study nurses and study physicians in-
volved in the study, were blinded until the
end of the trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All participants and clinical staff, for exam-
ple, study nurses and study physicians in-
volved in the study, were blinded until the
end of the trial
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether any were lost to follow-up
and any reasons
No ITT analysis carried out
Selective reporting (reporting bias) Low risk No selective outcome reporting
Other bias Unclear risk Funder: This study was financially sup-
ported by Schering-Plough (Essex Pharma
GmbH, Germany). In addition, the study
medication was provided by Schering-
Plough
Wu 2008
Methods Design: randomised 3-arm trial of azelastine 2 mg/d; azelastine 4 mg/d vs combined
azelastine and cimetidine 2 mg/d
Duration: 4 weeks
Participants Number of participants randomly assigned: 103
Sex: male 52%, female 48% (from 100 participants who were available for analysis)
Unit of allocation: participant
Country and setting: China; secondary care
Age between 16-81 years, mean age 39.16 years
Inclusion criteria of the trial
• Chronic idiopathic urticaria > 6 weeks (duration of disease between 6 weeks and
560 weeks (mean 29 weeks), urticaria not due to other causes, no antihistamine within
4 weeks, no immunosuppressant or other medications, consented)
Exclusion criteria of the trial
• Known allergies to azelastine and cimetidine; taking medications including
anticholinergic agent, beta-agonists, tranquilliser and medications that prolong QT
period in less than 4 weeks; other types of urticaria and angio-oedema; taking
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medication that prolonged QT interval; high-intensity profession; other organ
dysfunction diseases
• Previous unresponsiveness to antihistamine: not stated
Interventions Interventions, dose, duration
• Azelastine 4 mg/d (n = 33)
• Azelastine 2 mg/d (n = 34)
• Azelastine plus cimetidine 2 mg/d (n = 33)
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: not specified but assumed to be at endpoint (i.e. 4 weeks)
Outcomes Primary outcomes of the trial
• Side effects of treatment, diameter of largest weal, number of weals per day,
duration of weals (hours)
• Proportion with good/excellent response
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: dry mouth, sleepiness, lethargy
Clinician or participant report: clinician
Notes Main study report written in Chinese
Study investigators concluded that all 3 groups have similar efficacy, but azelastine 4 mg/
d and combined azelastine and cimetidine 2 mg had greater efficacy than azelastine 2
mg alone The difference in this comparison was statistically significant (P < 0.05)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear, described as open randomisation
Allocation concealment (selection bias) High risk No concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 103 were randomly assigned; 100 are in-
cluded in the analyses with no reasons given
for dropout
Selective reporting (reporting bias) High risk No clear definition of outcomes; unclear
whether assessment of compliance was car-
ried out
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Other bias Low risk None detected. Funder: not stated
Yin 2003a
Methods Design: randomised double-blind parallel-group comparing cetirizine and levocetirizine
Duration: 28 days
Participants Number of participants randomly assigned: 44 (22 in each group)
Sex: levocetirizine: 54% (female); cetirizine: 63% (female)
Age of participants (between 18 and 65), mean in years: levocetirizine 36.27; cetirizine
36.73
Unit of allocation: participant
Country and setting: China; secondary care
Inclusion criteria of the trial
• Clinical diagnosis of CSU (> 6 weeks); not taking medications within 4 weeks,
such as antibiotics, immunosuppression, etc.
Exclusion criteria of the trial
• Known to have allergic reaction to H1-antihistamine, levocetirizine and cetirizine;
other forms of urticaria and angio-oedema; unable to stop antihistamines such as
astemizole, loratadine < 4 weeks; taking medications that can prolong QT interval;
high-demand concentration job
• Previous unresponsiveness to antihistamine: unclear
Interventions Interventions, dose, duration
• Levocetirizine 5 mg
• Cetirizine 10 mg once daily
Duration of intervention: intermediate-term (28 days)
Length of follow-up: 7, 14, 28 days
Outcomes Timing of outcome assessment: 7, 14, 28 days
Primary outcomes of the trial
• Severity of itching, weal size, daily weal count, degree of weal swelling, duration
of weal, symptom reduction in score index
• Adverse events: reported sleepiness, dry mouth, headache
• Quality of life measures: none
Secondary outcomes of the trial
• None
Clinician or participant report: clinician
Notes Study investigators concluded that no significant difference in curative effect was noted
between the 2 groups. No serious adverse effects were found. Levocetirizine is effective
and safe in the treatment of CSU
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote (page 477): ‘randomised, double
blinded’
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ‘randomised, double blinded,’ but
no further details given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ‘randomised, double blinded,’ but
no further details given
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether any dropped out; not
stated
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk None detected. Funder: not stated
Yin 2003b
Methods Design: randomised open-label parallel-group 3-arm comparison of mizolastine vs ceti-
rizine vs loratadine
Duration: 28 days
Participants Number of participants randomly assigned: 96; mizolastine n = 30, cetirizine n = 34,
loratadine n = 32
Sex: 60% male, 40% female
Age of participants (18 to 72), mean age in years: mizolastine 45, cetirizine 38, loratadine
36.5
Unit of allocation: participant
Country and setting: China; secondary care
Inclusion criteria of the trial
• CSU, but no further definitions given
Exclusion criteria of the trial
• Not stated
• Previous unresponsiveness to antihistamine: unclear
Interventions Interventions, dose, duration
• Mizolastine 10 mg
• Cetirizine 10 mg vs loratadine 10 mg, once daily each medication, for 28 days
Duration of intervention: intermediate-term (28 days)
Length of follow-up: 5 weeks i.e. follow-up extended after the cessation of therapy
Outcomes Timing of outcome assessment: 14, 28 and a further follow up at 7 days post intervention
Primary outcomes of the trial
• Efficacy and safety, itching severity VAS; diameter of largest weal; number of
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weals per day; symptom score reduction index (SSRI)
• Quality of life measures: none
Secondary outcomes of the trial
• Adverse events: no obvious and severe side effects, but dry mouth, sleepiness,
headache, nausea reported
Clinician or participant report: clinician
Notes Study investigators concluded that all 3 antihistamines have high clinical efficacy and
safety in the treatment of CSU. No statically significant difference was noted among the
3 groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Open-label. randomised
Allocation concealment (selection bias) High risk No concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label, no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label, no blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropouts reported
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None detected. Funder: not stated
Zou 2002
Methods Design: randomised 2-arm parallel trial of desloratadine vs loratadine
Duration: 4 weeks
Participants Number of participants randomly assigned: 41 (desloratadine n = 21, loratadine n = 20)
Sex: 49% female, 51% male: desloratadine 42% female (12 men/9 women); loratadine
55% female (9 men/11 women)
Age of participants, mean in years: desloratadine 32.7; loratadine 31.8
Unit of allocation: participant
Country and setting: China; secondary care
Inclusion criteria of the trial
• Clinical diagnosis of CSU > 6 weeks, not taking medication within 4 weeks such
as antibiotics, immunosuppression, etc.
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Exclusion criteria of the trial
• Known to have allergic reaction to H1-antihistamine, loratadine and
desloratadine; taking medication that is known to prolong QT interval; known chronic
stomach ulcer; known ischaemic heart disease, liver disease and renal failure;
occupation that requires high concentration such as driver, pilot; pregnant women and
breastfeeding women
Interventions Interventions, dose, duration
• Desloratadine 5 mg once daily
• Loratadine 10 mg once daily
Duration of intervention: intermediate-term (4 weeks)
Length of follow-up: not mentioned
Concomitant rescue treatment not permitted
Outcomes Timing of outcome assessment: assumed to be at end of intervention period-4 weeks
Primary outcomes of the trial
• Study of curative effects and safety of desloratadine in the treatment of CSU
• Comparison of symptoms of itching severity, size of weal, weal number, weal
swelling severity, frequency, duration of weal
• Quality of life measures: not stated
Secondary outcomes of the trial
• Adverse events: desloratadine: severe headache, mouth dryness, sleepiness;
loratadine: mouth dryness, sleepiness
Clinician or participant report: participant
Notes Study investigators concluded that no significant difference in curative effect was noted
between the 2 groups. No serious adverse effects were found. Desloratadine was found
to be effective and safe in treating patients with CSU
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Double-blind randomised controlled trial
Allocation concealment (selection bias) Unclear risk Not mentioned in this study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants and personnel were blinded to
treatment group
Not clear about this, as it was not men-
tioned clearly in the method of assessment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors were blinded to treat-
ment group
Not clear, as it was not mentioned in the
method of assessment
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Zou 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropouts reported
Selective reporting (reporting bias) Low risk None, all prespecified outcomes were re-
ported
Other bias Unclear risk Funder: not stated. Severity of disease was
not clear. Duration of disease with deslo-
ratadine ranged from 6 weeks to 6 years,
and with loratadine from 6 weeks to 6.5
years
Zuberbier 2010
Methods Design: international multi-centre double-blind randomised placebo and active treat-
ment-controlled parallel-group 2-arm study comparing bilastine 20 mg vs levocetirizine
5 mg once daily and placebo
Duration: 28 days
Participants Number of participants randomly assigned: 525 (bilastine n = 173, levocetirizine n =
166, placebo n = 184, unclear numbers)
Sex: bilastine: 63% male, 27% female; levocetirizine: 54% male, 46% female; placebo:
40% male, 60% female
Age of participants, years: bilastine 41.7, levocetirizine 39.8, placebo 39.4
Unit of allocation: participants
Country and setting: Argentina, Belgium, France, Germany, Poland, Romania, Spain
(46 centres); secondary care
Inclusion criteria of the trial
• ”documented history of CU; characterized by erythematous skin weals
accompanied by itching attributable to no identifiable cause and occurring regularly at
least three times per week for 6 weeks prior to entry in the study; were recruited.
Eligible patients were additionally required to demonstrate a symptoms score of ‡2 (i.e.
moderate-to-severe intensity scores) for any two of the three features of pruritus,
number of weals, or minimum size of weals (rated on predefined scales of 0-3) for at
least 3 days during the screening period (day )7) and at randomisation visit (day 0)“
Exclusion criteria of the trial
• ”contact urticaria, urticaria caused by vasculitis and/or collagenosis,
paraneoplastic urticaria, parasitic urticaria, urticaria related with thyroid pathology,
eczema or atopic dermatitis); autoimmune disorders, Hodgkin’s disease and any
clinically significant condition (cardiovascular, neurological, hepatic, renal or
malignant diseases); systemic or topical corticosteroids within 4 weeks, astemizole
within 6 weeks, ketotifen within 2 weeks, any other systemic antihistamine (including
loratadine, desloratadine, ebastine, rupatadine, mizolastine, cetirizine or levocetirizine)
within 3 days, anti-leukotrienes within 3 days, sodium cromoglycate or nedocromil
within 2 weeks, and tricyclic antidepressants within 1 week of randomisation
• pregnant or breast-feeding women and patients with hypersensitivity to H1-
antihistamines, benzimidazoles or lactose“
• Previous unresponsiveness to antihistamine: not stated
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Zuberbier 2010 (Continued)
Interventions Interventions, dose, duration
• Bilastine 20 mg
• Levocetirizine 5 mg
• Placebo
(once daily)
Duration of intervention: intermediate-term (28 days)
Length of follow-up: 28 days
Outcomes Timing of outcome assessment: 0, 14 and 28 days (or at early discontinuation visit in
cases of withdrawal from the study)
Primary outcomes of the trial
• Reflective daily total symptoms score (TSS), DLQI scores; participants’ VAS
scores; impact of urticaria on participant sleep scores and evaluation of symptom scores
• Severity of pruritus, number of weals and maximum size of weals were assessed
daily in the morning and in the evening over the last 12-hour period (reflective) and at
the time of clinic visit (instantaneous), using 4-point scales of 0 to 3 (modified scale)
• Pruritus severity was scored as follows: 0 = absent; 1 = mild (not annoying); 2 =
moderate (causing little disruption of activity); and 3 = severe (intense itching causing
disruption of activity), whereas the number of weals was scored as 0 = absent, 1 = some
(≤ 10), 2 = numerous (> 10) and 3 = extensive areas of the body covered
• Similarly, size of weals (diameter of the greatest weal) was scored as follows: 0 =
absent, 1 = > 1.5 cm, 2 = > 1.5 to < 2.5 cm and 3 = > 2.5 cm
• Quality of life measures: Dermatology Life Quality Index (DLQI) questionnaire
Secondary outcomes of the trial
• Investigator’s assessment of treatment was evaluated as secondary efficacy measures
• Adverse events: Safety was assessed according to adverse events, laboratory tests
and electrocardiograms. No serious adverse events were noted in any of the groups
• Minor adverse events: bilastine: headache, somnolence, ”drug-related adverse
events,“ fatigue; levocetirizine: headache, somnolence, ”drug-related adverse events,“
fatigue: placebo: headache, somnolence, ”drug-related adverse events,“ fatigue
Clinician or participant report: both
Notes Study investigators concluded that no significant difference in efficacywas noted between
the 2 active groups; both were better than placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Probably done; quote (page 517): ”Ran-
domization to treatment was achieved ac-
cording to a computer-generated randomi-
sation code provided by the study sponsor
(FAES FARMA, SA, Spain)“
Allocation concealment (selection bias) Unclear risk Quote (page 518): ”treatments were allo-
cated to each patient in their chronological
order of entry into the study“
198H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zuberbier 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (page 518): ”The study medica-
tions were supplied as identical over-encap-
sulated tablets in individually coded alu-
minium blister packs to ensure blinding of
both the investigators and the patients to
treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As above
Comment: unclear whether investigators
had access to the randomisation list, but
this is unlikely given that randomisation
was carried out offsite, so we have judged
this as low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 457/525 completed. Withdrawals as fol-
lows: placebo (n = 35): lack of efficacy
24, adverse event 1, participant decision 3,
poor compliance with protocol 3, loss to
follow-up 2, “other” 2; bilastine (n = 15):
lack of efficacy 5, adverse event 3, partici-
pant decision 4, loss to follow-up 1, “other”
1; levocetirizine (n = 15): lack of efficacy
7; participant decision 4, poor compliance
with protocol 1, loss to follow-up 2, “other”
1
Comment: Although the study report
states ITT, the analysis did not include 3
participants who were randomly assigned
but did not receive any medication; an-
other 6 participants were not included in
the analysis
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Funder: FAES Farma (bilastine makers).
MDS Pharma Services Inc for technical
assistance for development of study, data
management and statistical analysis
AE: adverse event.
AEQLQ: Aerius Quality of Life Questionnaire.
ALAT: alanine transaminase.
ASAT: aspartate transaminase.
BMI: body mass index.
CIU: chronic idiopathic urticaria.
CPK: creatine phosphokinase.
CSU: chronic spontaneous urticaria.
DLQI: Dermatology Life Quality Index.
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ECG: electrocardiogram.
FBC: full blood count.
ITT: intention-to-treat.
K+: potassium ion.
LFT: liver function test.
MNW: mean number of weals.
MPS: mean pruritus score.
MTSS: mean total symptoms score.
Na2+: sodium ion.
NSAID: non-steroidal anti-inflammatory drug.
QoL: quality of life.
RCT: randomised controlled trial.
SAF: safety population.
SIWS: scale for interference of wheals with sleep
SD: standard deviation.
SSRI: symptom scores reduction index.
TSS: total symptoms score.
UAS: Urticaria Activity Score.
U/E: upper extremity.
URTI: upper respiratory tract infection.
VAS: visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aberer 2001 Letter to editor, no study results, not an RCT
Abushareeah 1997 CIU mentioned only in abstract, not defined further, no further information available
Alomar 1990b RCT of astemizole vs cetirizine with no placebo group, astemizole excluded as withdrawn
Andri 1993 Quote: ”...randomly divided into two 15 participant groups” Unclear if this is true randomisation. Terfe-
nadine vs cetirizine, terfenadine no longer in use
Anon 1992 RCT on astemizole
Anonymous 1989 No chronic ordinary urticaria; does not meet inclusion criteria. Only terfenadine: not in use
Anonymous 1990 CIU not defined
Anonymous 1992 CIU not defined, described only as urticaria
Arendt 1989 Included acute urticaria (less than 1 month’s duration)
Atsushi 1985 Acute urticaria, not CIU
Bakos 1985 Not proper randomisation (’divididos em 2 grupos de 10’)
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(Continued)
Baraf 1976 Chronic urticaria unspecified; other causes of pruritus included
Bernd 1989 Included physical urticaria
Bernstein 1986 Astemizole (not in use)
Bernstein 2002 All participants given same combination of antihistamines
Bian 1996 Not CSU by our definition
Bleehen 1987 All participants given same H1-antihistamine
Bloom 2004 Included participants with allergic rhinitis (’All patients had allergic rhinitis or CSU’)
Brunet 1990 Chronic urticaria unspecified; did not exclude physical urticaria/vasculitis
Cainelli 1986 Astemizole and terfenadine: not in use
Camarasa 2001 No definition of chronic idiopathic urticaria; methods do not state any diagnosis
Cassano 2007 Study of ciclosporin
Cerio 1984 RCT on terfenadine
Chatterjee 1996 RCT on terfenadine
Chen 2005 RCT, included other forms of urticaria
Church 2009 Chronic urticaria, not further specified
Cook 1983 No relevant data, described participants allocated to double-blind treatment in random order. Not ran-
domised. Compared chlorpheniramine plus cimetidine (no other active treatment). No information about
dose
Demaubeuge 1982 Chronic urticaria, not CSU
Devillier 2007 No clinical trials; not relevant to study
Devillier 2008 No clinical trials; review on pharmacokinetics and pharmacodynamics-not relevant to study
Dhurandhar 1987 Chronic urticaria treatment described, CSU not defined (duration of urticaria history not stated)
Diller 1983 No P values; outcome measures not meaningful
Dockx 1981 Included acute urticaria
Farshchain 2002 Quote: ”Patients were divided into two 75 person-groups.” Not an RCT
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(Continued)
Ferguson 1985 Terfenadine only (not in use)
Fox 1986 Astemizole only (not in use)
Fredriksson 1986 Included conditions other than CSU
Gao 2009 RCT, included other forms of urticaria
Ge 1987 Not a comparison of H1-antihistamines
Giannetti 1991 Included acute urticaria (1 month’s duration)
Gibson 1984 Included conditions other than CSU
Godse 2006 Montelukast vs cetirizine. Chronic urticaria not fully defined in terms of duration
Gong 1995 Chronic urticaria, not CSU
Gonzalez-Morales 1985 Terfenadine vs placebo
Greaves 1981 Chronic urticaria unspecified, random order administration, unclear whether randomised, self-assessment
questionnaire
Greene 1985 Included other causes of urticaria (e.g. vasculitis)
Grob 2009 Compared regular vs prn desloratadine in participants known to be responsive to the drug. All participants
given desloratadine, no comparison
Guaglianone 1988 Terfenadine only (not in use)
Guerra 1994 CSU not defined
Hair 2006 Review article
Hamerlinck 1994 RCT. Multi-centre parallel-group 2-arm double-blind study of loratadine vs astemizole. Astemizole no
longer in use, excluded
Hampel 2010 Rhinitis and urticaria put together, no separate data
Han 1992 Terfenadine only (not in use); looking at hives, not chronic ordinary urticaria
Hong 2010 CSU not defined, no efficacy data
Honsinger 1990 Astemizole only (not in use)
Huo 2014 Acupuncture combined with bloodletting and regular Western medication (loratadine), loratadine arm
not compared with active pharmacological intervention
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Ishibashi 1989 Included acute urticaria
Ishibashi 1990 Included acute urticaria
Ishibashi 1990a Included acute urticaria
Ishibashi 1990b Included acute urticaria
Ishibashi 1997 Included acute urticaria
Ishibashi 1997a Included acute urticaria
Ishibashi 1997b Included acute urticaria
Isola 1985 Terfenadine only (not in use); did not use proper randomisation
Jauregui 2006 Review article specific to effects of interventions on driving
Jia 1998 Included participants with acute and chronic urticaria with no separate data (CSU not defined)
Jolliffe 1985 Included physical urticaria (’1 had cold urticaria’)
Juhlin 1988 Not randomised
Jyothi 2011 Included acute urticaria
Kailasam 1987 Astemizole
Kalimo 1980 Included physical urticaria
Kalis 1985 Included physical urticaria
Kalis 1996 Included physical, cholinergic urticaria; urticaria less than 6 weeks’ duration
Kameyoshi 2007 Included acute urticaria (less than 1 month’s duration)
Kamide 1989 Included urticaria less than 6 weeks’ duration
Kaplan 2008 Included autoimmune urticaria
Kapp 2004 Included physical urticaria
Kapp 2006 Cost-effectiveness study
Kapp 2006a Included physical urticaria
Kawada 2011 Chronic urticaria not further specified
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(Continued)
Kawashima 2002 Phase III study of TAU-284 (bepotastine besilate) on chronic urticaria: a multi-centre double-blind com-
parative study with placebo. Included urticaria of less than 1 month’s duration
Khalaf 2008 Both groups received same antihistamine
Kietzmann 1990 RCT, compared only cetirizine vs terfenadine with no placebo group; therefore excluded, as terfenadine
not in use
Kim 2013 Retrospective observational single-centre study of participants with CSU in Korea; ’divided patients into
two study groups’
Kukita 1985 Terfenadine only (not in use)
Kukita 1990 Duration of disease less than 4 weeks (acute urticaria)
Kukita 1990a Duration of disease less than 4 weeks (acute urticaria)
Kukita 1991 Included acute urticaria
Kukita 1994 Included acute urticaria
Kukita 1994a Included acute urticaria
Kukita1985a Terfenadine only (not in use)
Kuokkanen 1971 Included physical urticaria
Kuokkanen 1975 Included physical urticaria
Kuokkanen 1977 Included physical urticaria
La Rosa 2001 Included acute urticaria
Lambert 1990 Astemizole vs terfenadine (not in use)
Lambert 1993 Included acute urticaria
Lambert 1993a Included acute urticaria
Lan 2002 Included acute urticaria with CSU, separate data not available
Lennox 2004a Validation study of DLQI
Li 2004 CSU not defined (abstract only)
Liu 2002 RCT of astemizole vs loratadine, no placebo group. Excluded, as astemizole now withdrawn
Magerl 2009 Included physical urticaria
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Magerl 2013 Randomised double-blind placebo-controlled study of safety and efficacy of miltefosine (not an H1-
antihistamine) in antihistamine-resistant chronic spontaneous urticaria
Maurer 2013a Randomised, omalizumab, not an H1-antihistamine
Meloy 2009 CSU not defined, rhinitis and urticaria combined, no separate data
Monroe 1981 Combined H1 and H2 therapy
Monroe 2005 CSU not defined, abstract only, no other details available
Monteseirin 1992 States randomly divided, but not randomised
Mora 2005 Abstract states ’randomly divided,’ but translation of methods indicates that participants were ’put into
groups numbered 1 to 4,’ without mention of randomisation
Nakayama 1980 Included acute urticaria
Neumann 1984 Included acute urticaria (4 weeks’ duration)
Nishiyama 1996 Included acute urticaria
Nsouli 2013 All participants taking same antihistamine, cetirizine
Ormerod 1986 RCT, but compared terfenadine with brompheniramine; terfenadine no longer in use, therefore excluded
Ortonne 1998 CSU not defined, mentions only chronic urticaria
Paul 1984 Chronic urticaria unspecified; no useful data
Paul 1985 Chronic urticaria unspecified
Paul 1988 Terfenadine only (not in use)
Paul 1988a Terfenadine only (not in use)
Paul 1988b Terfenadine only (not in use)
Paul 1989 Terfenadine only (not in use)
Paul 1989a Included acute urticaria
Paul 1989b RCT terfenadine
Pavic 2012 Review article: treatment in children
Peremans 1981 Included physical urticaria, excluded on that basis
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Presch 1996 RCT, compared only terfenadine with cetirizine, no placebo group, terfenadine no longer in use, therefore
excluded
Saihan 1983 Lack of data; study authors contacted; data not available
Salisbury 1987 Included acute urticaria
Salmun 2000 Included participants with allergic rhinitis
Sanchez-Borges 2013a Management of aspirin-exacerbated urticaria
Sanchez-Borges 2013b Review article on updosing
Shah 1986 Chronic urticaria unspecified
Shareeah 1998 Chronic urticaria, not CSU
Shereff 1984 CCT, not RCT
Sim-Davis 1983 Included acute urticaria (4 weeks’ duration)
Simons 1995 Randomised, but pharmacology study only, no clinical outcomes
Singh 1987 Not properly randomised: medications dispensed ”in random order,” but unclear whether this was true
randomisation. No details on number of participants in each group
Sobye 1968 Included acute urticaria (less than 1 month)
Staevska 2010 Included delayed pressure urticaria
Sussman 1991 Included physical urticaria
Taskapan 2000a Participants were divided, not randomly assigned
Tilles 2005 Chronic urticaria, not CSU
Valsecchi 1984 Chronic urticaria, CSU not defined
Van Cauwenberge 2004 Allergic disorders; not chronic ordinary urticaria
van Joost 1989 Included acute urticaria (4 weeks’ duration or less)
Vena 2002 Outcomes are histochemical only
Verhaegen 1980 Double-blind but not an RCT
Vijay 1994 RCT on astemizole
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Wang 1998 Included acute urticaria
Wang 2000 Test of domestic vs imported cetirizine, randomised, but no control or placebo group. No CSU, chronic
urticaria only
Warin 1966 CCT and included cholinergic urticaria
Watson 2000 Included acute urticaria
Weitgasser 1967 Other dermatoses included; not an RCT; clinical observation study
Weller 2010 Included chronic spontaneous urticaria; CSU not defined
Witte 2006 Inadequate data and reporting
Wolfram 1967 Not an RCT; included other dermatoses
Wozel 1990 Combination therapy H1 and H2; all participants took same combination
Wu 1992 Combined H1- and H2-antihistamines
Yamada 1968 Included physical urticaria, duration not specified
Youngchaiyud 1988 Chronic urticaria unspecified
Zabel 1984 Included acute urticaria (4 weeks’ duration)
Zhang 1990 Chronic urticaria unspecified
Zhang 1991 RCT taking terfenadine
Zhang 2001 Included acute urticaria, no separate data
Zhao 1994 RCT of loratadine vs astemizole (not in use), no placebo group
Zhi 2004 CSU duration of less than 4 weeks included (i.e. acute urticaria included)
Zhou 2003 Described as ’chronic urticaria’ but CIU not defined; also included acute urticaria with no separate data
Zuberbier 1995 Cholinergic urticaria
CCT: controlled clinical trial.
CIU: chronic idiopathic urticaria.
DLQI: Dermatology Life Quality Index.
RCT: randomised controlled trial.
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Characteristics of studies awaiting assessment [ordered by study ID]
Audi’cana 2007
Methods Double-blind randomised dose-ranging trial in 4 parallel groups
Participants CSU, number randomly assigned unclear
Interventions 10, 20 and 30 mg bilastine once daily vs placebo
Outcomes Unclear
Notes Unable to locate a copy at this time for further assessment
Blanca Gomez 1984
Methods Double-blind (CCT?)
Participants Unclear
Interventions H1- plus H2-blockers
Outcomes Unclear, included pruritus
Notes Unable to locate a copy at this time for further assessment
Boggs 1989
Methods RCT (double-blind randomised placebo-controlled parallel study)
Participants 37 participants
Interventions Terfenadine, 60 mg twice daily, vs placebo vs hydroxyzine, 25 mg four times daily
Outcomes Adverse effects including somnolence, therapeutic use
Notes Unable to locate a copy at this time for further assessment
Fan 2000
Methods RCT
Participants Urticaria
Interventions Astemizole and loratadine
Outcomes Unclear
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Fan 2000 (Continued)
Notes Unable to locate a copy at this time for further assessment
Feng 2001
Methods Design: unclear, states ’random allocation’
Participants Unclear, no abstract available
Interventions Unclear, includes cetirizine but no details about comparator arms
Outcomes Unclear
Notes Unable to locate a copy at this time for further assessment
Guo 2013
Methods RCT (randomly divided into 3 groups)
Participants One hundred and twenty cases of chronic urticaria
Interventions 38 participants in the combination therapy group orally received half pack of compound FKS decocted in water
twice daily and mizolastine tablet 10 mg once daily; 39 participants orally received mizolastine tablet 10 mg once
daily; 38 patients in the combination therapy group orally received half pack of compound FKS decocted in water
twice daily and mizolastine tablet 10 mg once daily; 39 participants orally received mizolastine tablet 10 mg once
daily for 4 weeks
Outcomes Efficacy, scores of symptoms and signs, improvement.
Notes Chinese language study; awaiting copy of paper and translation
Guo 2014
Methods RCT (randomly divided)
Participants 209 participants were randomly divided into 2 groups: experimental group (106 cases) and control group (103 cases)
Interventions One arm given mizolastine and ketotifen with gradual dose reduction for 10 weeks, while the other participants were
given mizolastine alone with gradual dose reduction for 10 weeks
Outcomes Total effective rates for experimental group and control group were 76.1% and 43.5%, respectively (P value < 0.
05). 4 weeks after treatment, recurrence rates for experimental group and control group were 10.4% and 22.8%,
respectively (P value < 0.05). Adverse effects included dry mouth and drowsiness
Notes Chinese language study awaiting copy of paper and translation
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Hatano 1981
Methods RCT or CCT, double-blind
Participants 121 participants with chronic urticaria
Interventions Azatadine maleate 2 mg/d (1 mg/tablet) was administered for 5 days to 61 participants with chronic urticaria, and
clemastine fumarate 2.68 mg/d (1.34 mg/tablet) was given to a matched control group of 60 participants
Outcomes Efficacy, itching, adverse effects
Notes Unable to locate a copy at this time for further assessment
Monroe 1992a
Methods RCT
Participants 203 participants with chronic idiopathic urticaria
Interventions Loratadine, hydroxyzine and placebo
Outcomes Efficacy and safety
Notes Unable to locate a copy at this time for further assessment
Okubo 2013
Methods Prospective randomised non-blinded comparative clinical study and assessment of quality of life
Participants n = 51
Interventions Cetirizine 10 mg once daily to 51 participants with urticaria. Participants with inadequate symptom control were
randomly assigned to cetirizine 20 mg once daily (dose-increase group) or olopatadine 5 mg twice daily (drug-change
group)
Outcomes Severity of weal and itching and quality of life (QoL) were measured by Skindex-16 were evaluated
Notes Awaiting interlibrary loan and, if available, full translation
Sil 2013
Methods Observer-blind RCT, single centre
Participants Chronic urticaria, characterised by frequent appearance of weals for > 6 weeks
Interventions Olopatadine (5 mg twice daily) or levocetirizine (5 mg/d) for 9 weeks, continuously for first 4 weeks and then on
demand basis for last 5 weeks
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Sil 2013 (Continued)
Outcomes Primary outcome measures were Urticaria Activity Score (UAS) and urticaria total severity score (TSS). Routine
haematological and biochemical tests and treatment-emergent adverse events were monitored for safety
Notes Awaiting interlibrary loan
Tanizaki 2013
Methods Unclear
Participants CSU and healthy participants
Interventions Conventional and double doses of fexofenadine HCl on CSU (and on histamine-induced skin responses by ion-
tophoresis using visual and laser Doppler imaging scales in healthy donors)
Outcomes Cutaneous manifestations in CSU (and histamine-induced flare and itch in healthy donors)
Notes Awaiting interlibrary loan
Wang 2002
Methods RCT
Participants Urticaria
Interventions Mizolastine vs cyproheptadine
Outcomes Unclear
Notes Unable to locate a copy at this time for further assessment
Zhang 2012
Methods RCT
Participants 136 participants with chronic idiopathic urticaria
Interventions Randomly assigned to 3 groups: mizolastine 10 mg daily; loratadine 10 mg daily; mizolastine 10 mg daily combined
with compound glycyrrhizin 75 mg 3 times a day
Outcomes Symptom score reduction index (SSRI)
Notes Awaiting interlibrary loan and, if available, full translation
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Zhang 2013
Methods RCT
Participants 92 participants with refractory urticaria
Interventions Montelukast combined with cetirizine, and control group with Tripterygium glycoside combined with cetirizine
Outcomes Total symptoms scores were calculated for participants at baseline and at week 2 and week 4 during treatment based
on individual scores for weal and pruritus; incidence of adverse events was recorded
Notes Chinese language study awaiting translation
Zhu 2012
Methods RCT
Participants 120 mixed group of acute/chronic urticaria with allergic rhinitis
Interventions Mizolastine vs cetirizine
Outcomes Therapeutic effect and adverse reactions
Notes Awaiting interlibrary loan and, if available, full translation
CCT: controlled clinical trial.
CSU: chronic spontaneous urticaria.
QoL: quality of life.
RCT: randomised controlled trial.
SSRI: symptom score reduction index.
TSS: total severity score.
UAS: Urticaria Activity Score.
Characteristics of ongoing studies [ordered by study ID]
CTRI/2014/04/004545
Trial name or title Comparison of efficacy, safety and cost-effectiveness of rupatadine and olopatadine, antihistaminics, in study
participants with urticaria
Methods To compare efficacy, safety and cost-effectiveness of rupatadine and olopatadine in participants with chronic
idiopathic urticaria: a randomised double-blind comparative parallel-group study
Method of generating randomisation sequence: random numbers table
Method of allocation concealment: prenumbered or coded identical containers
Blinding and masking: participant and Investigator blinded
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CTRI/2014/04/004545 (Continued)
Participants Target sample size 60, with CSU
Inclusion criteria
• Those who were willing to participate in the study and comply with its procedures by signing a written
informed consent
• Participant from Out-patient Department (OPD) of dermatology between ages of 18 and 65 years, of
either sex
• History of urticarial weal and/or angio-oedema for at least 3 days a week for 6 consecutive weeks with
no obvious cause before inclusion in study
• Mean total symptoms score (24 hours reflective) at screening. This includes 1 to 5 weals; at least
moderate severity of pruritus
• Participants who were taking any antihistamines except rupatadine and olopatadine were also included
in the trial only after a washout period of 7 days, irrespective of doses of previous drugs
• Those who understood and agreed to adhere to dosing and visit schedules, and agreed to assess and
record their symptom severity scores, medication times, concomitant medications and adverse events
accurately and consistently in a daily diary
Exclusion criteria
• History of asthma or any other disease requiring long-term use of inhaled or systemic corticosteroids
• Participants with acute spontaneous urticaria or all physical and other subtypes of urticaria such as
aquagenic, cholinergic, contact and exercise-induced urticaria
• Had been unresponsive to antihistamine treatment in the past
• History of allergies to study medication or unable to tolerate antihistamines
• Use of study drug in the last 7 days before baseline and not willing to take washout period
• Pregnant female, nursing mothers
• Participants with significant hematopoietic, cardiovascular, hepatic, renal, neurological, psychiatric or
autoimmune disease
Interventions • Olopatadine 5 mg once a day at night for 6 weeks
• Rupatadine 10 mg once a day at night for 6 weeks
Outcomes Primary outcomes assessed at 1, 3 and 6 weeks
• Efficacy of rupatadine and olopatadine in participants with CSU
• Difference in mean total symptoms score (MTSS) at baseline and at 6 weeks
• Observed difference in average mean number of weals (MNW), mean pruritus scale (MPS) and MTSS
from baseline to end of 1, 3 and 6 weeks
Secondary outcomes assessed at 1, 3 and 6 weeks
• Average change from baseline to end of 6-week treatment period
• 12-hour reflective MNW
• 2-hour reflective MPS
• Interference of weals with sleep
• Observed difference in scale for interference of skin condition with sleep (SIWS) between baseline and
6 weeks
Starting date 17 April 2014
Contact information Dr Ganesh N Dakhale
Department of Pharmacology, Government Medical College, Nagpur. 440003 Nagpur, MAHARASHTRA
India
8308833593
gndakhle@rediffmail.com
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CTRI/2014/04/004545 (Continued)
Government Medical College Nagpur, India
Notes Other study IDCTRI/2014/04/004545, ongoing, sponsored by IndiraGandhiGovernmentMedical College,
India
EudraCT: 2004-000771-34
Trial name or title A 6-week multi-centre double-blind randomised placebo-controlled parallel-group study to assess the efficacy
and safety of rupatadine 10 and 20 mg in the treatment of chronic idiopathic urticaria (CIU): a phase III
clinical trial
Methods RCT
Participants Male or female 12 to 65 years of age
Interventions • Rupatadine 10 and 20 mg for the treatment of CSU symptoms over 4-week treatment period
• Placebo
Outcomes Primary outcomes: Primary endpoint will be based on daily subjective assessment of the severity of each
symptom of CSU, as recorded by participants in their diaries:
• Change in mean pruritus score (MPS) over 4-week treatment period
Secondary outcomes
• Efficacy and safety of rupatadine 10 and 20 mg for the treatment of CSU symptoms over 6-week
treatment period in comparison with placebo
• Safety of rupatadine 10 and 20 mg for the treatment of CSU symptoms over 4-week treatment period
in comparison with placebo
• Participant discomfort assessed by using a VAS
• Participant QoL assessed by a specific questionnaire, the DLQI
Starting date 2004-10-28
Contact information J Uriach y Compañía, S.A.
Notes Ongoing
EudraCT: 2005-002749-38
Trial name or title A randomised double-blind placebo-controlled exploratory trial to evaluate 1-week oral treatment with
R129160 (60 mg twice daily) in participants with chronic idiopathic urticaria-oral treatment with R129160
(60 mg twice daily) in participants with chronic idiopathic urticaria
Methods RCT
Participants Male and female 18 to 64 years of age with CSU, Czech Republic, Belgium, Netherlands
Interventions • 60 mg R129160 (vapitidine)
• Placebo
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EudraCT: 2005-002749-38 (Continued)
Outcomes Primary outcomes
• Effect on itch associated with CSU
Starting date 18 July 2007
Contact information Barrier Therapeutics nv
Notes Not recruiting, no results posted
JPRN-UMIN000001163
Trial name or title Study of optimal treatment duration with antihistamine in idiopathic urticaria patients
Methods Parallel cluster-randomised by institution, open. Allocation concealment by centralised registration
Participants 120 (target sample size). Male or female 20 years of age or older
Inclusion criteria
• Participants with idiopathic urticaria
• Symptoms/signs free of urticaria for at least 48 hours at randomisation
• Symptom/signs resolved in the period of 2 to 6 weeks from onset of urticaria
• Not younger than 20 years old (no upper limit)
• Written informed consent
Exclusion criteria
• Pregnant or lactating women or women of childbearing potential not using contraception
• Participants with a history of hypersensitivity to fexofenadine hydrochloride
• Participants who use medications that interfere with efficacy evaluation (e.g. other antihistamines,
drugs with antiallergy action, systemic steroids)
• Others whom the physician judges are not suitable
Interventions 4 week treatment with fexofenadine (120 mg/d) vs no treatment
Outcomes Primary outcomes
• Cumulative recurrence rate at 3 months after relief of urticaria symptoms (signs)
Secondary outcomes
• Cumulative recurrence rate at 4 and 8 weeks after relief of urticaria symptoms (signs)
• Safety
Starting date 23 May 2008
Contact information Motoaki Inoue
Clinical Research Support Center Kyusyu
Secretariat
3-1-1 Umade, Higashi-ku Fukuoka, 812-8582
+81-92-631-2920
http://www.cres-kyusyu.or.jp
inoue@cres-kyushu.or.jp
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JPRN-UMIN000001163 (Continued)
Notes Also known as SOLIDARITIE. Closed, no results posted
Sponsored by West Japan Urticaria Therapy Study Group, Clinical Research Support Center Kyusyu
JPRN-UMIN000003290
Trial name or title A study of the antipruritic effect and onset of sleepiness with oral antihistamines. Comparison of sedative and
non-sedative antihistamine
Methods Randomised cross-over open allocation concealment by numbered containers
Participants Male and female 16 years of age and older
Inclusion criteria
• Diagnosed with atopic dermatitis, chronic urticaria and pruritus
• Participants who were scored NRS 3 and over for pruritus
• Participants who gave their written informed consent
Exclusion criteria
• Participants who have history of hypersensitivity to any of the study drugs
• Participants who had been taking an antihistamine drug within 7 days before registration
• Participants who are pregnant, might be pregnant, are lactating or are wishing a pregnancy during the
study period
• Participants who are complaining of sleepiness due to the influence of a regularly used drug that is not
an antihistamine
• Participants who are commonly complaining of intense sleepiness
• Participants who are considered unsuitable for this study by the investigator
Interventions • Bepotastine besilate (14 days), washout (7 days) and d-chlorpheniramine maleate or ketotifen (14 days)
• d-chlorpheniramine maleate or ketotifen (14 days), washout (7 days) and bepotastine besilate (14 days).
Outcomes Primary outcomes
• Incidence and severity of sleepiness (JESS score, a Japanese version of the Epworth Sleepiness Scale)
Secondary outcomes
• NRS scoring for pruritus
• NRS scoring for sleepiness
• QoL with relation to skin diseases (Skindex-16)
• Evaluation of severity of atopic dermatitis and evaluation of severity of pruritus in other skin diseases
• Safety
Starting date 3 May 2005
Contact information Hiramatsu Yusunari
Future Medical Research Institute LLC
Japan
hiramatsu@ebms.co.jp
Telephone: 03-5777-1001
EBMs Co, Ltd Clinical Business Division
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JPRN-UMIN000003290 (Continued)
Notes Sponsored by Non-Profit Organization Health Institute Research of Skin
Closed, no results posted
JPRN-UMIN000008062
Trial name or title A study evaluating efficacy of non-sedative antihistamine up-titration in patients with chronic urticaria who
did not respond to standard therapy
Methods Parallel randomised
Participants Male and female 16 years of age and older
Inclusion criteria
• Participants who have been diagnosed with chronic urticaria (unclear if meeting definition of CSU)
• Participants with urticaria with a severity level of 3 or higher according to “Guidelines for the Diagnosis
and Treatment of Urticaria and Angioedema” after treatment with oral bepotastine besilate for 2 weeks
• Participants who received an explanation of the study details and signed a written consent form
• Participants 16 years of age or older at the time of registration. For those younger than 20 years, their
guardians must also have signed the consent form
Exclusion criteria
• Participants with a known allergy to any component of the study drug
• Pregnant or possibly pregnant women, or breastfeeding women. Women who wish to become
pregnant during study participation
• Participants who are judged inappropriate to participate in the study by the investigator
Interventions • 14 days of treatment with bepotastine besilate (20 mg twice daily)
• 14 days of treatment with bepotastine besilate (10 mg twice daily)
Outcomes Primary outcomes
• Improvement in the degree of itching in the daytime and at nighttime
Secondary outcomes
• Improvement in the duration of rash
• Improvement in the degree of skin eruption (erythema, weal, area/extent)
• Change in QoL (Skindex-16)
• Overall improvement rating (degree of skin eruption, degree of itching)
• Degree of satisfaction regarding efficacy
• Safety
Starting date 1 June 2012
Contact information Sayumi Hasegawa
World Trade Center Bldg 24F 2-4-1, Hamamatsu-cho, Minato-ku, Tokyo 105-6124 Japan, Japan
hasegawa@ebms.co.jp
EBMs Co, Ltd Business Strategy Division
Notes Completed, no results posted
Funder: non-profit organisation, Health Institute Research of Skin
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JPRN-UMIN000008461
Trial name or title A study on the optimal treatment for chronic idiopathic urticaria insufficient for the second-generation
antihistamines
Methods Parallel, randomised, open
Participants Male and female 20 years of age or older.
Inclusion criteria
• Participants with idiopathic chronic urticaria > level 2
Exclusion criteria
• Participants with cholinergic urticaria, pregnant women, etc.
Interventions Antihistamines (details unclear)
Outcomes Primary outcomes
• Efficacy
Starting date 1 April 2011
Contact information Tamotsu Ebihara
35 Shiannomachi Shinjuku-ku Tokyo, JAPAN, Japan
ebitamo@yahoo.co.jp
Keio University School of Medicine, Department of Dermatology
Notes Ongoing, recruiting
Sponsored by Keio University School of Medicine
JPRN-UMIN000010265
Trial name or title Preliminary trial of the increase in antihistamines in dose and a combination of different antihistamines for
refractory spontaneous urticaria
Methods Open parallel-group randomised allocation concealed by numbered containers
Participants Target of 32 participants with idiopathic urticaria (definition and duration not stated), male or female 20
years of age or older
Inclusion criteria
• Adult participant with spontaneous urticaria
• Without reduction in daily urticaria scores of 4 or more over 3 days or longer, after 7 days of treatment
with 5 mg/d levocetirizine. Or with reductions in daily urticaria score of 1 or more in 3 days or more, out of
7 days, by taking levocetirizine 5 mg/d, and with daily urticarial score 4 or more in the last 3 days of the
subsequent 1 week of treatment
• Granted permission with written informed consent
• Able to score daily urticaria activities according to the formatted urticaria diary.
• Agreed to revisit the clinic for evaluation
Exclusion criteria
• History of drug allergy
• Pregnant or lactating
• Glaucoma, hyper-intraocular pressure or inferior urinary tract obstruction
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JPRN-UMIN000010265 (Continued)
• Hyperthyroidism or any cardiovascular disease
• Stegnotic gastrointestinal ulceration or pylorus stegnosis
• Taking central nervous depressant, alcohol, MAO inhibitor or anticholine agent
• Disease that discourages taking of anticholinergic drugs or antihistamines
• High renal or liver damage
• Decreased cognitive ability or comprehension.
• History of taking antileukotriene or H2-blocker within 2 weeks before agreement
• History of taking steroids by topical application or injection within 4 weeks before agreement
• Occupation driving or operating machines
• Any participants evaluated as inadequate by physicians.
Interventions • Levocetirizine 10 mg once daily
• Levocetirizine 5 mg/d and chlorpheniramine maleate 4 mg daily
Outcomes Primary outcomes
• Rate of complete response
Secondary outcomes
• Days symptom free
• Change in symptom scores during treatments
• Sleepiness
Starting date 1 April 2013
Contact information Takuma Kohsaka
Hiroshima University Hospital
Department of Dermatology
1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551
+81-82-257-5237
takumuchi0116@yahoo.co.jp
Notes Sponsored by Hiroshima Univeristy, and funded by GlaxoSmithKline, ongoing, completing 31 March 2015
NCT00199238
Trial name or title A 4-week dose-finding multi-centre double-blind randomised placebo-controlled parallel-group trial to assess
the efficacy and safety of different doses of rupatadine compared with placebo in the treatment of chronic
idiopathic urticaria
Methods RCT
Participants Male and female 12 to 65 years of age with CSU
Interventions • Rupatadine
• Placebo
Outcomes Primary outcomes
• Efficacy measure of each treatment will compare the frequency and severity of symptoms of CSU as
measured by the participant in terms of change in mean pruritus score (MPS) over the 4-week treatment
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NCT00199238 (Continued)
period
Secondary outcomes
• Change from baseline over 4-week treatment period in the mean number of weals (MNW) score
• Mean total symptoms score (MTSS), calculated as sum of MPS (mean pruritus symptoms)
• MNW scores and interference with sleep and daily activities due to urticaria symptoms
• Criteria for evaluation (safety): adverse effects, laboratory tests and vital signs
Starting date October 2002
Contact information Eva Arnaiz, PhD, J Uriach y Compania
Notes Terminated, no study results posted
NCT00199251
Trial name or title A 6-week multi-centre double-blind randomised placebo-controlled parallel-group study to assess the efficacy
and safety of rupatadine 10 and 20 mg in the treatment of chronic idiopathic urticaria (CIU): a phase III
clinical trial
Methods RCT
Participants Male and female 12 to 65 years of age with CSU
Interventions • Rupatadine 10 mg and 20 mg
• Placebo
Outcomes Primary outcomes
• Frequency and severity of symptoms of CSU as measured by the participant in terms of change in
mean pruritus score (MPS) over the 4-week treatment period
Secondary outcomes
• Change from baseline over the 4- and 6-week treatment period in mean number of weals (MNW) score
• Mean total symptoms score (MTSS), calculated as the sum of the MPS (mean pruritus symptoms) and
MNW (mean number of weals) scores
• Severity of symptoms of CSU as measured by the participant in terms of change in MPS over the 6-
week treatment period, using a visual analogue scale (VAS)
• Quality of life (QoL), which will be assessed by the Dermatology Life Quality Index (DLQI)
• Safety: ECGs baseline and final visit; clinical laboratory controls, physical examination, incidence of
adverse events
Starting date April 2004
Contact information J Uriach and Company
Notes Terminated, no study results posted
Other study ID IC010RUP304
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NCT00421109
Trial name or title Double-blind, randomised, placebo-controlled, phase III study comparing the efficacy and safety of bilastine
20 mg once daily and levocetirizine 5 mg for the treatment of chronic idiopathic urticaria
Methods RCT
Participants Male and female 18 to 70 years of age with CSU
Interventions • Bilastine 20 mg and levocetirizine 5 mg (once daily)
• Placebo
Outcomes Primary outcomes
• Change from baseline in the AM/PM total symptoms score (TSS3) over 28 days of the treatment
period according to participant’s assessment on the diary card (reflective symptoms)
Starting date July 2006
Contact information Faes Farma, S.A.
Principal Investigator: Olmos, MD Hosp Clinico San Carlos, Servicio Dermatologia (Madrid, Spain)
Principal Investigator: De Weert, MD Uz Gent/De Pintelaan 185 (Belgium)
Principal Investigator: Dubertret, MD Hopital St Louis/Sce Dermatologie/1 Av Claude Vellefaux (Paris,
France)
Principal Investigator: Simon, MD Univ Klinikum Leipzig/Klinik Für Dermatologie (Germany)
Principal Investigator: Kapinska-Mrowiecka, MD Szpital Specjalistyczny Im S Zeromskiego/Oddzial Der-
matologii/Os Mlodosci 11 (Krakow, Poland)
Principal Investigator: Benea, MD Spit Clin Dermato-Venero, Prof Dr/Scarlat Longhin/alea Serban Voda
216, Sector4 (Bucharest, Romania)
Principal Investigator: Herrero, MD Consultorio De Alergia 1° Piso/Hospital Juan A. Fernandez/Cervino
3355 (Buenos Aires, Argentina)
Notes Completed July 2007 (final data collection date for primary outcome measure), no study results posted
Other study IDs EudraCT 2006-001245-33, BILA 2006/UCI
NCT00751166
Trial name or title A comparative double-blind double-dummy study of desloratadine (dl) 5 mg once daily, cetirizine 10 mg
once daily and placebo once daily in patients with chronic idiopathic urticaria (CIU)
Methods RCT
Participants Male and female 12 to 70 years of age with CSU
Interventions • Desloratadine 5 mg once daily
• Cetirizine 10 mg once daily
• Placebo
Outcomes Primary outcomes
• Efficacy of study treatments with respect to change from baseline in average AM/PM 12-hour reflective
pruritus severity score (diary recordings)
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NCT00751166 (Continued)
Starting date March 2004
Contact information Schering-Plough
Notes Terminated May 2005, no study results posted. Study terminated, as could not be resupplied with study
medication in a timely manner
Other study ID P03736
NCT00751218
Trial name or title A comparative double-blind double-dummy study of desloratadine (dl) 5 mg once daily, cetirizine 10 mg
once daily and placebo once daily in patients with chronic idiopathic urticaria (CIU)
Methods RCT
Participants Male and female 12 to 70 years of age with CSU
Interventions • Desloratadine 5 mg once daily
• Cetirizine 10 mg once daily
• Placebo
Outcomes Primary outcomes
• Efficacy of study treatments with respect to change from baseline in the average AM/PM 12-hour
reflective pruritus severity score (diary recordings) after the first 7 days of treatment
Starting date May 2004
Contact information No contacts or locations posted, Schering-Plough
Notes Terminated August 2005, no study results posted
Other study ID P03735
NCT00783354
Trial name or title A pilot multi-centre double-blind randomised study for comparison of Aerius® “Continuous Treatment”
versus Aerius® “PRN Regimen” on chronic idiopathic urticaria patient quality of life
Methods RCT
Participants Male and female over 18 years of age with CSU
Interventions • Desloratadine
• Placebo
Outcomes Primary outcomes
• Changes from Visit 2 to Visit 4 in Vq-Derm Questionnaire score
• DLQI quality of life score
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NCT00783354 (Continued)
Starting date April 2003
Contact information Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough
Notes Known as ATTITUD. Completed April 2004, no study results posted
Other study ID P03147
CIU: chronic idiopathic urticaria.
CSU: chronic spontaneous urticaria.
DLQI: Dermatology Life Quality Index.
MAO: monoamine oxidase.
MNW: mean number of weals.
MPS: mean pruritus scale.
MTSS: mean total symptoms score.
NRS: numerical rating scale
OPD: Out-patient Department.
QoL: quality of life.
SIWS: scale for interference of wheals with sleep
VAS: visual analogue scale.
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D A T A A N D A N A L Y S E S
Comparison 1. Loratadine 10 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
with ’good’ or ’excellent’
response whilst taking
H1-antihistamines
2 124 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.91, 3.79]
1.1 Short-term duration of
intervention (10 mg)
1 12 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.42, 21.30]
1.2 Intermediate-term
duration of intervention (10
mg)
1 112 Risk Ratio (M-H, Random, 95% CI) 1.73 [0.81, 3.72]
Comparison 2. Loratadine 10 mg versus cetirizine 10 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
with complete suppression
of urticaria whilst taking
H1-antihistamines
2 103 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.76, 1.43]
1.1 Short-term duration of
intervention
1 37 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.64, 2.01]
1.2 Intermediate-term
duration of intervention
1 66 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.69, 1.47]
Comparison 3. Loratadine 10 mg versus desloratadine 5 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
with complete suppression
of urticaria whilst taking
H1-antihistamines
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Intermediate-term
duration of intervention
2 369 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
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2 Proportion of participants
with ’good’ or ’excellent’
response whilst taking
H1-antihistamines
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Intermediate-term
duration of intervention
3 410 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.64, 1.71]
Comparison 4. Loratadine 10 mg versus mizolastine 10 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
with complete suppression
of urticaria whilst taking
H1-antihistamines
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Intermediate-term
duration of intervention
3 316 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.64, 1.16]
2 Proportion of participants
with ’good’ or ’excellent’
response whilst taking
H1-antihistamines
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Intermediate-term
duration of intervention
3 314 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.55, 1.42]
3 Proportion of participants with
at least 50% improvement
in QoL whilst taking
H1-antihistamines
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Intermediate-term
duration of intervention
2 252 Risk Ratio (M-H, Random, 95% CI) 3.21 [0.32, 32.33]
4 Serious adverse events (i.e.
serious enough to require
withdrawal of treatment)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Intermediate-term
duration of intervention
2 267 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.04, 3.60]
Comparison 5. Loratadine 10 mg versus emedastine 2 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
with complete suppression
of urticaria whilst taking
H1-antihistamines
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Intermediate-term
duration of intervention
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
225H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2 Proportion of participants
with good or excellent
response whilst taking
H1-antihistamines
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Intermediate-term
duration of intervention
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Serious adverse events (i.e.
serious enough to require
withdrawal of treatment)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Intermediate-term
duration of intervention
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Loratadine 10 mg versus hydroxyzine 25 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
with complete suppression
of urticaria whilst taking
H1-antihistamines
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Short-term duration of
intervention
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Cetirizine 10 to 20 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
with complete suppression
of urticaria whilst taking
H1-antihistamines
2 178 Risk Ratio (M-H, Random, 95% CI) 2.72 [1.51, 4.91]
1.1 Short-term duration of
intervention (cetirizine 10 mg)
1 56 Risk Ratio (M-H, Random, 95% CI) 2.8 [1.17, 6.73]
1.2 Intermediate-term
duration of intervention
(cetirizine 10 mg)
1 122 Risk Ratio (M-H, Random, 95% CI) 2.66 [1.20, 5.90]
2 Serious adverse events (i.e.
serious enough to require
withdrawal of treatment)
3 389 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.68, 13.22]
2.1 Intermediate-term
duration of intervention
(cetirizine 10 mg)
2 247 Risk Ratio (M-H, Random, 95% CI) 4.60 [0.79, 26.67]
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2.2 Intermediate-term
duration of intervention
(cetirizine 10 to 20 mg)
1 142 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.07, 16.59]
Comparison 8. Cetirizine 10 mg versus hydroxyzine 25 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events (i.e.
serious enough to require
withdrawal of treatment)
2 261 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.25, 2.45]
1.1 Intermediate-term
duration of intervention
(cetirizine 10 mg)
1 123 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.27, 4.01]
1.2 Intermediate-term
duration of intervention
(cetirizine 5 to 25 mg)
1 138 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.04, 3.13]
Comparison 9. Desloratadine 5 to 20 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
with complete suppression
of urticaria whilst taking
H1-antihistamines
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Short-term duration of
intervention (desloratadine 5
mg)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Short-term duration of
intervention (desloratadine 10
mg)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Short-term duration of
intervention (desloratadine 20
mg)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 Intermediate-term
duration of intervention
(desloratadine 5 mg)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events (i.e.
serious enough to require
withdrawal of treatment)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Intermediate-term
duration of 5 mg of
intervention
3 466 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.42, 5.10]
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Comparison 10. Hydroxyzine 25 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events (i.e.
serious enough to require
withdrawal of treatment to
withdrawal)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Intermediate-term
duration of intervention
2 270 Risk Ratio (M-H, Random, 95% CI) 3.64 [0.77, 17.23]
Comparison 11. Levocetirizine 5 to 20 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
with complete suppression
of urticaria whilst taking
H1-antihistamines
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Short-term duration of
intervention (levocetirizine 5
mg)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Short-term duration of
intervention (levocetirizine 10
mg)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Short-term duration of
intervention (levocetirizine 20
mg)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 Intermediate-term
duration of intervention
(levocetirizine 5 mg)
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 12. Rupatadine 10 to 20 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
with ’good’ or ’excellent’
response whilst taking
H1-antihistamines
1 245 Risk Ratio (M-H, Random, 95% CI) 1.35 [1.03, 1.77]
1.1 Intermediate-term
duration of intervention
(rupatadine 10 mg)
1 122 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.86, 1.91]
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1.2 Intermediate-term
duration of intervention
(rupatadine 20 mg)
1 123 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.98, 2.06]
Analysis 1.1. Comparison 1 Loratadine 10 mg versus placebo, Outcome 1 Proportion of participants with
’good’ or ’excellent’ response whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 1 Loratadine 10 mg versus placebo
Outcome: 1 Proportion of participants with ’good’ or ’excellent’ response whilst taking H1-antihistamines
Study or subgroup Loratadine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Short-term duration of intervention (10 mg)
Monroe 1992 3/6 1/6 13.2 % 3.00 [ 0.42, 21.30 ]
Subtotal (95% CI) 6 6 13.2 % 3.00 [ 0.42, 21.30 ]
Total events: 3 (Loratadine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Intermediate-term duration of intervention (10 mg)
Belaich 1990 16/60 8/52 86.8 % 1.73 [ 0.81, 3.72 ]
Subtotal (95% CI) 60 52 86.8 % 1.73 [ 0.81, 3.72 ]
Total events: 16 (Loratadine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 66 58 100.0 % 1.86 [ 0.91, 3.79 ]
Total events: 19 (Loratadine), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
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Analysis 2.1. Comparison 2 Loratadine 10 mg versus cetirizine 10 mg, Outcome 1 Proportion of
participants with complete suppression of urticaria whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 2 Loratadine 10 mg versus cetirizine 10 mg
Outcome: 1 Proportion of participants with complete suppression of urticaria whilst taking H1-antihistamines
Study or subgroup Loratadine Cetirizine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Short-term duration of intervention
Patel 1997 12/20 9/17 30.1 % 1.13 [ 0.64, 2.01 ]
Subtotal (95% CI) 20 17 30.1 % 1.13 [ 0.64, 2.01 ]
Total events: 12 (Loratadine), 9 (Cetirizine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 Intermediate-term duration of intervention
Yin 2003b 20/32 21/34 69.9 % 1.01 [ 0.69, 1.47 ]
Subtotal (95% CI) 32 34 69.9 % 1.01 [ 0.69, 1.47 ]
Total events: 20 (Loratadine), 21 (Cetirizine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 52 51 100.0 % 1.05 [ 0.76, 1.43 ]
Total events: 32 (Loratadine), 30 (Cetirizine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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230H1-antihistamines for chronic spontaneous urticaria (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 Loratadine 10 mg versus desloratadine 5 mg, Outcome 1 Proportion of
participants with complete suppression of urticaria whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 3 Loratadine 10 mg versus desloratadine 5 mg
Outcome: 1 Proportion of participants with complete suppression of urticaria whilst taking H1-antihistamines
Study or subgroup Loratadine Desloratadine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention
Gu 2002 54/79 60/79 60.3 % 0.90 [ 0.74, 1.09 ]
Hao 2003 57/106 61/105 39.7 % 0.93 [ 0.73, 1.18 ]
Subtotal (95% CI) 185 184 100.0 % 0.91 [ 0.78, 1.06 ]
Total events: 111 (Loratadine), 121 (Desloratadine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Desloratadine Favours Loratadine
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Analysis 3.2. Comparison 3 Loratadine 10 mg versus desloratadine 5 mg, Outcome 2 Proportion of
participants with ’good’ or ’excellent’ response whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 3 Loratadine 10 mg versus desloratadine 5 mg
Outcome: 2 Proportion of participants with ’good’ or ’excellent’ response whilst taking H1-antihistamines
Study or subgroup Loratadine Desloratadine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention
Gu 2002 24/79 18/79 43.5 % 1.33 [ 0.79, 2.26 ]
Hao 2003 31/106 32/105 53.6 % 0.96 [ 0.63, 1.45 ]
Zou 2002 0/20 4/21 2.9 % 0.12 [ 0.01, 2.03 ]
Subtotal (95% CI) 205 205 100.0 % 1.04 [ 0.64, 1.71 ]
Total events: 55 (Loratadine), 54 (Desloratadine)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.31, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Loratadine 10 mg versus mizolastine 10 mg, Outcome 1 Proportion of
participants with complete suppression of urticaria whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 4 Loratadine 10 mg versus mizolastine 10 mg
Outcome: 1 Proportion of participants with complete suppression of urticaria whilst taking H1-antihistamines
Study or subgroup Loratadine Mizolastine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention
Guo 2003 10/23 18/23 21.3 % 0.56 [ 0.33, 0.93 ]
Liu 2003 68/104 68/104 47.6 % 1.00 [ 0.82, 1.22 ]
Yin 2003b 20/32 20/30 31.1 % 0.94 [ 0.65, 1.36 ]
Subtotal (95% CI) 159 157 100.0 % 0.86 [ 0.64, 1.16 ]
Total events: 98 (Loratadine), 106 (Mizolastine)
Heterogeneity: Tau2 = 0.04; Chi2 = 4.43, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Loratadine 10 mg versus mizolastine 10 mg, Outcome 2 Proportion of
participants with ’good’ or ’excellent’ response whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 4 Loratadine 10 mg versus mizolastine 10 mg
Outcome: 2 Proportion of participants with ’good’ or ’excellent’ response whilst taking H1-antihistamines
Study or subgroup Loratadine Mizolastine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention
Guo 2003 4/23 4/23 14.1 % 1.00 [ 0.28, 3.52 ]
Liu 2003 12/104 16/102 46.1 % 0.74 [ 0.37, 1.48 ]
Yin 2003b 10/32 9/30 39.8 % 1.04 [ 0.49, 2.21 ]
Subtotal (95% CI) 159 155 100.0 % 0.88 [ 0.55, 1.42 ]
Total events: 26 (Loratadine), 29 (Mizolastine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Loratadine 10 mg versus mizolastine 10 mg, Outcome 3 Proportion of
participants with at least 50% improvement in QoL whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 4 Loratadine 10 mg versus mizolastine 10 mg
Outcome: 3 Proportion of participants with at least 50% improvement in QoL whilst taking H1-antihistamines
Study or subgroup Loratadine Mizolastine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention
Guo 2003 7/23 0/23 34.3 % 15.00 [ 0.91, 248.21 ]
Liu 2003 19/104 13/102 65.7 % 1.43 [ 0.75, 2.75 ]
Subtotal (95% CI) 127 125 100.0 % 3.21 [ 0.32, 32.33 ]
Total events: 26 (Loratadine), 13 (Mizolastine)
Heterogeneity: Tau2 = 2.01; Chi2 = 2.86, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Loratadine 10 mg versus mizolastine 10 mg, Outcome 4 Serious adverse events
(i.e. serious enough to require withdrawal of treatment).
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 4 Loratadine 10 mg versus mizolastine 10 mg
Outcome: 4 Serious adverse events (i.e. serious enough to require withdrawal of treatment)
Study or subgroup Loratadine Mizolastine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention
Leynadier 2000 0/26 1/35 50.4 % 0.44 [ 0.02, 10.49 ]
Liu 2003 0/104 1/102 49.6 % 0.33 [ 0.01, 7.93 ]
Subtotal (95% CI) 130 137 100.0 % 0.38 [ 0.04, 3.60 ]
Total events: 0 (Loratadine), 2 (Mizolastine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Loratadine 10 mg versus emedastine 2 mg, Outcome 1 Proportion of
participants with complete suppression of urticaria whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 5 Loratadine 10 mg versus emedastine 2 mg
Outcome: 1 Proportion of participants with complete suppression of urticaria whilst taking H1-antihistamines
Study or subgroup Loratadine Emedastine Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention
Pons-Guiraud 2006 42/77 44/84 1.04 [ 0.78, 1.39 ]
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Analysis 5.2. Comparison 5 Loratadine 10 mg versus emedastine 2 mg, Outcome 2 Proportion of
participants with good or excellent response whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 5 Loratadine 10 mg versus emedastine 2 mg
Outcome: 2 Proportion of participants with good or excellent response whilst taking H1-antihistamines
Study or subgroup Loratadine Emedastine Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention
Pons-Guiraud 2006 69/77 68/83 1.09 [ 0.96, 1.24 ]
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Analysis 5.3. Comparison 5 Loratadine 10 mg versus emedastine 2 mg, Outcome 3 Serious adverse events
(i.e. serious enough to require withdrawal of treatment).
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 5 Loratadine 10 mg versus emedastine 2 mg
Outcome: 3 Serious adverse events (i.e. serious enough to require withdrawal of treatment)
Study or subgroup Loratadine Emedastine Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention
Pons-Guiraud 2006 1/77 1/84 1.09 [ 0.07, 17.14 ]
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Analysis 6.1. Comparison 6 Loratadine 10 mg versus hydroxyzine 25 mg, Outcome 1 Proportion of
participants with complete suppression of urticaria whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 6 Loratadine 10 mg versus hydroxyzine 25 mg
Outcome: 1 Proportion of participants with complete suppression of urticaria whilst taking H1-antihistamines
Study or subgroup Loratadine Hydroxyzine Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Short-term duration of intervention
Monroe 1992 3/6 3/6 1.00 [ 0.32, 3.10 ]
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Analysis 7.1. Comparison 7 Cetirizine 10 to 20 mg versus placebo, Outcome 1 Proportion of participants
with complete suppression of urticaria whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 7 Cetirizine 10 to 20 mg versus placebo
Outcome: 1 Proportion of participants with complete suppression of urticaria whilst taking H1-antihistamines
Study or subgroup Cetirizine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Short-term duration of intervention (cetirizine 10 mg)
Go 1989 14/28 5/28 45.3 % 2.80 [ 1.17, 6.73 ]
Subtotal (95% CI) 28 28 45.3 % 2.80 [ 1.17, 6.73 ]
Total events: 14 (Cetirizine), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
2 Intermediate-term duration of intervention (cetirizine 10 mg)
Breneman 1995 18/60 7/62 54.7 % 2.66 [ 1.20, 5.90 ]
Subtotal (95% CI) 60 62 54.7 % 2.66 [ 1.20, 5.90 ]
Total events: 18 (Cetirizine), 7 (Placebo)
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(. . . Continued)
Study or subgroup Cetirizine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
Total (95% CI) 88 90 100.0 % 2.72 [ 1.51, 4.91 ]
Total events: 32 (Cetirizine), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 3.33 (P = 0.00088)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 7.2. Comparison 7 Cetirizine 10 to 20 mg versus placebo, Outcome 2 Serious adverse events (i.e.
serious enough to require withdrawal of treatment).
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 7 Cetirizine 10 to 20 mg versus placebo
Outcome: 2 Serious adverse events (i.e. serious enough to require withdrawal of treatment)
Study or subgroup Cetirizine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention (cetirizine 10 mg)
Breneman 1995 2/60 0/62 24.1 % 5.16 [ 0.25, 105.38 ]
Breneman 1996 4/60 1/65 46.9 % 4.33 [ 0.50, 37.69 ]
Subtotal (95% CI) 120 127 71.0 % 4.60 [ 0.79, 26.67 ]
Total events: 6 (Cetirizine), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
2 Intermediate-term duration of intervention (cetirizine 10 to 20 mg)
Kalivas 1990 1/69 1/73 29.0 % 1.06 [ 0.07, 16.59 ]
Subtotal (95% CI) 69 73 29.0 % 1.06 [ 0.07, 16.59 ]
Total events: 1 (Cetirizine), 1 (Placebo)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Cetirizine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 189 200 100.0 % 3.00 [ 0.68, 13.22 ]
Total events: 7 (Cetirizine), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.15)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
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Analysis 8.1. Comparison 8 Cetirizine 10 mg versus hydroxyzine 25 mg, Outcome 1 Serious adverse events
(i.e. serious enough to require withdrawal of treatment).
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 8 Cetirizine 10 mg versus hydroxyzine 25 mg
Outcome: 1 Serious adverse events (i.e. serious enough to require withdrawal of treatment)
Study or subgroup Cetirizine Hydroxyzine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention (cetirizine 10 mg)
Breneman 1996 4/60 4/63 73.6 % 1.05 [ 0.27, 4.01 ]
Subtotal (95% CI) 60 63 73.6 % 1.05 [ 0.27, 4.01 ]
Total events: 4 (Cetirizine), 4 (Hydroxyzine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
2 Intermediate-term duration of intervention (cetirizine 5 to 25 mg)
Kalivas 1990 1/69 3/69 26.4 % 0.33 [ 0.04, 3.13 ]
Subtotal (95% CI) 69 69 26.4 % 0.33 [ 0.04, 3.13 ]
Total events: 1 (Cetirizine), 3 (Hydroxyzine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 129 132 100.0 % 0.78 [ 0.25, 2.45 ]
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(. . . Continued)
Study or subgroup Cetirizine Hydroxyzine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 5 (Cetirizine), 7 (Hydroxyzine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
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Analysis 9.1. Comparison 9 Desloratadine 5 to 20 mg versus placebo, Outcome 1 Proportion of participants
with complete suppression of urticaria whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 9 Desloratadine 5 to 20 mg versus placebo
Outcome: 1 Proportion of participants with complete suppression of urticaria whilst taking H1-antihistamines
Study or subgroup Desloratidine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Short-term duration of intervention (desloratadine 5 mg)
Hoxha 2011 3/34 0/12 2.60 [ 0.14, 46.97 ]
2 Short-term duration of intervention (desloratadine 10 mg)
Hoxha 2011 11/34 0/12 8.54 [ 0.54, 134.83 ]
3 Short-term duration of intervention (desloratadine 20 mg)
Hoxha 2011 21/34 0/12 15.97 [ 1.04, 245.04 ]
4 Intermediate-term duration of intervention (desloratadine 5 mg)
Di Lorenzo 2004 18/40 0/40 37.00 [ 2.31, 593.70 ]
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Analysis 9.2. Comparison 9 Desloratadine 5 to 20 mg versus placebo, Outcome 2 Serious adverse events
(i.e. serious enough to require withdrawal of treatment).
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 9 Desloratadine 5 to 20 mg versus placebo
Outcome: 2 Serious adverse events (i.e. serious enough to require withdrawal of treatment)
Study or subgroup Desloratidine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of 5 mg of intervention
Monroe 2003 3/116 2/110 49.9 % 1.42 [ 0.24, 8.35 ]
Nettis 2004 0/25 0/25 Not estimable
Ring 2001 3/95 2/95 50.1 % 1.50 [ 0.26, 8.78 ]
Subtotal (95% CI) 236 230 100.0 % 1.46 [ 0.42, 5.10 ]
Total events: 6 (Desloratidine), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Hydroxyzine 25 mg versus placebo, Outcome 1 Serious adverse events (i.e.
serious enough to require withdrawal of treatment to withdrawal).
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 10 Hydroxyzine 25 mg versus placebo
Outcome: 1 Serious adverse events (i.e. serious enough to require withdrawal of treatment to withdrawal)
Study or subgroup Hydroxyzine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention
Breneman 1996 4/63 1/65 51.7 % 4.13 [ 0.47, 35.92 ]
Kalivas 1990 3/69 1/73 48.3 % 3.17 [ 0.34, 29.79 ]
Subtotal (95% CI) 132 138 100.0 % 3.64 [ 0.77, 17.23 ]
Total events: 7 (Hydroxyzine), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Levocetirizine 5 to 20 mg versus placebo, Outcome 1 Proportion of
participants with complete suppression of urticaria whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 11 Levocetirizine 5 to 20 mg versus placebo
Outcome: 1 Proportion of participants with complete suppression of urticaria whilst taking H1-antihistamines
Study or subgroup Levocetirizine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Short-term duration of intervention (levocetirizine 5 mg)
Hoxha 2011 9/37 0/12 6.50 [ 0.41, 104.06 ]
2 Short-term duration of intervention (levocetirizine 10 mg)
Hoxha 2011 17/37 0/12 11.97 [ 0.77, 185.38 ]
3 Short-term duration of intervention (levocetirizine 20 mg)
Hoxha 2011 30/37 0/12 20.87 [ 1.37, 317.60 ]
4 Intermediate-term duration of intervention (levocetirizine 5 mg)
Nettis 2006 27/51 0/49 52.88 [ 3.31, 843.81 ]
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Analysis 12.1. Comparison 12 Rupatadine 10 to 20 mg versus placebo, Outcome 1 Proportion of
participants with ’good’ or ’excellent’ response whilst taking H1-antihistamines.
Review: H1-antihistamines for chronic spontaneous urticaria
Comparison: 12 Rupatadine 10 to 20 mg versus placebo
Outcome: 1 Proportion of participants with ’good’ or ’excellent’ response whilst taking H1-antihistamines
Study or subgroup Rupatadine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermediate-term duration of intervention (rupatadine 10 mg)
Gimenez-Arnau 2007 60/94 14/28 46.3 % 1.28 [ 0.86, 1.91 ]
Subtotal (95% CI) 94 28 46.3 % 1.28 [ 0.86, 1.91 ]
Total events: 60 (Rupatadine), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
2 Intermediate-term duration of intervention (rupatadine 20 mg)
Gimenez-Arnau 2007 69/94 15/29 53.7 % 1.42 [ 0.98, 2.06 ]
Subtotal (95% CI) 94 29 53.7 % 1.42 [ 0.98, 2.06 ]
Total events: 69 (Rupatadine), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.065)
Total (95% CI) 188 57 100.0 % 1.35 [ 1.03, 1.77 ]
Total events: 129 (Rupatadine), 29 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.030)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.70), I2 =0.0%
0.5 0.7 1 1.5 2
Favours Placebo Favours Rupatadine
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A P P E N D I C E S
Appendix 1. Skin Group Specialised Register search strategy
(Urticaria or hives) and (astemizole or brompheniramine or chlorpheniramine or cinnarizine or clemastine or cyclizine or cyproheptadine
or dimenhydrinate or dimethindene or diphenhydramine or doxylamine or flunarizine or hydroxyzine or ketotifen or meclizine or
methapyrilene or mianserin or pheniramine or promethazine or pyrilamine or terfenadine or tripelennamine or triprolidine or azelastine
or bromodiphenhydramine or carbinoxamine or cetirizine or chlorodiphenhydramine or chlorphenamine or deschlorpheniramine or
loratadine or desloratadine or dexbrompheniramine or dexchlorpheniramine or dimetindene or ebastine or embramine or fexofenadine
or levocetirizine or meclozine or olopatadine or phenindamine or phenyltoloxamine or rupatadine or “H1 receptor antagonist*” or
“H1 antagonist*” or “h1 antihistamine*”)
Appendix 2. CENTRAL search strategy
#1 (urticaria):ti,ab,kw
#2 MeSH descriptor Urticaria explode all trees in MeSH products
#3 (hives):ti,ab,kw
#4 (#1 OR #2 OR #3)
#5 “H1 antihistamine*”:ti,ab,kw
#6 (“H1 antagonist*”):ti,ab,kw
#7 MeSH descriptor Histamine H1 Antagonists explode all trees in MeSH products
#8 astemizole in Title, Abstract or Keywords in all products
#9 brompheniramine or chlorpheniramine in Title, Abstract or Keywords in all products
#10 cinnarizine or clemastine or cyclizine or cyproheptadine in Title, Abstract or Keywords in all products
#11 dimenhydrinate or dimethindene or diphenhydramine in Title, Abstract or Keywords in all products
#12 doxylamine or flunarizine or hydroxyzine or ketotifen or meclizine or methapyrilene in Title, Abstract or Keywords in all products
#13 mianserin or pheniramine or promethazine or pyrilamine in Title, Abstract or Keywords in all products
#14 terfenadine or tripelennamine or triprolidine in Title, Abstract or Keywords in all products
#15 “H1 receptor antagonist*”:ti,ab,kw
#16 MeSH descriptor Astemizole explode all trees
#17 MeSH descriptor Brompheniramine explode all trees
#18 MeSH descriptor Chlorpheniramine explode all trees
#19 MeSH descriptor Cinnarizine explode all trees
#20 MeSH descriptor Clemastine explode all trees
#21 MeSH descriptor Cyclizine explode all trees
#22 MeSH descriptor Cyproheptadine explode all trees
#23 MeSH descriptor Dimenhydrinate explode all trees
#24 MeSH descriptor Dimethindene explode all trees
#25 MeSH descriptor Diphenhydramine explode all trees
#26 MeSH descriptor Doxylamine explode all trees
#27 MeSH descriptor Flunarizine explode all trees
#28 MeSH descriptor Hydroxyzine explode all trees
#29 MeSH descriptor Ketotifen explode all trees
#30 MeSH descriptor Meclizine explode all trees
#31 MeSH descriptor Methapyrilene explode all trees
#32 MeSH descriptor Mianserin explode all trees
#33 MeSH descriptor Pheniramine explode all trees
#34 MeSH descriptor Promethazine explode all trees
#35 MeSH descriptor Pyrilamine explode all trees
#36 MeSH descriptor Terfenadine explode all trees
#37 MeSH descriptor Tripelennamine explode all trees
#38 MeSH descriptor Triprolidine explode all trees
#39 (azelastine or bromodiphenhydramine or carbinoxamine or cetirizine ):ti,ab,kw
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#40 (Chlorodiphenhydramine or chlorphenamine or Deschlorpheniramine):ti,ab,kw
#41 MeSH descriptor Loratadine explode all trees
#42 (desloratadine or loratadine or Dexbrompheniramine):ti,ab,kw
#43 (Dexchlorpheniramine or Dimetindene or ebastine or Embramine ):ti,ab,kw
#44 (Fexofenadine or Levocetirizine or Meclozine or Olopatadine):ti,ab,kw
#45 (Phenindamine or Phenyltoloxamine or Rupatadine):ti,ab,kw
#46 MeSH descriptor Cetirizine explode all trees
#47 (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #
20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #
35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46)
#48 (#4 AND #47)
Appendix 3. MEDLINE (Ovid) search strategy
1. randomised controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (animals not (human and animals)).sh.
10. 8 not 9
11. exp Urticaria/ or urticaria.ti,ab.
12. hives.ti,ab.
13. or/11-12
14. exp Histamine H1 Antagonists/ or h1 antihistamine$.ti,ab.
15. astemizole.ti,ab. or exp Astemizole/
16. brompheniramine.ti,ab. or exp Brompheniramine/
17. chlorpheniramine.ti,ab. or exp Chlorpheniramine/
18. cinnarizine.ti,ab. or exp Cinnarizine/
19. clemastine.ti,ab. or exp Clemastine/
20. cyclizine.ti,ab. or exp Cyclizine/
21. cyproheptadine.ti,ab. or exp Cyproheptadine/
22. dimenhydrinate.ti,ab. or exp Dimenhydrinate/
23. dimethindene.ti,ab. or exp Dimethindene/
24. diphenhydramine.ti,ab. or exp Diphenhydramine/
25. doxylamine.ti,ab. or exp Doxylamine/
26. flunarizine.ti,ab. or exp Flunarizine/
27. hydroxyzine.ti,ab. or exp Hydroxyzine/
28. ketotifen.ti,ab. or exp Ketotifen/
29. meclizine.ti,ab. or exp Meclizine/
30. methapyrilene.ti,ab. or exp Methapyrilene/
31. mianserin.ti,ab. or exp Mianserin/
32. pheniramine.mp. or exp Pheniramine/
33. promethazine.ti,ab. or exp Promethazine/
34. pyrilamine.ti,ab. or exp Pyrilamine/
35. terfenadine.ti,ab. or exp Terfenadine/
36. tripelennamine.ti,ab. or exp Tripelennamine/
37. triprolidine.ti,ab. or exp Triprolidine/
38. azelastine.ti,ab.
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39. bromodiphenhydramine.ti,ab.
40. Carbinoxamine.ti,ab.
41. exp Cetirizine/
42. cetirizine.ti,ab.
43. Chlorodiphenhydramine.ti,ab.
44. chlorphenamine.ti,ab.
45. Deschlorpheniramine.ti,ab.
46. exp Loratadine/
47. desloratadine.ti,ab.
48. loratadine.ti,ab.
49. Dexbrompheniramine.ti,ab.
50. Dexchlorpheniramine.ti,ab.
51. Dimetindene.ti,ab.
52. ebastine.ti,ab.
53. Embramine.ti,ab.
54. Fexofenadine.ti,ab.
55. Levocetirizine.ti,ab.
56. Meclozine.ti,ab.
57. Olopatadine.ti,ab.
58. Phenindamine.ti,ab.
59. Phenyltoloxamine.ti,ab.
60. Rupatadine.ti,ab.
61. H1 receptor antagonist$.ti,ab.
62. H1 antagonist$.ti,ab.
63. or/14-62
64. 10 and 13 and 63
Appendix 4. EMBASE (Ovid) search strategy
1. astemizole.ti,ab. or exp Astemizole/
2. brompheniramine.ti,ab. or exp Brompheniramine/
3. chlorpheniramine.ti,ab. or exp Chlorpheniramine/
4. cinnarizine.ti,ab. or exp Cinnarizine/
5. clemastine.ti,ab. or exp Clemastine/
6. cyclizine.ti,ab. or exp Cyclizine/
7. cyproheptadine.ti,ab. or exp Cyproheptadine/
8. dimenhydrinate.ti,ab. or exp Dimenhydrinate/
9. dimethindene.ti,ab. or exp Dimethindene/
10. diphenhydramine.ti,ab. or exp Diphenhydramine/
11. doxylamine.ti,ab. or exp Doxylamine/
12. flunarizine.ti,ab. or exp Flunarizine/
13. hydroxyzine.ti,ab. or exp Hydroxyzine/
14. ketotifen.ti,ab. or exp Ketotifen/
15. meclizine.ti,ab. or exp Meclizine/
16. methapyrilene.ti,ab. or exp Methapyrilene/
17. mianserin.ti,ab. or exp Mianserin/
18. pheniramine.mp. or exp Pheniramine/
19. promethazine.ti,ab. or exp Promethazine/
20. pyrilamine.ti,ab. or exp Pyrilamine/
21. terfenadine.ti,ab. or exp Terfenadine/
22. tripelennamine.ti,ab. or exp Tripelennamine/
23. triprolidine.ti,ab. or exp Triprolidine/
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24. azelastine.ti,ab.
25. bromodiphenhydramine.ti,ab.
26. Carbinoxamine.ti,ab.
27. exp Cetirizine/
28. cetirizine.ti,ab.
29. Chlorodiphenhydramine.ti,ab.
30. chlorphenamine.ti,ab.
31. Deschlorpheniramine.ti,ab.
32. exp Loratadine/
33. desloratadine.ti,ab.
34. loratadine.ti,ab.
35. Dexbrompheniramine.ti,ab.
36. Dexchlorpheniramine.ti,ab.
37. Dimetindene.ti,ab.
38. ebastine.ti,ab.
39. Embramine.ti,ab.
40. Fexofenadine.ti,ab.
41. Levocetirizine.ti,ab.
42. Meclozine.ti,ab.
43. Olopatadine.ti,ab.
44. Phenindamine.ti,ab.
45. Phenyltoloxamine.ti,ab.
46. Rupatadine.ti,ab.
47. H1 receptor antagonist$.ti,ab.
48. H1 antagonist$.ti,ab.
49. exp histamine H1 receptor antagonist/
50. exp azelastine/
51. exp bromodiphenhydramine/
52. exp carbinoxamine/
53. exp desloratadine/
54. exp dexbrompheniramine/
55. exp dexchlorpheniramine/
56. exp dimetindene/
57. exp ebastine/
58. exp embramine/
59. exp fexofenadine/
60. exp levocetirizine/
61. exp meclozine/
62. exp olopatadine/
63. exp phenindamine/
64. exp phenyltoloxamine/
65. exp rupatadine/
66. h1 antihistamine$.ti,ab.
67. or/1-66
68. exp *urticaria/
69. urticaria.ti,ab.
70. hives.ti,ab.
71. or/68-70
72. random$.mp.
73. factorial$.mp.
74. (crossover$ or cross-over$).mp.
75. placebo$.mp. or PLACEBO/
76. (doubl$ adj blind$).mp.
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77. (singl$ adj blind$).mp.
78. (assign$ or allocat$).mp.
79. volunteer$.mp. or VOLUNTEER/
80. Crossover Procedure/
81. Double Blind Procedure/
82. Randomized Controlled Trial/
83. Single Blind Procedure/
84. 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83
85. 67 and 71 and 84
Appendix 5. PsycINFO (Ovid) search strategy
1. double-blind.tw.
2. random$ assigned.tw.
3. control.tw.
4. 1 or 2 or 3
5. urticaria.ti,ab.
6. hives.ti,ab.
7. 5 or 6
8. 4 and 7
Lines 1-3 of this strategy are a therapy filter for PsycINFO (Ovid) created by the Health Information Research Unit at McMaster
University.
WH A T ’ S N E W
Last assessed as up-to-date: 3 June 2014.
Date Event Description
15 July 2015 Amended Correction to publication date of included study Zou 2002. Previously cited as 2003. 2002 is the correct
publication year
C O N T R I B U T I O N S O F A U T H O R S
Link with editorial base and co-ordinate contributions from co-authors, supervision (AS, CB).
Draft protocol (AS, SNC, CC, LB, CH).
Run search (AS, SNC, MS, CB).
Identify relevant titles and abstracts from searches (AS, SNC, MS, CB).
Obtain copies of trials (AS, MS, SNC, CB).
Select trials (AS, SNC, MS, CB, CC).
Extract data from trials (AS, CB, MS, SNC, CC).
Enter data into RevMan (CB, MS, BC).
Carry out data analyses and draft Effects of Interventions section of the review (BC, CB, MS).
Interpret data (BC, CB, MS, SNC).
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Draft final review (CB, MS, SNC, BC).
Update review (MS, CB, SNC, BC).
Disclaimer
The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the National Institute
for Health Research (NIHR), the National Health Service (NHS) or the Department of Health, UK.
D E C L A R A T I O N S O F I N T E R E S T
Maulina Sharma: “I have represented the Cochrane Skin Group as a stakeholder for a NICE (National Institute for Health and Care
Excellence) scoping workshop for chronic spontaneous urticaria: omalizumab 2014. I have received an honorarium as a speaker for a
general practitioner (GP) educational event, which was donated to the charitable funds of the department. I have attended training
and continuing medical education (CME) events that may have been sponsored in part by pharmaceutical industry. I have been a
subinvestigator for clinical trials conducted in the Department of Dermatology, George Eliot Hospitals NHS Trust, Nuneaton, UK
(2005 to 2006), in particular, the CUTE study (NCT00264303). I was not involved in writing of the results and received no payments
for my involvement with the clinical trials.”
Cathy Bennett: “I am the proprietor of Systematic Research Ltd, a company providing research services; I am an employee of this
company and received a consultancy fee for the production of this review. I have also received consultancy fees for other Cochrane
reviews and work in evidence-based medicine.”
Stuart N Cohen: Nothing to declare.
Ben Carter: Nothing to declare.
Dr Karsten Weller was a clinical referee: “I received lecture fees or advisory board fees from Novartis, Uriach, FAES, MSD (Essex
Pharma), UCB or was involved in clinical studies with drugs from these companies.”
S O U R C E S O F S U P P O R T
Internal sources
• Queen’s Medical Centre, UK.
External sources
• The National Institute for Health Research (NIHR), UK.
The NIHR, UK, is the largest single funder of the Cochrane Skin Group
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We now use the term chronic spontaneous urticaria.
We changed the wording of the ’Types of participants’ criteria to clarify that we mean angio-oedema without weals rather than angio-
oedemawithout urticaria, as the latter uses the term ‘urticaria’ as a descriptor rather than a disease.We used ’autoinflammatory syndrome’
rather than ‘associated abnormalities,’ as Muckle-Wells and Schnitzler’s syndrome are not urticaria.
We clarified that we have included any first-generation (’sedating’) or second-generation (’non-sedating’) H1-antihistamines at any
dose (including topical interventions and H2RAs given concomitantly) given as single therapy or as combination therapy. Comparators
consisted of no treatment, that is, placebo, or another active (pharmacological) compound. We included studies that compared the
same drug but at different doses, but we excluded non-pharmacological interventions such as acupuncture.
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We collected additional data from the reports of studies, such as country and setting, to obtain further information about clinical
heterogeneity between our included studies.
Wedidnot carry out subgroup analyses on the basis of first-generation (’sedating’) and second-generation (’non-sedating’) antihistamines,
as included studies with relevant outcome data were too few to allow meaningful comparisons.
We clarified that duration of intervention is categorised as follows: up to two weeks (short-term) and longer than two weeks up to three
months (intermediate-term). Our analyses are now subgrouped by duration of intervention, as we are not looking for a cure but would
like to identify which antihistamine will suppress or give good or excellent response for urticaria immediately and over the longest time.
We excluded studies that investigated the effects of astemizole or terfenadine (withdrawn from use).
We describedmoderate statistical heterogeneity as > 50% in the protocol, but we revised this in the full review tomoderate heterogeneity
at I² > 60%.
For some comparisons, we used Fisher’s exact test because of the small number of participants,
We had stated that we would use funnel plots when at least three studies were included in the meta-analysis, but theCochrane Handbook
for Systematic Reviews of Interventions recommends a minimum of 10 studies for sufficient power.
We included in our methods section updated information about assessment of risk of bias using the ’Risk of bias’ tool of The Cochrane
Collaboration, and details about how we dealt with cross-over trials are provided in the Unit of analysis issues section.
N O T E S
We provide brand names as a guide to the consumer and do not endorse any product over another.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Cetirizine [therapeutic use]; Cyproheptadine [analogs & derivatives; therapeutic use]; Histamine H1 Antagonists [adverse effects;
∗therapeutic use]; Hydroxyzine [therapeutic use]; Loratadine [analogs & derivatives; therapeutic use]; Randomized Controlled Trials
as Topic; Urticaria [∗drug therapy]
MeSH check words
Humans
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